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Antibiotic resistance is a serious worldwide threat. Alternative solutions to the 
limited pipeline of new antibiotics are urgently needed. Nanotechnology and drug 
delivery can be used to develop new therapies from old antimicrobials by control-
ling their distribution in the body. 
The goal of this thesis was to investigate the formation and activity of polyion 
complex (PIC) nanoparticles as vehicles for the delivery of two cationic antibiot-
ics: poly(ethylene imine), used as model to develop these nanomaterials, and the 
FDA-approved antimicrobial peptide polymyxin B. These antibiotics were com-
bined with two types of polyanions to form PIC particles with distinct antimicrobial 
properties: 1) Anionic peptides, degradable by bacterial enzymes led to bacteria-
targeted nanoparticles; 2) Acidic polymers assembled particles for passive re-
lease, which tuned the activity of the antibiotic in the absence of a specific trigger. 
All the PIC particles prepared were characterised, and their physiological stability 
and antimicrobial properties evaluated. To improve the stability and activity of 
these nanoparticles, several characteristics of their anionic components were op-
timised: 1) their multivalency, as a function of the peptide’s anionic residues and 
polymer’s DP; 2) the acidity of the polymers; and 3) the number of cross-linking 





This thesis is dedicated to my parents, 
for their constant, endless and valuable support over the years. 
 
 
Esta tesis está dedicada a mis padres, 













“The saddest aspect of life right now is that science gathers knowledge 






I would like to start by thanking my supervisor, Dr Francisco Fernández-Trillo, for 
giving me the opportunity to work in, and actually start, his group. I have learnt a 
great deal about science and academic life from Paco, but more importantly, he 
has been a good counsellor in scientific and personal matters. I will miss your 
cheer-up sessions over coffee or beer when experiments didn’t work. 
Big thank you to my two other mentors during these years of PhD: my co-super-
visor Dr Anna Peacock, and my microbiology tutor Dr Anne Marie Krachler. 
Thank you to the rest of Paco’s group, past and present, for creating an enjoyable 
work atmosphere, specially my UG/PG students (a.k.a. minions) Menisha and 
Marion, for their contribution to this thesis; the rest of minions I have mentored 
(Maria, Nico, Löic, Louise, Rob, Nada, Greg, Joel and Nathan), for enduring my 
supervision; Nico, for his coffee-breaks and help with bacterial work; Zelu, for his 
doses of “constructive” criticism; Adam and Oli, for the good times we had during 
this time in Birmingham (and Amsterdam); and Daniel, for the commutes to the 
lab and your help whenever I needed it. 
To my brother from another mother, Xavi. This time in Birmingham would have 
never been the same without you. I don’t realise now how much I will miss you, 
but I know for sure we’ll still be good friends wherever we go. Thank you and 
Mariyuki for the time we lived together. 
To my best friend, the person with this strange power that makes my worries 
disappear when I am with her. The person I have shared this time in Birmingham 
with. In the distance or presence, she was always there: my girlfriend Laura. 
To my family (Papá, Mamá, Noe, Paulita y María), for making me feel like I never 
left home every time I visit you. 
To all other people who have contributed to this thesis, both scientifically and 
personally: Dr Marie-Christine Jones for access to DLS, the O’Reilly group in 
Warwick, the analytical technicians in our school (Chi, Peter, Allen and Cécile), 
my friends in Chemistry: Dr Para, Edgar and Elsa, and to all the “puteros”! 
Finally, I would like to acknowledge the editorial work done by the Royal Society 
of Chemistry and Elsevier on the published work presented in this thesis. 
 iv 
Table of contents




Instrumentation and analysis parameters 2 
Data interpretation 3 
References and notes 6 
CHAPTER 1 - Polyion complex (PIC) particles: preparation and biomed-
ical applications 
8 
1.1. Article 10 
1.2. Nanotechnology for antimicrobial delivery – PIC nanoparticles 28 
CHAPTER 2 - Enzyme-responsive polyion complex (PIC) nanoparticles 
for the targeted delivery of antimicrobial polymers 
 
40 
2.1. Article 42 
2.2. Supplementary information 49 
2.3. Additional figures 63 
CHAPTER 3 - Elastase-sensitive peptides with higher multivalency form 
more stable polyion complex (PIC) nanoparticles with compromised sus-
ceptibility to enzymatic degradation 
64 
3.1. Article 66 
3.2. Supplementary information 74 
CHAPTER 4 - Preparation and antimicrobial evaluation of polyion com-
plex (PIC) nanoparticles loaded with polymyxin B 
96 
4.1. Article 99 
4.2. Supplementary information 108 
4.3. Composition of commercial polymyxin B 112 
 v 
CHAPTER 5 - Effect of polyelectrolyte strength and degree of polymeri-
sation on the formation, stability and activity of antimicrobial polyion com-
plex (PIC) particles carrying polymyxin B 
117 
5.1. Article 119 


























































































Dynamic Light Scattering (DLS): 
data acquisition and interpretation 
 
Overview 1,2 
DLS is a particle characterisation technique that correlates the fluctuations in the 
amount of light scattered by a particle suspension over time with particle size. 
Colloidal particles undergo Brownian motion as solvent molecules collide into 
them transferring kinetic energy, thus causing the particles to move in random 
directions. As such, the intensity of light scattered by a particle suspension will 
vary with time as particles in Brownian motion exit and enter the illuminated space 
in the sample (i.e. under analysis). As solvent collisions with smaller particles are 
more efficient, smaller particles undergo faster Brownian motion. On this basis, 
DLS correlates the frequency of the fluctuations in the light scattered by a particle 
suspension over time with the diffusion coefficient (D) of the particles – the speed 
at which they move. The calculated value of D can then be transformed into a 
size parameter known as hydrodynamic diameter (DH) using the Stokes-Einstein 
equation (Eq. 1); where KB represents Boltzmann’s constant, T is the absolute 





																			 𝐸𝑞. 1 																																				 
 
The DH of a particle is defined as the diameter of a theoretical sphere that diffuses 
in the same fashion as the particle under analysis (i.e. has the same D). DLS 
therefore gives a theoretical size value for the particles under analysis inferred 
from the speed at which they diffuse. 
 
The analysis of particle size by DLS offers a rapid, controlled and non-destructive 
methodology to probe for differences in nanoparticle formulations and their sta-
bility. For this reason, it has been used throughout this thesis as first characteri-
sation point for the study of nanoparticles. 
 2 
It is not the aim of this overview to introduce the fundamentals of DLS, but rather 
to give a basic understanding of the acquisition and processing of DLS data to 
guide the discussion below. The reader is referred to specialised literature for 
more information about DLS.1-4 
 
Instrumentation and analysis parameters 
All DLS data presented in this thesis was acquired on Zetasizer Nano instruments 
(Malvern Instruments Ltd.), using either models ZS or ZSP as indicated in the 
experimental section of each chapter. All samples described in this thesis were 
analysed under the same conditions regardless of the instrument used: temper-
ature = 37 °C, solvent’s viscosity = 0.6687,5 solvent’s refractive index = 1.330,5 
particles’ refractive index = 1.450,6 particles’ absorption = 0.001,6 measuring an-
gle = 173° (non-invasive backscatter), run duration = 60 s, fixed measurement 
position = 4.65 mm, and automatic attenuation – unless monitoring average scat-
tering intensities (kcps) while studying the enzymatic degradation of nanoparti-
cles, where the attenuator was fixed to the value automatically set by the instru-
ment at the start of the experiments –. 
 
At this stage, it must be noted that NaCl was added to nanoparticle samples for 
physiological stability experiments, which causes an increase in viscosity that 
was not accounted for during DLS analysis. The addition of NaCl to a 154 mM 
concentration should increase the viscosity of the medium by 2.3 %, having a 
negligible effect on its refractive index (0.15 %).7 Therefore, and given the inverse 
correlation between viscosity and DH in the Stokes-Einstein equation (Eq. 1), the 
actual DH values measured in the presence of 154 mM NaCl are 2.3% smaller 
than what is reported in this Thesis. Nevertheless, given that all samples ana-
lysed under these conditions have the same error, thus making the data compa-
rable, and since during physiological stability assays we studied stability trends, 
and not absolute changes in size, the impact of this error in the interpretation of 




Data interpretation 2-4 
Three steps are required to obtain a particle’s DH by DLS: i) First, the instrument 
records the fluctuations in the intensity of light scattered by a particle suspension 
over time. ii) The instrument then produces an autocorrelation function (ACF), or 
correlogram, which is a single exponential decay function for monodisperse par-
ticles that contains information about their diffusion. iii) Finally, the ACF must be 
deconvoluted into a diffusion coefficient using an algorithm. Two main types of 
fits can be used in the deconvolution of ACF curves: Cumulants and non-negative 
least squares (NNLS) algorithms. Care should be taken when choosing a model 
for ACF fitting, as each model has its own limitations and may produce misleading 
results if not suitable for a particular ACF.   
 
The Cumulants algorithm is the ISO recommended interpretation of monomodal 
particle samples and applies a single exponential fit to the ACF. The DH extracted 
by Cumulants is called Z-Average size, and it is the most stable and comparable 
parameter produced by DLS. The Cumulants fit also produces a width parameter 
for the size population known as polydispersity index (PdI), which is dimension-
less and directly proportional to the broadness of the size distribution. The Cu-
mulants fit is hence the standard for DLS interpretation, but it provides no infor-
mation about the modality of the size distribution. As such, the Cumulants algo-
rithm assumes a single particle size family, and is therefore unsuitable for the 
analysis of samples with multiple particle size groups. 
 
On the other hand, NNLS algorithms apply multi-exponential fits to ACFs for the 
extraction of several size populations, thus giving a more complete picture of the 
particle size distribution. There is a range of available NNLS algorithms for DLS 
analysis, all characterised by a different fitting roughness. In practice, the best 
NNLS algorithm to use will depend on the type of sample, the working range of 
the DLS instrument, and most importantly the noise-to-signal ratio in the ACF. 
Regardless of the algorithm, NNLS fits produce a Size-Intensity distribution pro-
portional to the scattering intensity of each particle family, which are Gaussian 
distributions characterised by a mean size value and a standard deviation.  
 4 
All the nanoparticles described in this thesis were analysed using Malvern’s 
Zetasizer software,5 which can simultaneously apply the Cumulants and a NNLS 
fit to ACF curves. Only Malvern’s General Purpose algorithm was used as NNLS 
fit to analyse the particles presented in this thesis, chosen for having an interme-
diate level of roughness with a moderate estimate of noise, which provides an 
average resolution. As such, all samples analysed for this work count with both a 
Z-Average and intensity-weighed mean size, calculated by Cumulants and NNLS 
General Purpose algorithms, respectively (Figure 1). 
 
At this stage, we must clarify that all DH values reported in this thesis corre-
spond to the mean size found in Size-Intensity distributions obtained using 
Malvern’s General Purpose NNLS algorithm, and never indicate the Z-Aver-
age size of the particles. The mean Size-Intensity value was chosen over Z-
Average to report DH for the latter being unsuitable for multimodal samples, which 
appeared during the physiological stability experiments described in this thesis. 
Figure 1 Data obtained by DLS for PIC particles prepared from B-PEI25 and P1SH at a 
[N:COOH] ratio of 1:0.3 (see Chapter 2, Fig 2a). The mean size of Gaussian distribution 
found in the Size-Intensity plot and its standard deviation are reported on the top-right 
area (Peak 1), and were obtained using Malvern’s General Purpose NNLS algorithm. 
In addition, the Z-Average size and PdI obtained by Cumulants are also reported on the 
top-left corner. 
 5 
For this reason, and to keep the parameters of DH analysis constant throughout 
the thesis, Z-Average values were disregarded. All plots describing particle DH 
represent the mean value ± one standard deviation (SD) of the only size 
population found in their Size-Intensity plots obtained by NNLS General 
Purpose analysis. Additionally, a polydispersity index (PdI) is reported in 
the supplementary information of each chapter, which does not correspond 
to that obtained by Cumulants, but was rather obtained by applying the for-







																			 𝐸𝑞. 2 																																				 
 
All PIC nanoparticles reported in this thesis displayed a single Size-Intensity pop-
ulation when analysed by DLS immediately after their preparation. As such, these 
nanomaterials can be accurately described with their mean size ± SD values ob-
tained through NNLS General Purpose analysis. However, during physiological 
stability assays the nanoparticles increased in size, and in some cases, more 
than one Size-Intensity population was fitted by the software (e.g. Chapter 2, Fig. 
S11 or Chapter 4, Fig. 3A-B). This evolution of the size of PIC nanoparticles into 
two or more distinct size populations justifies the choice of NNLS algorithms for 
DLS analysis. 
 
In Chapters 2 and 3, the relative change in the size of PIC nanoparticles under 
simulated physiological conditions is reported as a single size value ± error ver-
sus time (Chapter 2, Fig. 3 and Chapter 3, Fig. 3). The values plotted in these 
graphs correspond to the average DH of three DLS measurements performed on 
the same sample (i.e. technical replicates) ± the SD of this average.  All the sam-
ples studied in these experiments presented a single Size-Intensity population at 
all times, with the exception of one single sample and time point: P1SH at a 1:0.3 
ratio after 1 hour (Chapter 2, Fig. S11); This sample was represented in Fig. 3 of 
that same Chapter only considering its larger size population, assuming the 
 6 
smaller size mode was an intermediate in the process of these nanoparticles be-
coming larger, as suggested by the disappearance of the smaller population over 
time (Chapter 2, Fig. S11). 
 
Finally, the reader should also note that all plots reporting both the DH and ζ-
potential of PIC particles (e.g. Figure 2), indicate the values for these two 
parameters calculated for the same sample, which is denoted by its charge 
ratio (e.g. [N:COOH]) in the X axis. 
 
 
References and notes 
1 Malvern Instruments Ltd., Dynamic Light Scattering: An Introduction in 30 
Minutes, Technical Note Malvern, 2014. 
2 Malvern Instruments Ltd., Dynamic light scattering - common terms defined, 
Whitepaper Malvern, 2014. 
3 Malvern Instruments Ltd., Application of Dynamic Light Scattering (DLS) to 
Protein Therapeutic Formulations: Principles, Measurements and Analysis - 
1. Basic Principles, Whitepaper Malvern, 2014. 
4 Malvern Instruments Ltd., Application of Dynamic Light Scattering (DLS) to 
Protein Therapeutic Formulations: Principles, Measurements and Analysis - 
3. DLS Deconvolution Algorithms, Whitepaper Malvern, 2014. 
Figure 2 Representation of PIC nanoparticle characterisation for different formulations 
(i.e. [N:COOH] values): The two dots contained inside each rectangle represent the DH 
(left axis) and ζ-potential (right axis) of the same sample, denoted by the [N:COOH] value 
enclosed in the same rectangle. This example was taken from Chapter 3, Fig. 2A. 
 7 
5 The solvent’s viscosity and refractive index used for DLS analysis were cal-
culated using the Zetasizer software (v 7.11) by Malvern Instruments Ltd., 
and were the values obtained for a 5 mM tris(hydroxymethyl)aminomethane 
(Tris) solution in water at 37 °C. 
6 Particles’ refractive index and absorption set from the default values given by 
Malvern’s Zetasizer software for protein-based materials.  
7 5 mM Tris in water + 154 mM NaCl showed a calculated viscosity of 0.6840 





Polyion complex (PIC) particles: preparation 
and biomedical applications 
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Overview: In this Chapter, we give an introduction to PIC particles covering their 
composition, their behaviour in solution and the key factors that affect their self-
assembly. In addition, the biomedical applications of PIC particles described in 
the literature are reviewed in the last two sections, gene delivery being the most 
thoroughly described application due to the prevalence of PIC particles in current 
gene therapy research, but also covering the delivery of other charged therapeu-
tics such as proteins and antineoplastics. 
In this thesis, PIC particles were selected as the ideal nanomaterial to prepare 
the target antibiotic vehicles, given the simplicity of their preparation and for being 
a modular system, whose properties can be easily tuned during their assembly 
by using different polyelectrolyte structures and mixtures. As such, PIC particles 
are the common theme in all the Chapters of this thesis, so the parameters de-
scribed in this Chapter that affect their self-assembly and stability help under-
stand and justify the observations described throughout the thesis. Likewise, the 
explanations given in this Chapter about the affinity and binding between oppo-
sitely charged polyelectrolytes guided the modifications of the polyanions ex-
plored in this thesis, and thus the optimisation of the initial PIC particles designed. 
 9 
At the end of this Chapter, the current need for new antimicrobial therapies is 
introduced, covering the current state of the art in polymer-based antimicrobial 
nanotechnologies with a focus on PIC nanoparticles, presenting the recent de-
velopments and challenges ahead in this area. 
 
Contributions: FFT wrote section 1, II wrote sections 2 and 4 and AW and FFT 
wrote section 3 of this review. All authors revised the manuscript and contributed 
to the final version. 
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a b s t r a c t
Oppositely charged polyions can self-assemble in solution to form colloidal polyion
complex (PIC) particles. Such nanomaterials can be loaded with charged therapeutics such
as DNA, drugs or probes for application as novel nanomedicines and chemical sensors to
detect disease markers. A comprehensive discussion of the factors affecting PIC particle
self-assembly and their response to physical and chemical stimuli in solution is described
herein. Finally, a collection of key examples of polyionic nanoparticles for biomedical
applications is discussed to illustrate their behaviour and demonstrate the potential of
PIC nanoparticles in medicine.
! 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Macromolecules carrying multiple charges (a.k.a. polyelectrolytes) are ubiquitous in nature and include nucleic acids,
proteins or polysaccharides. The presence of these charges often dictates the physical properties of these biopolymers,
including their self-assembly or their solubility in physiological environments. More importantly, charge-charge interactions
often mediate relevant biological processes, from the package of DNA around histones [1], to the initial adhesion of microbes
to surfaces and hosts [2]. It is not surprising then that researchers have tried to imitate these important polyionic interac-
tions to develop synthetic systems that can interact with biology. As such, polyionic complexes (PIC), a.k.a. polyelectrolyte
complexes (PECs) [3] or interpolyelectrolyte complexes (IPECs) [4], have been investigated as novel platforms to stabilise and
deliver drugs [5,6], proteins [7,8] or nucleic acids [9–11].
The morphology of the complexes formed depends on the topology of the polyelectrolytes employed and the way these
are assembled. For instance, ionic-hydrophilic block copolymers have been used for the preparation of PIC micelles [12,13]
and PIC vesicles (PICsomes) [14], while the sequential assembly of polyelectrolytes on surfaces and colloidal templates has
been exploited for the preparation of layer-by-layer films [15] and capsules [16] respectively.
In this review we will focus on the preparation and biomedical applications of PIC particles, formed by the neutralisation
of non-stoichiometric mixtures of polyelectrolytes. Other morphologies and their biomedical applications have been
extensively reviewed elsewhere and interested readers are encouraged to read that literature [12–17].
2. Self-assembly of PIC nanoparticles
The preparation of PIC particles was first reported by Fuoss and Sadek in the late 1940’s as a straightforward turbidimetric
study of polyion condensation [18]. Over the last decades, more sophisticated instrumentation has allowed a deeper
http://dx.doi.org/10.1016/j.eurpolymj.2016.06.003
0014-3057/! 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: f.fernandez-trillo@bham.ac.uk (F. Fernandez-Trillo).
European Polymer Journal 81 (2016) 198–215
Contents lists available at ScienceDirect
European Polymer Journal
journal homepage: www.elsevier .com/locate /europol j
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understanding of PIC particle assembly. It is now well established that non-stoichiometric mixtures of oppositely charged
polyions lead to the formation of PIC particles, which consist of a neutral core entrapping 1:1 mixtures of oppositely charged
polymers surrounded by a shell of excess polyion chains (Fig. 1) [19,20]. The charged corona stabilises the coacervate by
repelling other PIC particles in solution. In contrast, stoichiometric mixtures of polyions lead to unstable shell-deficient
PIC particles, which flocculate due to the hydrophobic attraction between neutral coacervates [21,22].
General models rationalise that PIC formation is primarily based on the electrostatic attraction between oppositely
charged polyions [3,18,23,24]. However, it has been demonstrated that the increase in entropy upon counterion release from
polyelectrolytes is the main driving force in PIC particle self-assembly [25,26].
PIC particles are often polydisperse systems with diameters comprised between 10 nm and 1 lm. Particle size is usually
measured from indirect techniques, mainly static and dynamic light scattering, which maintain the integrity of the nanopar-
ticles in solution. Imaging techniques are often used to support the results from light scattering, but it must be noted that in
this case the size of PIC particles can be affected during sample preparation and analysis (especially in the case of drying and
staining) [27].
The self-assembly of PIC particles is a reversible process where nanoparticles coexist in equilibrium with free polyions in
solution (Fig. 1) [26,28]. This dynamic nature of PIC particles inherently compromises their integrity upon dilution and addi-
tion of other charged species, which can cause electrostatic shielding and polyion exchange from these nanomaterials [29].
As a result, the stability of PIC particles can be seriously compromised in biological settings, where high concentrations of
small electrolytes and charged proteins can be found [30]. However, PIC particles can be easily stabilised by cross-linking
of the polyelectrolyte components, minimising this way the exchange with free polymers in solution (see Section 2.7). On
the other hand, the structural damage caused by physiological electrolytes to PIC particles can be beneficial, for example
by increasing the permeability of these nanomaterials thus triggering the release of preloaded cargos [31,32].
Finally, it must be highlighted that only certain polyelectrolytes, mixed under suitable conditions, lead to disperse and
stable PIC particles. Several factors need to be optimised during the formulation of these nanomaterials, in particular molec-
ular weight, concentration and charge density of the polyelectrolytes, pH and ionic strength of the (aqueous) media, or
relative ratio and mixing order of both polyelectrolytes. These parameters are normally interdependent, and have to be
optimised in parallel. Often, stable colloidal PIC particles are therefore prepared at high dilution and low ionic strength, with
an excess of one of the polyions, ideally with weak ionic groups in one of the polymers and a considerable mismatch in their
molecular weights [28,33]. Under different conditions, coacervates separate from solution and coalesce into dense materials
known as compact polyelectrolyte complexes, which have also shown great potential in some biomedical applications such as
synthetic cartilage and enzymatically active biocomposites [34]. To give the reader a deeper understanding of the variables
affecting the complexation of polyelectrolytes, we will now describe how these factors affect PIC particle formation,
explaining their fundamentals and influence on the characteristics of PIC particles.
2.1. Charge density, molecular weight and topology
The binding properties of polyions to other charged species show a strong dependency on the density and number of
charged groups in the polyelectrolyte’s structure. As a result of the cooperative nature of polyelectrolyte binding, polymers
with higher charge densities show stronger avidity for charged substrates.
The simplest way to increase charge density is to increase the polyelectrolyte’s molecular weight. Given the partially
entangled conformation of polymers in solution [35], higher molecular weight leads to larger polyelectrolyte cores. This
molecular weight dependency was nicely demonstrated by Fischer et al. with a comparative study on the preparation of
DNA polyplexes from poly(diallyldimethylammonium chloride) (PDADMA) of four different molecular weights
(5–244 KDa) [36]. Higher charge densities, corresponding to higher PDADMA molecular weights, formed more stable
polyplexes as indicated by the higher tolerance of complexed DNA to ultrasonication and enzymatic digestion. The authors
explained these results from the possible rearrangement of polyions with low charge densities, weakly bound to the
polyplex. It has been rationalised that the stability of PIC particles is influenced by the number of charged groups per
Fig. 1. Representation of polyion self-assembly into PIC nanoparticles and subsequent counterion release (charged spheres). In this example, the excess of
polycation in the mixture leads to the formation of a neutral core surrounded by the excess of cationic material.
I. Insua et al. / European Polymer Journal 81 (2016) 198–215 199
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polymer chain (i.e. multivalency), and above an ‘upper critical length’ polyions can form stable complexes [37]. Nonetheless,
a significant difference in the molecular weight of the polyions is often required for the colloidal stability of PIC particles [38].
Alternatively, charge density can be ‘‘diluted” by the addition of neutral monomers to the polyelectrolyte. Dautzenberg
et al. evaluated the formation and stability of PIC particles from poly(styrene sulfonate) (PSS) and four PDADMA copolymers
of comparable molecular weight, which contained increasing amounts (0, 25, 47 and 76%) of neutral N-methyl-N-
vinylacetamide (p(DADMA)-co-(NMVA)) [21]. As the NMVA content in the copolymers increased (lower charge density),
bigger particles formed with up to twice the size of those from 100% PDADMA. In addition, the destabilising effect of NaCl
on PIC particles was significantly reduced with higher PDADMA contents. Nanoparticles prepared from pure PDADMA
remained unaffected by concentrations of NaCl twice higher than those causing particles with weaker charge densities to
swell. These results reinforce the direct correlation between charge density and the binding avidity of polyelectrolytes.
The topology of polyelectrolytes can also have a profound effect on their charge density. It is known that branched and
dendritic polyelectrolytes show increased binding affinities to charged surfaces compared to their linear analogues [24]. This
effect is due to the higher spatial density of monomers in branched structures and thus results in an increase in avidity. As
such, branched polyelectrolytes can electrostatically cross-link multiple counter-polyion chains, creating tighter polymeric
networks [39]. Dunlap et al. showed that, under the same conditions, whereas linear poly(ethylene imine) (PEI) formed
polyplexes of 20–50 nm and left uncomplexed DNA fragments, branched PEI of similar molecular weight fully condensed
DNA and formed significantly larger complexes (100–200 nm), probably due to interparticular condensation as a result of
its higher binding capacity than linear PEI [40]. The high charge density of branched PEI is responsible for its remarkable
capacity to tightly complex DNA, thus setting a benchmark for other transfection agents [41].
Although challenging due to their low charge density, PIC particles have been successfully prepared from small molecules
bearing certain motifs that aid the nucleation process. For example, the Behr group studied the self-assembly of small
cationic detergents with DNA into lipidic polyplexes or lipoplexes [42]. The authors prepared a dimerisable detergent
(C14CO) that could condense DNA despite its low charge density, aided by the hydrophobic interactions between aliphatic
chains (Fig. 2). After the initial aggregation of C14CO with plasmid DNA, the oxidative dimerisation of this detergent into
(C14CO)2 caused a drop in its critical micellar concentration, thus increasing the packing and stability of the complex.
2.2. Polyelectrolyte concentration
Recent work by Starchenco and co-workers rationalised the mechanism of PIC particle self-assembly as the sequential
nucleation of polyions as primary molecular complexes, which then aggregate into colloidal complexes (Fig. 3A) [44]. The
authors explained this behaviour by the increase in the Debye length of the nanoparticles as they become bigger, thus
creating more intense repulsive electrostatics between the ‘‘secondary” complexes. In this article, the size of PIC particles
from PSS/PDADMA was studied as a function of polyelectrolyte concentration. As shown in Fig. 3B, a linear correlation
was found between polymer concentration and complex size, regardless of the molecular weight of PSS used
(4.6–1132 KDa). It was observed that, at the lowest concentration of polyions tested (50 lM), particles with a radius of
23 and 50 nm were found when using the lowest and highest PSS molecular weight, respectively. As observed here, the size
of PIC particles can be finely tuned by a combination of polyion length and concentration.
Often during the assembly of PIC particles, high concentrations of the starting polyelectrolytes lead to the formation of
micron-sized complexes with poor colloidal stability [28,33]. As a consequence, it can be generalised that dispersed PIC
nanoparticles can only form in polyelectrolyte mixtures below a critical concentration, above which the system flocculates
or precipitates (ca. <1 mg/mL) [3]. The concentration restraints during PIC particle preparation can be a limitation when it is
required to prepare concentrated dispersions of these complexes. Nevertheless, Müller et al. showed that it was possible to
Fig. 2. Plasmid DNA is condensed into monomolecular particles with a thiol-containing cationic detergent. The particles are stabilised by spontaneous
oxidation of the detergent. Adapted from Ref. [43].
200 I. Insua et al. / European Polymer Journal 81 (2016) 198–215
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centrifuge and redisperse PIC particles from PDADMA and poly(maleic acid-alt-a-methylstyrene), and that consecutive cen-
trifugation cycles allowed to refine the polydispersity of the complexes, ultimately achieving monomodal size distributions
without affecting their initial size during the process [45]. Ouyang et al. found the same effect on PSS/PDADMA complexes of
318 nm in diameter and polydispersity index (PDI) = 0.38 [46]. After one centrifugation, the size of these complexes dropped
to 250 nm, showing a much narrower size distribution (PDI = 0.06). After a second centrifugation, particle size was
maintained (251 nm) and the PDI could be narrowed further down to 0.04. As such, it is possible to obtain concentrated
PIC particles dispersions by centrifugation, although the final morphology of the complexes may be affected.
2.3. pH
From a biomedical perspective, polyelectrolytes can be classified as either weak or strong whether they undergo partial or
full ionisation at physiological pH, respectively [35]. As a result, as opposed to strong polyelectrolytes, the charge density of
weak polyions will strongly depend on the pH found in different tissues and organelles (4.5–7.4) [47]. Variations within this
pH range can lead to significant changes in polyelectrolyte binding and PIC particle stability from the loss or gain of valency
(i.e. charges per molecule). A good example of this pH-responsive behaviour of polyion complexes was reported by Han et al.,
where the authors studied a system comprised of a strong poly(allylamine) (PAH) and weak poly(acrylic acid) (PAA)
polyelectrolytes at different pHs (Fig. 4) [48]. At low pH (2.0–2.5), PAA is only deprotonated to a small extent so that more
swollen and loose complexes are formed as a consequence of its low charge density. However, at higher pH (3.5–5.5) the PAA
chains are more ionised, and thus more packed complexes form with PAH from an increase in the number of electrostatic
cross-links.
Weak polyions can therefore change their (de)protonation degree and charge density with changes in biological pH. In
addition, the different chemical environments and sterics result in a range of different pKa values for the same monomer
in different positions of the polyelectrolyte. This is specially the case for branched polymers and translates into broad
Fig. 3. (A) Schematic presentation of the processes occurring during mixing of polyelectrolytes and formation of PIC particles. (B) PIC particle size (rm)
dependence on polyelectrolyte concentration (CPEL) using different PSS molecular weight with PDADMA. n!/n+ = 1.5. Adapted with permission from Ref.
[44].
Fig. 4. Illustration of the pH-dependent binding between poly(allylamine hydrochloride) and poly(acrylic acid). Adapted from Ref. [48].
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buffering capacity. As such, the changes in pH found in different physiological settings have been exploited to trigger the
release of drugs and DNA from PIC particles by changes in the ionisation of the complexing polyions. A classic example of
this behaviour is the so-called ‘proton sponge’ effect displayed by PEI, which allows polyplexes to escape the acidic
endosome after cellular uptake (Section 3). For example, branched PEI (B-PEI) displays a wide buffering window from
approximately pH 2–10 regardless of its molecular weight (Fig. 5) [49,50], and can therefore buffer the influx of protons into
the endosome, ultimately causing an increase in osmotic pressure that causes the organelle to burst and release the polyplex
into the cytosol.
Other relevant examples of pH-responsive PIC particles include enzyme [51] and antimicrobial [52] delivery, which are
based on nanoparticle disassembly or swelling upon polyion (de)protonation, respectively. As shown by Sui et al., reversible
pH-responsive PIC particles can be prepared by blending a weak polyacid (PAA) with a strong polybase (PDADMA) into
PDADMA-co-PAA [53]. Mixing this copolymer with PSS at pH 4.1 led to the formation of PIC particles, which dissolved at
pH > 5.7 due to the deprotonation of PAA in the copolymer and subsequent repulsion between PSS and this partially anionic
copolymer. When the solution was acidified again, PIC particles reformed at pH 4.5–5.5, thus demonstrating the reversibility
of the process.
Similarly, the pH chosen to self-assemble two polyions can affect their charge densities and therefore the final character-
istics of the resulting nanoparticles. Feng et al. studied the effect of pH during PIC particle preparation from carboxymethyl
cellulose (CMetC) and poly(vinylamine) (PVAm) in different proportions (i.e. mixing ratios) [22]. The authors observed a
mixing ratio-dependent effect that originated more positive or negative PIC particles from more acidic or basic pH,
respectively (Fig. 6A). This result is consistent with the higher (de)protonation of polyions at higher pH values. However,
lower CMetC (weaker polyion) contents led to less pronounced changes in PIC particle charge, as expected from the higher
pH-sensitivity of CMetC over PVAm. Size-wise, although an increase in one unit of pH led to a 4-fold increase in size at a
10/20 ratio (CMetC/PVAm), PIC particle size was not very sensitive to changes in pH above their isoelectric points (Fig. 6B).
2.4. Ionic strength
The addition of small electrolytes can aid the self-assembly of PIC particles by shielding the intramolecular charge
repulsions of polyions, thus increasing the flexibility of the polymers and their ability to self-assemble [54]. On the other
hand, high salt concentrations can lead to strong electrostatic screening between polyelectrolytes and quench the nucleation
of PIC particles [3]. Therefore, the ionic strength of the medium must be carefully selected to successfully assemble PIC
particles.
To this end, Dautzenberg et al. studied the effect of NaCl during the assembly of PIC particles from PSS and p(DADMA)-co-
(NMVA) copolymers (Fig. 7A–C) [21]. In general, the sizes of PIC particles decreased when the polyions were mixed in the
presence of higher concentrations of NaCl, probably due to a better packing of more flexible polyelectrolytes. The difference
Fig. 5. Buffering capacity of branched poly(ethylene imine) (B-PEI). (A) Titration of 25 KDa B-PEI acidified with HCl (also titrated in the same concentration
as control). (B) Potentiometric titration of 0.5, 1.1 and 12 KDa B-PEIs, compared to that of ethanolamine as control for a small monofunctional amine.
Adapted from Refs. [49,50].
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in sizes found between copolymers in water decreased in 10 mM NaCl, ultimately forming particles of the same size at
100 mM NaCl. Overall, polyions with stronger charge densities (i.e. lower NMVA content) were more tolerant to NaCl during
PIC particle preparation. The authors also observed that particles prepared in pure water swelled from 100 nm up to 1 lm in
diameter when exposed to NaCl once assembled (Fig. 7D) [21]. This post-assembly effect of NaCl is due to its infiltration
within the core of the complexes, thus neutralising the electrostatic cross-links between polyelectrolytes and subsequently
Fig. 6. Effect of pH during preparation of PIC particles from carboxymethyl cellulose (CMetC) and poly(vinylamine) (PVAm) at different mixing ratios
(labels: CMetC/PVAm) on their charge (A) and size (B). Adapted from Ref. [22].
Fig. 7. Size of PIC particles prepared from PSS and p(DADMA)-co-(NMVA) with 100% (d), 75% (.), 53% (N) and 24% (r) of PDADMA (i.e. cationic) content in
pure water (A), 10 mM (B) and 100 mM (C) NaCl. (D) Swelling of PIC particles prepared in water at increasing NaCl concentrations. Adapted from Ref. [21].
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causing pre-formed complexes to swell. In later work, the same group studied the kinetics and mechanism of salt-induced
PIC particle swelling by static light scattering [19]. The authors observed that the increase in size occurs quickly after the
addition of NaCl (ca. < 10 min) as a combination of swelling and subsequent aggregation of swollen complexes. Once again,
copolymers with higher charge density (i.e. PDADMA content) showed improved tolerance to the swelling effect caused by
NaCl due to their higher avidity, requiring in some cases twice the concentration of NaCl to swell compared to less charged
copolymers (Fig. 7D).
Wang et al. studied the effect of increasing concentrations of KBr on complexes made from PDADMA and PSS [55]. The
authors found dense PIC particles in the absence of KBr, which started swelling with increasing amounts of KBr (doping)
due to electrostatic shielding. Higher KBr concentrations (ca. 1.5 M) led to disperse colloidal PIC particles, which dissolved
above 1.8 M KBr. It is noteworthy that the dilution of concentrated KBr samples with water re-assembled PIC particles,
evidencing the reversible nature of salt doping effects. Also the high molecular weights of the polymers used in this study
(200 KDa PSS and 400 KDa PDADMA) required higher concentrations of KBr to shield such multivalent interactions and
trigger these phase transitions. It is expected that PIC particles made from shorter polyelectrolytes with weaker avidities
would require lower doping levels to undergo similar structural changes: e.g. particles in Fig. 7D from 66 KDa PSS and
100 KDa PDADMA required only about 0.35 M NaCl to swell twice in size.
Physiological electrolytes may also cause swelling and compromise the functionality and stability of PIC particles in bio-
logical settings. If salt-tolerant particles are required, the assembled chains of polyelectrolytes can be covalently cross-linked
to maintain the complex together even after the weaker electrostatic forces have been screened with salt [56,57].
Nevertheless, the swelling of PIC particles with small electrolytes has been exploited to release entrapped drugs from within
the complex as a result of its increased permeability [31,32].
2.5. Mixing ratio
This is the proportion of positive and negative charges in the polyelectrolytes that are mixed. Mixing ratio not only affects
the final size and charge of PIC particles, but also their biological activity. It must be pointed out that, as seen in the previous
section, the degree of ionisation of polyelectrolytes is pH-dependent, and therefore the ‘effective’ mixing ratio will vary for
the same mixture of polyions at different pH values [6]. Mixing ratios are denoted regardless of the pH by the fraction or
percentage of acidic and basic monomers in solution (e.g. ‘N:P’ ratios are normally used in polyplex formulations to indicate
the ‘N’ number of amine monomers complexed with ‘P’ phosphate groups in the nucleic acid).
Non-stoichiometric mixing ratios are necessary to give colloidal PIC particles a stabilising shell of the polyion in excess
(Fig. 1). On this basis, and as long as other variables such as pH, ionic strength and the polyions structure are kept constant,
the absolute value and variations in f potential of PIC particles can be predicted from changes in their mixing ratio.
Given the strong dependency of numerous PIC particle systems on mixing ratio, it is always necessary to assess a range of
ratios in order to draw consistent and representative conclusions of PIC particle behaviour. The range of mixing ratios usually
evaluated varies from very positive-rich mixtures in polyplexes (up to 50 in N:P) [58] whereas other systems just explore
values closer to equimolarity (e.g. 0.2–1.8 [59] or 0.5–2.0 [4] in n!/n+).
A thorough mixing ratio study was conducted by Drogoz et al., who studied the formation of PIC particles from mixtures
of chitosan and dextran sulphate two orders magnitude above and below equimolarity [54]. Firstly, the authors observed
that the absolute charge of the complex was that of the polyion in excess. Secondly, the size of the nanoparticles was dis-
tributed in three ranges of [NH3+]/[SO4!] ratios: above 10 (420 nm), between 10 and 1 (250 nm) and below 1 (200 nm)
(Fig. 8). The authors explained these three particle sizes from the different nucleation mechanisms taking place in excess
of either polymer. At mixing ratios close to neutrality, unstable complexes formed and flocculated. The authors also found
that at high excess of either polyion (5-fold and above), more than 70% of this polymer stays uncomplexed free in solution.
Comparing this to other examples in the literature, whereas mixing ratio has the same effect on the f potential for other PIC
Fig. 8. Average hydrodynamic diameter of PIC particles from chitosan and dextran sulphate at different [NH3+]/[SO4!] ratios. Adapted from Ref. [54].
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particles, its influence in size is not consistent and seems to be influenced by other variables (e.g. molecular weight and
strength of the polyions) [56,60,61].
2.6. Mixing order
The order in which polyelectrolytes are mixed together will dictate what polyion is in excess at the beginning of the
assembling process. It is very important to notice that for the preparation of non-stoichiometric PIC particles, for example
at [n+/n!] = 2, if the polyanion is added to the polycation there is always an excess of positive charge in the complexes,
and repulsive forces between them help maintain colloidal stability. However, if the same polymer mixture is prepared
by addition of polycation (in excess) to polyanion, the negative charge of the initial coacervates will reach a neutral value
half way through the addition of polycation. As a result, neutral particles can flocculate if polyelectrolytes are mixed in
the wrong order. Therefore, it is suggested that the polyion in deficit is added to the one in excess, which results in different
nucleation dynamics depending on the nature of the polyelectrolytes [54].
The effects of the order of addition become evident when titrating mixing ratios of polyelectrolytes. For example,
Dautzenberg et al. observed that the mixing order of polyelectrolytes not only affected the size of the resulting nanoparticles,
causing up to a 2-fold change in size, but also the stability of these complexes to NaCl, probably due to a different packing of
the polymers [21]. Other studies in the literature have shown rather dissimilar results, finding either a strong dependency or
almost negligible effect on the final morphology of the complexes [3,62]. Discrepancies between studies should be attributed
to the effects of other variables (e.g. molecular weight and polyion strength), and therefore each case should be evaluated
individually.
2.7. PIC particle cross-linking
PIC nanoparticles, in particular those prepared from low molecular weight polymers, partially ionised polyions or when
exposed to high salt concentrations, are in equilibrium with free polyions in solution [28]. This equilibrium can be displaced
towards the release of polyions from the nanoparticles in circumstances that weaken their electrostatic binding (Fig. 1). As a
result, PIC particles can disassemble when diluted or exposed to other charged species [29].
Alternatively, the stability of PIC particles can be greatly enhanced by covalently cross-linking the complexed polyions,
thus preventing the detachment of polymer chains from the nanoparticle. In essence, cross-linking works by ‘polymerising’
polyelectrolyte chains, thus dramatically increasing the overall molecular weight of the polymer and consequently its bind-
ing affinity (see Section 2.1.). To this end, polyelectrolytes can be cross-linked during or after particle self-assembly, depend-
ing on whether the polyelectrolytes carry cross-linking groups in their structure or if a third component that cross-links pre-
assembled complexes is added to the system, respectively.
An illustrative example of PIC particle post-cross-linking was reported by Hsieh et al., who prepared nanoparticles from
poly(acrylic acid) (PAA) and poly(L-lysine) (PLL) cross-linked at their core and/or shell [56]. The amines or carboxylic acids
found in the shell of these PIC particles were cross-linked using genipin or cystamine, respectively. PLL chains in the core
were cross-linked by silica deposition using orthosilicic acid as precursor. These cross-linked particles tolerated up to a
150-fold dilution.
The post-assembly cross-linking of PIC particles has the advantage of not requiring the functionalisation of the polymers
with cross-linking groups, thus being applicable to virtually any polyelectrolyte with the suitable functional group (e.g. ami-
nes or carboxylic acids in the case described). Given the wide application of polyamines in gene delivery, other amine cross-
linkers have been applied to polyplex preparation, including glutaraldehyde [63], citric acid [64], carboximidates and N-
hydroxysuccinimide esters [65].
Alternatively, functionalised polyelectrolytes allow to cross-link the PIC particles as they are formed. By far, the most used
group to functionalise and cross-link the polyions in PIC particles are thiols, given their mild reaction conditions and rever-
sible cross-link into disulphide bridges. For example, McKenzie et al. described the preparation of disulphide cross-linked
polyplexes from plasmid DNA and PLL decorated with cysteine residues [66]. Polyplexes prepared from a difunctional
Cys-PLL-Cys (Fig. 9A) did not show an increase in stability compared to a control PLL of the same molecular weight. However,
when three cysteines were incorporated to PLL (Cys-PLL-Cys-PLL-Cys), the resulting nanoparticles tolerated 2.5 times the
maximum concentration of salts Cys-PLL-Cys polyplexes could stand. The effect of this extra cysteine can be explained from
the cross-linking of PLL into branched structures (Fig. 9B), leading to a higher charge density as discussed in Section 2.1.
However, a dramatic increase in particle size was observed for Cys-PLL-Cys-PLL-Cys polyplexes (1.4 lm) compared to the
analogous Cys-PLL-Cys (52 nm), an effect the authors attributed to inter-particle cross-linking by the former polyion. When
exposed to reducing conditions, the disulphide cross-links in these polyplexes broke, leading to a sudden loss in the PLL’s
apparent molecular weight and thus triggering the disassembly of the nanoparticle and DNA release (Fig. 9A).
As described, cross-linking short polyions through labile cross-linkers allows the preparation of stimuli-responsive PIC
particles, which can breakdown in the presence of agents that degrade such labile linkers, thus causing a sudden loss of
charge density and binding affinity between polyions. As so, the reducing conditions found in the cytosol have been
exploited to trigger intracellular drug and nucleic acid delivery through the reduction of disulphide cross-linked vehicles
[67].
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Our group combined two different labile linkers to develop dual-stimuli-responsive PIC particles, which disassembled in
the presence of enzymes and reducing agents [68]. In this system, PEI was complexed with a short anionic peptide bearing
two cysteine residues to allow their oxidative cross-linking (P1SH, Fig. 10), endowing PIC particles with redox-responsive
properties like those in the previous example. In addition, the amino acid sequence in those peptides could be specifically
degraded by a bacterial elastase (LasB), thus providing another point to cleave the cross-linked peptide chains and ultimately
the PIC particles themselves.
As just illustrated, the integrity of the cross-links in such particles is of paramount importance to ensure particle stability,
but at the same time, labile cross-links can be designed as sacrificial groups that trigger particle disassembly and release of
their cargo when cleaved.
3. Application of PIC particles in gene therapy
Possibly the widest application of PIC particles in biomedicine has been the non-viral delivery of nucleic acids [69–71].
Nucleic acids are strong polyelectrolytes that present one negative charge per nucleotide at neutral pH. This high negative
charge density in nucleic acids poses a big challenge when trying to deliver them across negatively charged cellular and
nuclear membranes to enable gene therapy (Fig. 11). Moreover, foreign nucleic acids will be readily degraded in biological
environments, thus compromising their half-life in vitro and in vivo. In natural systems, this is often compensated by pro-
Fig. 9. (A) Formation of cysteine-containing PLL/plasmid DNA nanoparticles. The thiol groups in cysteine (Cys) residues can cross-link PLL molecules
through oxidation into disulphide bridges. These cross-links will break under reducing conditions (e.g. human cytosol), destabilising the nanoparticles and
thus allowing the release of DNA. (B) Schematic representation of the linear and branched cross-linking of these polyplexes that forms upon oxidation of PLL
containing two and three Cys residues, respectively. Adapted from Ref. [66].
Fig. 10. LasB-triggered disassembly of responsive PIC particles prepared from branched PEI (red polycation) and anionic peptide P1SH. The cysteine residues
allowed peptide cross-link (in yellow) and the -GLA- amino acid sequence in the peptide (dark blue) hydrolysed by LasB. Adapted from Ref. [68]. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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tecting the nucleic acids by complexation with positively charged proteins, such as histones [72], or within viral capsids [73].
Not surprisingly, the gene delivery community has placed its attention into mimicking nature’s strategy using positively
charged polyelectrolytes [69–71].
Often, it has been argued that PIC particles made with nucleic acids and cationic polyelectrolytes, a.k.a. polyplexes, can
address some of the limitations observed in viral gene delivery (i.e. immunogenicity and scalability). However, as will be
explained in the following sections, synthetic polyplexes developed so far for non-viral delivery have been found to have
separate issues on their own that need to be overcome including stability, toxicity, cellular uptake, endosomal escape and
for nucleic acids, delivery to the nuclei.
3.1. Toxicity
Most of the polymers employed in non-viral gene delivery are strong cationic polyelectrolytes, such as PEI, PLL or chi-
tosan. However, it has been long established that most cationic polymers are cytotoxic and cause damage to cells [74,75].
The mechanism for this toxicity though is still widely debated. PEI and other polycations can cause disruption of lipidic bilay-
ers. This is thought to be driven by electrostatic (and possibly hydrophobic) interactions between the negatively charged lipi-
dic membrane and these polyelectrolytes, which often results in depolarisation of the membrane and the formation of pores
[76]. This is further evidenced by the release of cytosolic contents such as lactate dehydrogenase [77].
Yet it is also postulated that cationic polyelectrolytes (i.e. PEI) can trigger cell apoptosis [78] by release of cytochrome c
from mitochondria upon intracellular interaction of the polymer with organelles. A similar interaction may be expected here
where interaction of PEI with the anionic organelle membrane leads to pore formation and release of the organelle contents
[79]. Even if these two mechanisms are working in isolation or cooperatively towards cell death, this toxicity does need to be
considered in the future development of PIC particles for gene delivery.
Several strategies have been reported to minimise the toxicity of these polyplexes. For instance, Zhao et al. found that
inclusion of chitosan in a PEI/DNA complex significantly reduced the toxicity when compared to the PEI/DNA complex alone
[58]. The authors argued that this decrease in cytotoxicity was related to the lower toxicity of chitosan, due to its increased
steric hindrance and charge shielding ability.
The simplest way to reduce toxicity of cationic polymers though is reducing the molecular weight of the polyelectrolyte
used [74,80]. In depth studies have demonstrated that both PEI and PLL have lower toxicity when the molecular weight is
reduced [77,80]. However, as mentioned in the previous section, reducing the molecular weight of the polyelectrolytes has a
dramatic effect on the stability of the PIC particles formed. With gene delivery, this is often translated into a lower transfec-
tion efficiency [81]. As such, much work has focused in the application of cross-linkers that can reversibly increase the
polyelectrolyte molecular weight (Section 2.7) [82].
Fig. 11. Schematic representation of the uptake of polyplexes into cells, illustrating the different challenges faced in the development of PIC particles for
gene delivery.
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Disulphide formation has often been the preferred method of cross-linking. Of relevance to the delivery of nucleic acids is
the ability of these cross-linkers to be cleaved in the presence of reducing media. This is what happens upon entry into the
cell, where the concentration of glutathione is increased up to 100-fold when compared to the extracellular environment
[83]. Using this strategy, transfection efficiencies with cross-linked 1.8 KDa PEI are equivalent to that of PIC particles made
with 25 KDa PEI [84].
It was thought until recently that dendritic polymers could have reduced toxicity compared to linear analogues [85,86].
However a comprehensive study had not been completed on a comparison of the toxicities of linear vs. dendritic PLL. Klok
et al. found that dendritic equivalents of PLL and hyper-branched versions have improved transfection efficiencies compared
to their linear analogues (Fig. 12) [87]. However, when carrying out a toxicity study it was found that dendritic and hyper-
branched PLL has greater cytotoxicity compared to an equivalently sized linear analogue [88]. The key factors that were
highlighted for this increase in cytotoxicity were osmotic shock and cell membrane damage. Osmotic shock causes initial
disruption to cells which leads to a marked decrease in EC50 values for dendritic and hyper-branched structures. Whilst
the membrane disruption characteristics show that the dendritic and hyper-branched structures also cause cell apoptosis
due to their interaction with mitochondria which leads to the release of cytochrome c as discussed previously [78]. What
is interesting to note for the studies by Kadlecova is that although there is increased cytotoxicity seen for both the dendritic
and hyper-branched forms of PLL, the hyper-branched structure is much simpler in its synthesis however, and has almost
identical effects in terms of toxicity and transfection.
Finally, it is worth mentioning that conjugation of PEG to one of the polyelectrolytes is another strategy to minimise
toxicity of the polyplexes. This strategy results in the formation of PIC micelles [12,13], which are stabilised by a PEGylated
corona. It is thought that the reduction in toxicity is achieved thanks to the formation of a hydration shell around the
polymer reducing interactions with the membrane during delivery [89,90]. This strategy has been used successfully, for
example when coupled to PEI, to reduce the toxicity of the polyplexes used for in vitro delivery studies [91,92]. Further
examples can be found in specialised reviews [12,13,93].
3.2. Transfection efficiency
The other key factor to consider when developing a non-viral gene delivery vehicle is transfection efficiency. How effi-
ciently a gene is expressed (or knocked-down for small interfering RNA) is normally a consequence of several factors, includ-
ing circulation half-life, uptake, endosomal escape and transfer to the nuclei in the case of plasmid DNA [94,95].
Representative examples of the effect of these factors over transfection efficiency will be described in the next sections.
3.2.1. Circulation half-life
As mentioned earlier, nucleic acids when introduced in biological environment (i.e. the body or serum) have a very poor
circulation half-life. This is because nucleic acids are quickly degraded by extracellular nucleases, which are responsible for
the elimination of any foreign genetic material [96]. Complexation of these nucleic acids in polyplexes is thus the first step to
improve their circulation half-life. Normally, polycations are added in excess and nucleic acids are therefore contained
within the neutral core, protected this way by the cationic corona from the action of these nucleases.
However, as described in the first section, the stability of the formed polyplexes would strongly depend on several factors.
Assuming that parameters such as concentration, pH and ionic strength can be maintained constant when comparing
different polyelectrolytes in the same application, factors such as polyelectrolyte molecular weight and topology dictate
the stability of the formed polyplexes. This is often the case when comparing pDNA (normally over one thousand base pairs)
to oligonucleotides such as siRNA, which have a significantly smaller size (20–25 base pairs). This was nicely illustrated by
Fig. 12. Comparison of the percentage of eGFP positive cells obtained after 24 h transfection with polylysine analogues of comparable molecular weight.
Reproduced from [87].
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Seymour et al. with their reducible polycation-based system [97]. While a weight ratio of 5:1 (N:P 1.9:1) was enough to
achieve complete retention of pDNA in an agarose gel, weight ratios of up to 20 (N:P 7.5:1) were insufficient to fully
conjugate all of the siRNA employed. As expected, polyplex formation in the absence of other salts, resulted in full conjuga-
tion of the siRNA with the 20:1 weight ratios, highlighting once again the role of ionic strength in the formation and stability
of PIC particles.
Another explanation for the reduced half-life of polyplexes is opsonisation, whereby soluble proteins (opsonins) bind to
the surface of complexes leading to their targeted destruction through phagocytosis and subsequent removal from
circulation [98]. This process is thought to occur due to the non-specific binding of serum proteins to the positively charged
polymer [99].
It is commonly understood that circulation half-life of drugs in the body can be improved through the attachment of
hydrophilic residues [100]. Again, in gene delivery this is often achieved through the introduction of PEG residues within
the polymeric structure [12,13,89,93]. Kissel et al. evaluated the effect of PEGylation on the pharmacokinetic study carried
in vivo of PEI polyplexes [101]. Less than 1%/mL of the injected dose (ID) was detected after 2 hours, following injection of
polyplexes containing 1.5 lg of pDNA. However, over 20% was still in blood when these polyplexes were PEGylated (Fig. 13).
3.2.2. Uptake
To be transfected, polyplexes have to be efficiently taken up by the cell. This is normally facilitated by the excess of
positive charge in the corona of the polyplex. This has been demonstrated for instance using PEI [102], where transfection
efficiency was increased with increasing amount of PEI (i.e. N/P ratios) (Fig. 14). However, increasing PEI content in the PIC
particle also resulted in an increase in cytotoxicity, and thus transfection efficiency eventually was compromised.
Alternatively targeting ligands, that are recognised by the cell surface thus promoting binding and endocytosis of the
polyplexes, can be employed to improve transfection efficiency. For instance, Behr and co-workers demonstrated that the
use of glycosylated or RGD PEI derivatives, resulted in higher transfection efficiencies when compared to polyplexes
prepared with ‘‘pristine” PEI [103]. Typically, transfection efficiencies increased by 1–2 orders of magnitude for the targeted
PIC particles. Other targeting ligands such as antibodies, folic acid or prostaglandins have been [104] or could be employed
[105] in the development of targeted polyplexes.
3.2.3. Endosomal escape
One of the key barriers that polyplexes need to overcome to mediate efficient transfection is the endosome. Uptake nor-
mally results in polyplexes trapped within the endosome, where the cell will try to either digest them or recycle the contents
[106]. However, nucleic acids need to be transported into the cytosol, where they can carry out their function (e.g. siRNA) or
be further trafficked into the nuclei (pDNA).
Part of the reason why PEI has garnered more interest than other polycations is because of its inherent ability to act as a
buffer within the endosome (Fig. 5), causing osmotic swelling and potential leakage of the endosome contents (‘The proton
sponge effect’) [107]. Behr et al. hypothesised that the reason for endosomal rupture is the protonation of the amine groups
in PEI which subsequently leads to an influx of Cl! counterions and water. It is known that protons can be pumped against
the electrochemical gradient that is formed due to the presence of ATPase V type pumps, which helps support this hypoth-
esis [108]. This influx then leads to osmotic swelling, eventually rupturing the endosome.
However, there is still debate as to whether this is the method for endosomal release. Benjaminsen et al. recently found
that PEI complexes reach lysosomes to a high extent, but do not cause a change in lysosomal pH [49]. Instead Benjaminsen
states that the failure of the ‘proton sponge model’ is that the swelling caused by this process would not cause rupture. This
opinion directly contradicts computational calculations that have been made which support the proton sponge effect
Fig. 13. Pharmacokinetic study showing the effect of PEGylation on circulation half-life as measured by radioactive isotopes 125I. Reproduced from [101].
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[109,110]. Here it has been modelled that osmotic swelling is highly dependent on polymer pKa as protonation needs to be
caused by entry into the endosome.
In line with Benjaminsen’s observations, some have argued that the sponge effect should result in an increase in pH [111].
However this doesn’t have to be the case because if enough ATP is present in the cytosol, the lysosome could counteract PEI
buffering with the influx of more protons. Even if the pH is not changed, osmotic swelling should occur upon the recruitment
of protons to neutralise the endosomal pH. An alternative explanation to the proton sponge effect is that complexes are
released from lysosomes through small membrane damage, and that the lysosome in fact stays intact [112]. Overall,
whatever the actual mechanism of this ‘sponge effect’ polymers with high buffering capacity, such as PEI have a beneficial
effect on endosomal escape.
Other common polycations such as PLL lack this ability to facilitate endosomal escape [113]. One way of addressing this
issue is through the introduction of lysosomotropic reagents such as chloroquine to DNA polyplexes [114]. This method has
successfully increased the transfection efficiency of PLL based delivery systems [115,116]. However, it has been found that
these lysosomotropic reagents are also toxic [117], possibly due to the increased membrane permeabilisation that they cause
[118]. As such, this method of delivery is limited in its application.
An alternative strategy to improve endosomal escape is through the introduction of histidine residues to the polymer
[119]. It is thought that histidine can successfully increase transfection efficiency acting again as a proton sponge within
the polyplex. This is due to the imidazole present in histidine that has a pKa of !6 meaning that in slightly acidic media
of the endosome it is will become protonated. Evidence for the success of this process can be seen through its escape from
negatively charged liposomes in acidic media [120].
Niidome et al. employed this strategy to prepare novel PLL dendrimers. While no beneficial effect was observed for his-
tidine capped-PLL polyplexes prepared at neutral pH, a significant increase in their transfection efficiency was observed
when the histidine containing polyplexes where prepared at pH 5. The authors demonstrated that the latter polyplexes were
more stable upon incubation in buffer, demonstrating the role of histidine protonation in polyplex formation.
4. Other biomedical applications of PIC particles
While gene delivery has been possibly the field where PIC particles have made the biggest impact, there are other areas
where these particles have had a significant contribution [17]. In this section we will describe representative examples of the
application of PIC particles for the encapsulation and delivery of proteins and small molecules. Interested readers are
referred to specialised reviews [5–8].
Proteins and polysaccharides are other biomacromolecules that often present multiple charges in their backbone.
Chitosan, alginate or hyaluronic acid are charged polysaccharides that have been commonly employed as biocompatible
polyelectrolytes in the formulation of PIC particles [121]. They often play a passive/structural role, although their enzymatic
degradation has been exploited to trigger the release of encapsulated materials [122]. Proteins however tend to have an
active role and researchers have been interested in the application of PIC particles to protect and deliver ‘functional’ proteins
such as enzymes [51]. When compared to polysaccharides and nucleic acids, proteins normally present a lower density of
charges. Moreover, the presence of positively and negatively charged residues complicates things further and the overall
charge of the protein will depend on their isoelectric point and the pH at which the formulation has to be prepared.
A good example of the challenges in the preparation of PIC particles from functional proteins has been described by
Giannotti et al., who prepared PIC particles from N-trimethyl chitosan and the anionic lysosomal enzyme a-galactosidase
A (a-GalA) [51]. These complexes only formed at pH values between 7.3 and 8.0, whereas no particles formed at pH
Fig. 14. Transfection efficiency (A) of PEI/pDNA increases with increasing equivalents of PEI, and has its maximum at 9–13.5 equivalents when toxicity
towards 3T3 cells (B) starts to be apparent. Reproduced from [102].
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4.5–5.5, as expected from the neutralisation of a-GalA at pH values close to its isoelectric point (pI ! 5.7). Similarly, these
nanoparticles disassembled at acidic pH, which could be exploited to trigger enzyme release inside the lysosomes, where
the authors found these complexes are accumulated in vitro. Although a fair 62% of the initial activity of a-GalA was retained
after complexation into PIC particles, there is still room for improving this result and develop complexes that do not affect
the complexed enzyme and maintain its full activity.
More challenging is the encapsulation of small peptides, which very often have few charge residues and thus weak charge
densities, making their complexation into PIC particles particularly unfavourable (see Section 2.1). This is the case for insulin,
whose molecular weight is almost 15 times smaller than that of the enzyme a-GalA discussed above. Despite this intrinsic
limitation, Jintapattanakit et al. complexed acidic insulin with N-trimethyl chitosan into PIC particles, which they evaluated
as potential vehicles for the oral delivery of insulin [123]. The oral administration of peptides is limited by their degradation
by endogenous proteases. However, the authors found that the stability of free insulin to digestion by trypsin, used as a
model gastric protease, was almost doubled when the peptide was complexed inside PIC particles. However, a recent report
highlights how despite increasing the stability to proteases, it is the release and subsequent absorption of insulin in the gas-
trointestinal tract that currently limits the efficacy of PIC particles for this application [124]. Alternative ways of stabilising
and administering such complexes must be explored to circumvent this limitation.
The complexation of short charged peptides with very few charges can be facilitated by the addition of cross-linkers,
which allow peptide polymerisation and thus increase their binding affinity (Section 2.7). Our group has recently exploited
this strategy for the targeted delivery of antimicrobial PEI (Fig. 10) [68]. Incorporation of cysteine residues into a short pep-
tide sequence allowed self-assembly with as little as three negative charges per peptide, otherwise not possible. The peptides
were designed to incorporate a short sequence that was cleavable by Pseudomonas aeruginosa’s elastase. When these
nanoparticles were exposed to the bacterial elastase, the cross-linked peptides were hydrolysed, reducing this way charge
density, thus causing particles to disassemble and release the PEI. PIC particles were stable in the absence of this bacterial
elastase, and were not able to elicit an antimicrobial effect on a P. aeruginosamutant that was unable to produce this enzyme.
More challenging is the complexation of singly charged molecules such as the chemotherapeutic doxorubicin (DOX) that
presents a single amine group in its structure. Hsieh et al. prepared DOX-loaded PIC particle system from PAA/PLL blends,
cross-linking the amines in PLL with genipin [56]. In this paper, the authors illustrate how the release kinetics of DOX (or
virtually any loaded drug) could be tuned by changing the degree of cross-linking, thus changing the permeability of the
nanoparticles. In addition, the weak polyelectrolyte PAA endowed PIC particles with pH-responsive behaviour, accelerating
the release of DOX under acidic conditions.
Alternatively, PIC particles can have a ‘‘passive” role in the delivery of small molecules, where electrostatic interactions
between the polyelectrolytes and the drug to be delivered do not play a role in the encapsulation. For example, non-ionic
chemotherapeutic paclitaxel has been encapsulated into the hydrophobic core of PIC particles prepared in this case from
hyaluronic acid and styrylpyridinium [125]. The UV cross-linking of styrylpyridinium in the core stabilised the assembled
particle, which was then loaded with paclitaxel. High cellular uptake and sustained drug release were achieved from these
nanoparticles, proving the utility of PIC particles as vehicles for non-charged drugs as well.
5. Conclusions and outlook
This review gives an overview of the preparation and biomedical applications of PIC particles. A comprehensive descrip-
tion of the factors affecting PIC particle self-assembly has been included: Here, we highlight the effect of polyelectrolyte
molecular weight, concentration and charge density, pH and ionic strength of the (aqueous) media, or relative ratio and mix-
ing order of both polyelectrolytes, in particle preparation and stability. Understanding how to optimise PIC particle prepa-
ration and stability is of key importance for the development of biomedical application of these nanomaterials.
Representative examples of their application in gene, protein and small molecule delivery have been included to illustrate
the particular challenges faced in these applications, in particular the issues surrounding toxicity and transfection efficiency
in gene delivery. Selected examples of the use of targeted and responsive delivery systems have been included, which high-
light how polymer synthesis and characterisation can allow the field of PIC particles, as well as other polyelectrolyte complex
nanomaterials, to eventually develop truly mimics of natural delivery systems.
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1.2. Nanotechnology for antimicrobial delivery – PIC nanoparticles 
Since the first clinical application of antibiotics in the 1940s, microorganisms have 
developed different mechanisms to resist and survive the antimicrobial agents we 
use.1,2 The development of drug resistance is a normal evolutionary process for 
microorganisms, but it has been accelerated by the excessive use and misuse of 
antibiotics.3 The current situation is very concerning: in developed countries 
worldwide, over 50% of diagnosed infections by common human pathogens dis-
play resistance to commonly used antibiotics,3 and an estimated impact of €1.5 
billion and 25,000 deaths is caused by multidrug-resistant infections in the Euro-
pean Union yearly.4 In this regard, the limited pipeline of new antibiotics cannot 
supply new drugs to treat these drug-resistant infections at the required pace,3,5,6 
and alternative methods to tackle infection that go beyond the conventional use 
of antibiotics are urgently needed.5 Two main alternative antimicrobial therapies 
are currently under study: 
i) The clinical use of new antimicrobial agents with novel mechanisms of action 
(e.g. antibodies, enzymes, bacteriophages, nucleic acids, etc.).6  
ii) The formulation of ‘traditional’ antibiotics as nanomaterials for drug delivery, to 
improve their therapeutic action via three complimentary mechanisms:7-9 
a. Targeted delivery and accumulation at infected sites for higher efficiency. 
b. Controlled and/or burst release to maintain antimicrobial drug concentra-
tions for long periods, thus maximising treatment efficacy and preventing 
sub-antimicrobial drug levels to induce antimicrobial resistance. 
c. Reduced toxicity to the host by minimising undesired drug-cell interac-
tions. 
 
This Thesis aims to expand the knowledge on the second approach by exploring 
PIC nanoparticles as drug delivery vehicles for antimicrobial therapy. Therefore, 
and to put this Thesis in context, an overview of the recent developments in anti-
microbial nanotherapy will be now discussed, pointing out the current challenges 
in the field and highlighting the examples of PIC nanoparticles for antimicrobial 
delivery. Given the focus of this Thesis on polymeric PIC nanoparticles, and due 
to the extensive literature about antimicrobial nanotechnology, only polymer-
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based nanomaterials for antibiotic delivery will be covered in this section. The 
reader is referred to specialised reviews for information about other nanomateri-
als explored in antimicrobial application.7-10 
 
Considering polymers in solution as structurally disorganised nanomaterials, 
these are the simplest platforms that have been exploited for antimicrobial deliv-
ery though nanotechnology. The covalent conjugation of polymers to antibiotics 
has shown to protect these drugs from inactivation by bacterial enzymes (i.e. β-
lactamases) and thus overcome this mechanism of drug resistance in bacteria.11 
These antibiotic-polymer conjugates showed up to 20 times higher stability to β-
lactamases and up to 350 times higher antimicrobial activity against β-lactamase-
producing bacteria than pristine penicillin. The linker group connecting the poly-
mer and antibiotic is critical to preserve the activity of the drug,12 and these poly-
mers can be modified with additional antimicrobial functionalities to work syner-
gistically with the conjugated antibiotics.11 Alternatively, polymers with pending 
cationic groups have also shown to electrostatically bind anionic β-lactam antibi-
otics (e.g. penicillin), also protecting them from degradation by bacterial β-lac-
tamases, and releasing the complexed antibiotic in the presence of bacteria by 
exchange of polymer-drug pairs with anionic bacterial components.13 This ion-
paired conjugate was later improved by incorporation of a boronic acid derivative 
in the polymer to bind sugars present in bacterial membranes, which translated 
into a 2 to 3-fold increase in the antimicrobial activity of penicillin with low toxicity 
to the host.14 Ferguson et al. covalently conjugated the antimicrobial peptide col-
istin, only used as last resort against multidrug-resistant infections due to its high 
toxicity,15 with the polysaccharide dextrin to drive the accumulation of macromo-
lecular colistin-polymer conjugates at infected parts of the body displaying en-
hanced permeability as a result of inflammation (Figure 15).16 Once accumulated 
in the infected area, dextrin can be broken down by endogenous amylase to re-
lease and trigger the antimicrobial activity of colistin. Not only this drug-polymer 
system displayed comparable antimicrobial activity to that of the free drug, but 
also its in vivo evaluation on a murine model revealed prolonged circulation times 
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and decreased toxicity for the polymer-conjugated colistin, showing great po-
tential for a clinical translation. 
 
Polymers, and derivatives thereof, have also been assembled into structurally-
organised nanomaterials (e.g. particles, vesicles, etc.) for application as antibiotic 
delivery systems. These systems present void spaces or compartments where 
drug can be loaded to minimise undesired interactions between antimicrobial 
agents and healthy host cells, and engineered to tune the release of drug and 
thus control the antimicrobial action. Nanogels are one example of such materi-
als, which consist of highly hydrated and cross-linked polymeric particles that can 
release pre-loaded drugs that diffuse out of their soft and porous structure. The 
sustained release of pre-loaded antibiotics from nanogels can be controlled by 
Figure 15 Proposed mechanism of action of dextrin-colistin conjugates: Poly-
mer-drug conjugates cannot diffuse into normal tissue due to the tight junctions 
between endothelial cells around it, and only small amounts of free colistin, 
formed by systemic degradation of drug-polymer conjugates, can reach this 
non-infected tissue (a); Enhanced permeability between endothelial cells 
around infected tissue allow dextrin-polymer conjugates to diffuse through, 
where dextrin can be degraded by host amylase and thus the antimicrobial 
activity of colistin can be regenerated (b). Reprinted with permission from ref-
erence [16]. Copyright 2014 American Chemical Society. 
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adjusting the cross-linking degree of these materials, allowing to tune the antimi-
crobial effect while also reducing the toxicity of loaded antibiotics to host cells.17,18 
Nanogels loaded with the topical disinfectant chlorhexidine have also been ap-
plied as surface coatings for sustained antimicrobial release, with potential appli-
cations as coatings for biomedical devices (e.g. catheters) or in food packaging 
to prevent bacterial colonisation.19 
 
Another type of polymeric nanomaterial studied in antibiotic delivery are den-
drimers, which are hyperbranched polymers emerging from a central core that 
originate soft globular-shape nanoparticles.20 Dendrimers have been used to in-
crease the water solubility of hydrophobic antibiotics such as erythromycin21 or 
sulfamethoxazole22, working as soluble depots of drug that increased the antimi-
crobial activity of the drug by 2 to 3-fold.21 Jain and co-workers developed a 
sugar-coated dendrimer loaded with the antifungal and antiprotozoal drug am-
photericin B, which allowed the targeted uptake of these dendrimers by macro-
phages infected with the intracellular protozoan Leishmania donovani.23 Macro-
phage targeting was achieved by recognition of sugar groups on the surface of 
dendrimers by membrane receptors expressed by these cells. These amphoteri-
cin B-loaded dendrimers not only displayed lower toxicity towards red blood cells 
and macrophages in vitro than two commercial formulations of this drug, including 
a nano-formulation of amphotericin B as liposomes (AmBisome®), but also 
showed superior anti-leishmanial activity ex vivo and in vivo than any of these 
two commercial preparations (Figure 16). This example is particularly relevant to 
demonstrate the potential of drug delivery to improve the activity of traditional 
antibiotics against intracellular pathogens (e.g. viruses, fungi, protozoa and bac-
teria), which are intrinsically more difficult to kill due to the limited access and 
accumulation of antibiotic inside host cells.8,24,25 
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Polymers can also be assembled into hollow nanocapsules that contain an in-
ternal liquid compartment where drugs can be incorporated. For example, cap-
sules loaded with the antibiotic imipenem and the adjuvant cilastatin, which pro-
tects imipenem from proteolytic inactivation, were prepared by coating an emul-
sified mixture of these drugs with poly(Ɛ-caprolactone).26 These capsules dis-
played up to a 250-fold increase in antimicrobial activity against drug-resistant 
bacteria than the free drugs, protected imipenem from degradation by bacterial 
carbapenemases, reduced the formation of bacterial biofilms by ca. 75%, and 
sustained the release of imipenem for at least 7 days. This work is an excellent 
example of the potential of nanotechnology to redesign ‘obsolete’ antibiotics (i.e. 
Figure 16 Structure of anti-leishmanial dendrimers, consisting of hyper-
branched poly(propylene imine) cores conjugated with a glycosylated peptide 
(MDP) to give sugar-coated dendrimers, to be loaded with amphotericin B (A). 
Decreased hemolytic toxicity of ‘empty’ (MdPPI) and amphotericin B-loaded 
(MdPPIA) dendrimers compared to commercial formulations of amphotericin 
B (Fungizone® and AmBisome®) (B). Increased ex vivo (IC50) and in vivo (in-
hibition of parasites) anti-leishmanial activity of MdPPIA compared to commer-
cial amphotericin B fomulations (C). Reprinted from reference [23], with per-
mission from Elsevier. 
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those to which bacteria have become resistant) into medicines with superior ther-
apeutic performance. 
 
Despite the study of PIC particles for drug delivery has mostly been focused on 
gene therapy, there are a few examples in the literature that apply these poly-
meric nanoparticles as vehicles for antimicrobial agents. Brocchini et al. com-
plexed the monocationic antimicrobial amphotericin B with poly(glutamic acid) 
into PIC nanoparticles for evaluation against L. donovani.27 It was found that 
these PIC nanoparticles could release amphotericin B in a sustained manner and 
kill this pathogen inside infected macrophages in vitro with the same activity as 
the free drug, while displaying less toxicity towards red blood and epithelial cells. 
As such, PIC particles increased the therapeutic index of amphotericin B (i.e. the 
ratio between the active and toxic dose of a drug), potentially allowing to admin-
ister higher doses of drug for stronger antimicrobial effects. Müller and collabora-
tors developed a three-component PIC nanoparticle system consisting of poly(L-
lysine) and cellulose sulphate complexes, which were then loaded with the anti-
biotic rifampicin to be applied as bone implant coatings for sustained drug re-
lease.28 The authors demonstrated the influence of the pH and ionic strength of 
the medium on the release kinetics of rifampicin from films prepared by deposition 
of these PIC nanoparticles, but there was no antimicrobial evaluation reported on 
the article to assess the therapeutic potential of these films. Another ternary PIC 
nanoparticle for antimicrobial delivery was reported by Cerchiara et al., prepared 
by simultaneous aggregation of chitosan, carboxymethylcellulose and the antibi-
otic vamcomycin.29 These PIC nanoparticles were designed for drug delivery in 
the colon to tackle gastrointestinal pathogens, so the dose of vancomycin that 
reaches the colon after oral administration can be increased by loading the drug 
inside these nanoparticles, thus protecting vancomycin from acidic degradation 
in the stomach and systemic absorption in the intestine. The sustained release of 
drug was affected by the polyelectrolyte composition of the PIC particles and the 
medium’s pH. One formulation was identified that displayed significantly faster 
drug release at pH 7.4 than 2.0, which respectively simulate the conditions in the 
colon and stomach – ideal for a localised drug release in the colon. Although this 
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particular formulation showed the same antimicrobial activity against Staphylo-
coccus aureus than free vancomycin in vitro, it could surpass the traditional use 
of this antibiotic by preventing side effects derived from systemic drug absorption, 
and protect this peptide-based antibiotic from degradation by gastric proteases. 
Cavallaro and co-workers developed PIC nanoparticles by complexation of the 
cationic antimicrobial tobramycin with polypeptides bearing grafted glucuronic 
acid groups, and evaluated the formulation, drug release and antimicrobial action 
of these complexes towards their application in pulmonary infections (Figure 
17).30 It was found that these PIC nanoparticles could release of tobramycin in a 
controlled fashion, with ca. 50% of the loaded drug released after 6 hours. The 
authors further coated these tobramycin-loaded PIC nanoparticles with mannitol 
through spray-drying, which led to microparticles of 1-4 µm in diameter from the 
Figure 17 Top: Structures of polyelectrolytes assembled to form tobramycin-
loaded PIC nanoparticles. Bottom: Scanning electron micrograph of the micro-
particles obtained after coating tobramycin-loaded PIC nanoparticles with 
mannitol (A, scale bar = 10 µm) and their size distribution (B); Release of to-
bramycin from mannitol-coated microparticles (MPs-E) across synthetic mem-
branes mimicking lung mucus, compared to the diffusion of the free drug (C); 
Anti-biofilm action against Pseudomonas aeruginosa of mannitol-coated mi-
croparticles (MPs-E), PIC nanoparticles (T:P 1:5 w/w) and free drug (tobramy-
cin), measured as living bacterial cells within the biofilms (CFU/mL) after treat-
ment, compared to an untreated control (P.a. 15442) (D). Adapted from refer-
ence [30] with permission of Future Medicine Ltd. 
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original tobramycin/polypeptide complexes of ca. 90 nm. Mannitol was incorpo-
rated due to its capacity to overcome the mucus barrier of the lungs, known to 
cause an influx of water in the mucus that facilitates drug diffusion. Mannitol-
coated PIC microparticles showed faster initial tobramycin release across syn-
thetic membranes mimicking the lung mucus found in cystic fibrosis patients, and 
lower toxicity against human bronchial cells than the free drug. Furthermore, 
these microparticles displayed stronger antimicrobial activity and prevented the 
formation of bacterial biofilms more efficiently than the free drug and parent PIC 
nanoparticles in vitro. This novel ‘nano-to-micro’ approach to further re-formulate 
PIC nanoparticles arises as a powerful tool to develop new-generation antimicro-
bial therapies, capable of not only improving the activity and compatibility of tra-
ditional antibiotics, but also modify the properties of the biological environment to 
the advantage of the therapeutic action. 
 
In conclusion, polymeric nanomaterials are versatile platforms to access new an-
timicrobial therapies from known drugs, allowing to control the distribution, action 
and stability of antibiotics in the body. Examples have been presented in this 
section to point out the application of different polymer-based antimicrobial deliv-
ery systems to direct the accumulation of drug to infected sites (e.g. inflamed 
tissue16 and host macrophages23), protect antibiotics from inactivation by drug-
resistant bacteria,11,13,26 to sustain the release – and therefore the action – of drug 
from different nanomaterials,17,18,26-29 and to reduce the toxicity of antimicrobial 
agents towards host cells.14,16-18,23,27,30 As such, antimicrobial delivery through 
nanotechnology opens new avenues to ‘recycle’ traditional antibiotics into more 
powerful and efficient nanomedicines to fight the rise of antimicrobial resistance. 
From all the polymer-based nanomaterials presented in this section, PIC nano-
particles offer important advantages that make them particularly attractive for 
drug delivery: 
• Accessibility – PIC nanoparticles can be assembled from affordable commer-
cial polymers under mild conditions using very simple lab equipment. 
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• Scalability – From a production and commercialisation point of view, the as-
sembly of PIC nanoparticles is a one-step process of easier scaling than more 
complex nanomaterials that require several formulation steps. 
• Versatility – Not only PIC particles allow the formulation of virtually any 
charged small molecule and/or polymer into defined nanomaterials, but also 
their properties and structure can be adjusted in many different ways: 
o The size, charge, colloidal stability and drug loading of PIC nanoparticles 
can be varied by simply adjusting the mixing ratio of polyelectrolytes.31 
o Structural variations of the polymeric component(s) of PIC nanoparticles 
(e.g. Mw, pKa and topology) can be exploited to access particles with differ-
ent stabilities and drug release kinetics.31 
o Similarly, the addition of cross-linking agents to PIC nanoparticles offers an-
other simple method to control particle stability and therapeutic action as a 
function of cross-linking degree.31 
o Being held together by (relatively) weak intermolecular forces, the structure 
of PIC particles changes with biological conditions that weaken/strengthen 
these interactions (e.g. pH29 and osmotic pressure), which can translate into 
changes in drug release in response to different biological media. 
o PIC particles that disassemble in the presence of specific stimuli (e.g. re-
ducing agents and enzymes) can be obtained by using sacrificial polyelec-
trolytes degradable by these stimuli.31 
o As discussed in this section, PIC particles also offer the possibility of tuning 
their structure and therapeutic action post-assembly, for example being ap-
plied as surface coatings28 or undergoing a second complexation with addi-
tional polyelectrolytes to give PIC microparticles.30 
 
Despite the recent advances in nanotechnology for antimicrobial delivery, im-
portant challenges remain to be addressed for the development of optimal anti-
microbial nanotherapies. Firstly, bacteria-targeted nanomaterials capable of spe-
cifically directing antibiotics to the focus of infection would allow maximum drug 
efficiency with minimum toxicity to the host. To this end, nanomaterials capable 
of sensing and responding to bacteria – or their markers – with high specificity 
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are necessary, so bacteria can trigger the release of drug upon encounter with 
the nanoparticles. Secondly, nanomaterials capable of burst-releasing high 
doses of antibiotic would provide a powerful means to attack pathogens with high 
antimicrobial levels on a first exposure. As such, burst drug release can be ap-
plied as initial therapy to deliver a strong antimicrobial effect to the pathogens, to 
then apply sustained drug release to maintain therapeutic antimicrobial levels 
over long periods with low toxicity. Ideally, both bacteria-targeting and burst re-
lease should be combined for localised and potent antimicrobial nanotherapies. 
Finally, a third challenge is directly linked to PIC nanoparticles, and it is their ex-
ploration for biomedical applications beyond gene delivery. The literature outside 
this application is scarce – in particular for the delivery of traditional antibiotics, 
the developments over the last five years are limited to the paragraph dedicated 
to PIC nanoparticles in this section –, and gene delivery has clearly dominated 
the therapeutic research of PIC nanoparticles over the last decades. 
 
It is the aim of this Thesis to address some of these challenges and explore PIC 
nanoparticles for antimicrobial drug delivery, studying their rational design, self-
assembly, structural characterisation, stability, bacteria-triggered disassembly, 
and antimicrobial action. As such, this Thesis may not only contribute to the de-
velopment of powerful tools to tackle the current threat of antimicrobial re-
sistance, but it will also create valuable knowledge to understand the properties 
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Overview: In this Chapter, we present a novel PIC particle system for the tar-
geted delivery of antimicrobial polymers in the presence of pathogenic Pseudo-
monas aeruginosa. These nanoparticles consist of a cationic antimicrobial poly-
mer and an anionic peptide, which can be degraded by elastase B (LasB), a vir-
ulent factor released by P. aeruginosa during infection. Thus, the peptide com-
ponent can be hydrolysed by LasB, triggering the disassembly of the nanoparticle 
and release of the antimicrobial on-demand. 
The first milestone in this thesis was to develop these bacteria-targeted nanopar-
ticles, as they would have the most useful properties for a potential clinical appli-
cation: the localised delivery of antimicrobials in the presence of bacteria could 
not only improve the efficiency of the antimicrobials by accumulating them in bac-
terial niches, but also avoid any toxic effects derived from their unspecific inter-
action with healthy organs. Since, as explained in Chapter 1, large and highly 
multivalent polyelectrolytes can assemble PIC nanoparticles more easily, we de-
cided to start our investigations exploring an antimicrobial polymer, poly(ethylene 
imine) (PEI), as an inexpensive model to develop these nanomaterials. 
 41 
This paper covers the study of the antimicrobial properties of a number of PEIs, 
the optimisation of the peptide sequence, the distinct characteristics and physio-
logical stability of different particle formulations, and the specific enzyme-respon-
sive and antimicrobial properties of these PIC particles. 
These nanoparticles displayed a remarkable enzyme specificity, being degraded 
by bacterial and not a human elastase used as control, and displayed strain-spe-
cific antimicrobial properties only towards a pathogenic strain of P. aeruginosa 
and not a non-virulent mutant (i.e. LasB-deficient). The capacity of these nano-
particles to vectorise the activity of antimicrobial polymers opens up a new op-
portunity to develop more efficient therapies and fight multidrug resistance. 
 
Contributions: All authors contributed to the experimental set-up and dis- 
cussed the results. II and FFT designed the nanoparticle synthesis and charac-
terisation; and II, FFT and AMK designed the microbiological assays. EL and ZZ 
designed and performed the AFM experiments. II carried out all other experi-
ments. II and FFT analysed the data and wrote the paper, with all other authors 
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Enzyme-responsive polyion complex (PIC)
nanoparticles for the targeted delivery of
antimicrobial polymers†
Ignacio Insua,a Evangelos Liamas,b Zhenyu Zhang,b Anna F. A. Peacock,a
Anne Marie Krachlerc,d and Francisco Fernandez-Trillo*a,d
Here we present new enzyme-responsive polyion complex (PIC) nanoparticles prepared from antimicro-
bial poly(ethylene imine) and an anionic enzyme-responsive peptide targeting Pseudomonas aerugino-
sa’s elastase. The synthetic conditions used to prepare these nanomaterials allowed us to optimise
particle size and charge, and their stability under physiological conditions. We demonstrate that these
enzyme responsive PIC nanoparticles are selectively degraded in the presence of P. aeruginosa elastase
without being affected by other endogenous elastases. This enzyme-responsive PIC particle can exert an elas-
tase-specific antimicrobial effect against P. aeruginosa without affecting non-pathogenic strains of these bac-
teria. These targeted enzyme-responsive PIC nanoparticles constitute a novel platform for the delivery of
antimicrobial peptides and polymers, and can be a powerful tool in the current race against antimicrobial
resistance.
Introduction
There is an increasing concern with the emergence of
microbial strains that can resist the action of current
antimicrobials.1–3 As evidenced over the last decades, the
limited pipeline of new antibiotics cannot cope with this
increasing number of resistant microbes,4–6 and new anti-
microbial strategies are needed that go beyond the development
of new drugs.7,8 One such strategy is the re-evaluation of drug
candidates, which have been discarded due to toxicity and side
effects. This is the case for antimicrobial peptides,9–11 that are
amongst the few last-resort treatments against multidrug
resistant strains.12,13
Despite being powerful antimicrobial agents, the wide-
spread use of antimicrobial peptides in the clinic is limited by
their inactivation by serum proteases, toxicity to eukaryotic
cells and high production cost.9–11 The positively-charged
amphiphilic structure of antimicrobial peptides is responsible
for damaging bacterial membranes and cytosol components,
resulting in a fast and multi-target antimicrobial action with
broad spectra, but also in toxicity to the host.9–11 Polymeric
mimics of these peptides have been developed as an affordable
alternative with increased protease stability and selectivity for
prokaryotic cells. However, the clinical application of these
polymer mimics is compromised by poor bioavailability,
limited diffusion in tissues, polyelectrolyte complexation with
negatively charged microbial peptidoglycans and extracellular
polymers, and insufficient toxicological characterisation.14,15
Further strategies to improve the therapeutic profile of anti-
microbial peptides and mimics include masking of the
positive charge.16 However this often results in a reduced
antimicrobial activity as a consequence of slow or incomplete
cleavage of the masking group.
Less explored has been the use of controlled (and ideally
targeted) delivery when optimising antimicrobial therapeutic
profile.17,18 However, this is a very attractive alternative to
improve the medical profile of current antimicrobials: strat-
egies that can deliver antimicrobials at the site of infection can
minimise off-target effects such as toxicity or the emergence of
reservoirs of microbial resistance genes in non-pathogenic
strains such as commensal bacteria.5
Towards this end, here we present a new targeted enzyme-
responsive nanoparticle that selectively delivers antimicrobial
polymers in the presence of Pseudomonas aeruginosa, whose
infections are very hard to treat.19 In our system, the toxicity of
cationic antimicrobial poly(ethylene imine) (PEI) was mini-
mised through polyelectrolyte complexation with an anionic
peptide, to form well-defined polyion complex (PIC) nano-
particles (Scheme 1). We demonstrate that our synthetic
†Electronic supplementary information (ESI) available: Peptide synthesis,
further details of PIC nanoparticle characterisation and full data from micro-
biology assays. See DOI: 10.1039/c6py00146g
aSchool of Chemistry, University of Birmingham, B15 2TT Birmingham, UK
bSchool of Chemical Engineering, University of Birmingham, B15 2TT Birmingham,
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cSchool of Biosciences, University of Birmingham, B15 2TT Birmingham, UK
dInstitute of Microbiology and Infection, University of Birmingham, B15 2TT
Birmingham, UK. E-mail: f.fernandez-trillo@bham.ac.uk
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approach is highly modular, letting us tune particle size and
charge, and the stability of the PIC nanoparticles under
physiological conditions. By introducing a P. aeruginosa’s
elastase (LasB) cleavable sequence into our anionic peptide,
PIC nanoparticles could be degraded in the presence of this
P. aeruginosa’s virulence factor,20,21 and more importantly,
remained unchanged when treated with human leucocyte elas-
tase (HLE), a human elastase secreted at the site of infection.
Finally, we demonstrate that these enzyme-responsive PIC
nanoparticles have a targeted antimicrobial effect against
P. aeruginosa and that this antimicrobial effect is not observed




Enzymes (Pseudomonas aeruginosa Elastase (LasB): EC
3.4.24.26 and Human Leucocyte Elastase (HLE): EC 3.4.21.37)
were purchased from Merck Millipore. Branched poly(ethylene
imine) 25 kDa average molecular weight (B-PEI25), 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid (HEPES), Luria Bertani
(LB) broth (Miller) and Dulbecco’s modified eagle medium
(DMEM) were bought from Sigma-Aldrich®. Fluorescamine
and dimethylsulphoxide (DMSO) were purchased from Acros
Organics™. Ethylenediaminetetraacetic acid (EDTA) was pur-
chased from Alfa Aesar®. Nylon 0.45 µm syringe filters were
purchased from Camlab. P. aeruginosa strains were kindly
donated by Suzanne M. J. Fleiszig. We studied PAO1V as a
pathogenic strain and a deletion strain of lasA and lasB genes
of PAO1V was used as LasB-negative control (ΔlasAB).22 Live/
Dead® BacLight™ viability kit was purchased from Thermo
Fisher Scientific Inc.
Instrumentation
Dynamic light scattering (DLS) and ζ-potential measurements
were carried out in a Zetasizer Nano ZS (Malvern Instruments
Ltd) stabilised at 37 °C. DLS was read at 173° (backscattering)
for 60 seconds in triplicate and ζ-potentials were recorded 30
times at 140 V. A FLUOstar Omega (BMGLabtech Gmbh)
microplate reader was used to measure fluorescamine reac-
tions. Atomic force microscopy (AFM) measurements were
carried out in 5 mM HEPES buffer at pH 7.4 with intermittent
contact mode, using a NanoWizard® II (JPK Instruments Ltd)
fitted with SiNi cantilevers (BudgetSensors®) with a spring
constant of 0.27 N m−1. PIC particle size was measured from
AFM images with ImageJ software (version 1.48v). FACS was
performed on an Attune® Acoustic Focusing Cytometer
(Applied Biosystems™) measuring 10 000 events per sample.
BacLight™ fluorescent dyes were excited at 488 nm and emis-
sion was read at 515–545 and 640 nm for green and red
probes, respectively.
Enzymatic degradation – fluorescamine assay
Stock solutions of peptide (1 mM) or succinyl casein (0.5 mg
mL−1) were prepared in 2.5 mM Na2B4O7 buffer at pH 8.0 with
10 mM CaCl2 and 10% DMSO. 125 µL of these substrate solu-
tions were added to a 96-well black-walled microplate and
mixed with 125 µL of the same buffer without DMSO, contain-
ing 0.6 µg of enzyme (LasB or HLE). Solutions of enzymes and
substrates alone were prepared as blanks. Every sample was
prepared in triplicate. The microplate was incubated at 37 °C
for 4 hours under orbital shaking. After 4 hours, 50 µL of
0.1 M ethylenediaminetetraacetic acid (EDTA) in water at pH
8.0 were added to each well to quench all enzymatic activity.23
Then, each sample was mixed in a 1 : 1 volume with a 1 mM
solution of fluorescamine24 in methanol. The microplate was
incubated at 37 °C under orbital shaking for 30 minutes. After
this time, fluorescence was measured exciting at 355 nm and
reading the emission at 460 ± 10 nm.
Preparation of PIC nanoparticles
For nanoparticles prepared at a 1 : 0.3 N : COOH ratio (defined
as the ratio between amines in PEI and carboxylic acids in the
peptides), stock solutions of B-PEI25 (2.5 mM in amines) and
Ac-C-E-GLA-E-C-OH (P1SH) (0.25 mM) in 5 mM 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer at
pH 7.4 were prepared. Then, both solutions were filtered and
mixed drop-wise under stirring. The reaction mixture was
stirred at room temperature for 24 hours open to air to allow
Scheme 1 Assembly and oxidative cross-linking of PIC nanoparticles from P1SH (Ac-C-E-GLA-E-C-OH) and antimicrobial branched PEI. Degra-
dation of PIC nanoparticles by LasB and subsequent PEI release.
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thiol oxidation with atmospheric oxygen. PIC nanoparticles
prepared at different N : COOH ratios were obtained by chan-
ging the concentration of peptide stock solution and mixing
with 2.5 mM B-PEI25 following the same protocol (Table S2†).
After 24 hours, samples were analysed directly by DLS and
ζ-potential without prior filtration.
Enzymatic degradation of PIC nanoparticles
1 mL of PIC nanoparticles prepared at 1 : 0.3 N : COOH ratio
was incubated at 37 °C with 50 µL (5 µg) of LasB in 2.5 mM
Na2B4O7 buffer at pH 8.0. As controls, PIC nanoparticles were
incubated under the same conditions with HLE (5 µg) or
Na2B4O7 buffer to assess the enzymatic specificity and effect of
salts in the buffer, respectively. Each sample was prepared in
triplicate from three different batches of PIC nanoparticles.
DLS data was acquired over time (1–4 hours). The number of
amines was monitored after 4 hours of incubation as
described before (fluorescamine assay).
Antimicrobial activity of PIC nanoparticles
1 mL aliquots of P. aeruginosa PAO1V and ΔlasAB cultures in
LB broth (OD600 = 1.0) were centrifuged and resuspended in
1 mL of DMEM. These samples were incubated at 37 °C for
6 hours under orbital shaking to allow LasB production. After
this time, samples were centrifuged and half of the super-
natant replaced with the same volume of 5 mM HEPES buffer
at pH 7.4 (live control), PIC nanoparticles (prepared at a 1 : 0.3
N : COOH ratio as described above) and 1.25 mM B-PEI25 in
5 mM HEPES buffer at pH 7.4. A dead control was also prepared
by replacing all the supernatant after centrifugation with 70%
v/v aqueous 2-propanol. Samples were resuspended and incu-
bated at 37 °C under orbital shaking. Each sample was prepared
in triplicate. Every hour, 200 µL of each sample were taken and
the rest was kept shaking at 37 °C. These 200 µL aliquots were
incubated in the dark for 10 minutes with 1 µL of a 10-fold
diluted 1 : 1 mixture of BacLight™ probes in DMEM. Dead
control samples had to be centrifuged and resuspended in assay
buffer before staining with fluorescent dyes. Then, samples were
analysed by FACS setting gates for dead bacteria in green versus
red emission dot plots from the live and dead controls.
Results and discussion
Peptide synthesis and enzymatic degradation
Our goal was to develop a delivery method that did not require
chemical modification of the antimicrobial. PIC particles25 are
ideal for this purpose because the cationic antimicrobial pep-
tides or mimics thereof can be encapsulated within a particle
formed upon polyelectrolyte complexation with negatively
charged materials. This strategy of complexing oppositely
charged materials has been extensively used to deliver other
“precious” therapeutics, in particular nucleic acids.26
In our case, PIC nanoparticles would be prepared by the
combination of a tailor-made anionic peptide and the posi-
tively charged backbone of the antimicrobial (Scheme 1). In
addition, we wanted our system to be selectively degraded in
the presence of pathogenic bacteria, but not in their absence:
for example, in the presence of commensal bacteria or non-
pathogenic strains, unable to produce virulence factors. As
such, our system would be pathogen specific and enable a tar-
geted delivery of the antimicrobial. Here we chose
P. aeruginosa as a model pathogen: P. aeruginosa is an opportu-
nistic pathogen commonly associated with hospital-acquired
infections, often colonising wounds and immunocompro-
mised patients.19 Interestingly, amongst the virulence factors
that P. aeruginosa secretes to mediate infection, LasB,20,21 a
zinc-metalloprotease, constituted an excellent target to develop
our system. LasB has elastolytic activity and a preference to
cleave sites with small hydrophobic residues.27,28 Thus, we
designed our anionic peptides to contain a short LasB-cleavable
sequence (e.g. GLA,27 Scheme 1) flanked by two glutamic acids,
responsible for providing overall negative charge to our peptide.
We postulated that multivalency would be lost upon LasB
mediated cleavage of the peptide, resulting in degradation of
the particle and delivery of the antimicrobial (Scheme 1).
Two peptides were prepared at this stage: P1, containing
the Gly-Leu-Ala sequence27 and P2, containing a tetraalanine
site,28 both sequences having been reported to be cleaved by
LasB. The N-terminus of both peptides was capped as a
neutral acetamide to mask the cationic amine functionality.
All peptides were prepared by solid-phase synthesis in good to
excellent yields and high purity without any chromatographic
purification (see ESI: section 3, Fig. S1–S6† for experimental
details and characterisation).
A fluorogenic assay was then used to evaluate enzymatic
degradation of these peptides.24 Peptides were incubated with
LasB, treated with fluorescamine and the increase in emission
at 460 nm correlated with the amount of amines produced
upon enzymatic hydrolysis of the peptides. In each assay,
degradation of succinyl casein by the evaluated elastases was
monitored, to confirm that the enzymes had not lost their
activity upon storage.29 Additionally, the values obtained from
fluorescence measurements were normalised to that produced
by a model peptide (H2N-LA-E-OH (P3), Fig. S7†), which
should be produced upon enzymatic hydrolysis of P1.27 In our
hands, the GLA sequence in P1 was degraded to a higher
extent than the tetraalanine in P2, showing an increase in
amine content of 60% after four hours (Fig. 1). More impor-
tantly, when these peptides were incubated with HLE, a
human elastase secreted by the immune system during inflam-
mation, little to no degradation was observed for both pep-
tides. This demonstrated that both of these peptides were
excellent candidates to develop LasB-responsive nanoparticles,
which would only be degraded by LasB, even if endogenous
elastases were present in the media. All subsequent experi-
ments were performed with P1 because it is degraded to a
greater extent by LasB.
PEI as a model antimicrobial polymer against P. aeruginosa
Having established the peptide sequence to be employed in
the synthesis of our enzyme-responsive PIC nanoparticles, we
Paper Polymer Chemistry






















































































then turned our attention to the choice of antimicrobial. PEI
has been reported as an efficient antimicrobial against both
Gram positive and Gram negative bacteria.30,31 Its antimicro-
bial activity can be tuned as a function of its degree of branch-
ing and molecular weight. Moreover, PEI has been extensively
applied as a starting material for the preparation of polyelec-
trolyte complexes.25 These features, and its commercial avail-
ability, made it an ideal candidate with which we could
optimise the preparation of our PIC nanoparticles.
However, the antimicrobial activity of PEI towards
P. aeruginosa had not been reported. Thus, five commercial
PEIs of various molecular weights and branching were evalu-
ated for their antimicrobial activity against P. aeruginosa. A
pathogenic P. aeruginosa strain (PAO1V) was cultured overnight
in the absence or presence of different concentrations of PEI
and viability checked using a LIVE/DEAD® staining assay
(Fig. S8†). This assay reports on membrane integrity and thus
is especially suited to evaluate the activity of antimicrobial pep-
tides and mimics. As expected, activity depended on the
amount of PEI used. Aggregates could be visibly observed on
the sides of the cuvettes for the larger polymers at the highest
concentration tested (0.1 mg mL−1), compromising the
characterisation of the system. These aggregates may form as a
result of the clustering of bacteria by the cationic polymers,32,33
or these polymers being trapped by debris from dead bacteria.
Increasing the molecular weight resulted in an increase in the
percentage of dead cells. Moreover, the results at 0.01 mg mL−1
suggested that branching had a beneficial effect on antimicro-
bial activity. Therefore, B-PEI25 was selected as the candidate
PEI to prepare our enzyme-responsive PIC nanoparticles.
PIC nanoparticle synthesis
Enzyme-responsive PIC nanoparticles were prepared by mixing
stock solutions of the peptide (in 5 mM HEPES buffer at
pH 7.4) with a 2.5 mM stock solution of B-PEI25 prepared in the
same buffer. Initial attempts to make PIC nanoparticles with
P1 did not result in the formation of stable aggregates. Thus,
we decided to introduce two cysteine residues in our peptides,
to allow for chemical oxidation during the nanoparticle for-
mation and cross-linking of the peptides. This strategy has
been employed in the synthesis of other PIC complexes, such
as nucleic acid polyplexes.34–36 PIC nanoparticles were success-
fully made with this modified peptide (P1SH), by mixing
peptide and B-PEI25 stock solutions and allowing the nano-
particles to oxidise overnight under stirring and open to air
(Scheme 1). The kinetics of thiol cross-linking was studied by
monitoring the decrease of accessible free thiols during nano-
particle formation using Ellman’s reagent.37 Complete
depletion of thiols was observed after nine hours for P1SH in
the presence of B-PEI25, whereas only 13% of initial thiols con-
tained in P1SH had oxidised after ten hours in its absence
(Fig. S9†). This result is in agreement with the literature,
where it is proposed that electrostatic complexation of polyions
increases the local concentration of thiols and thus increases
oxidation rates.38
Different mixtures of B-PEI25 to P1SH (expressed as
N : COOH ratio) were evaluated to determine the optimal ratio
to prepare PIC nanoparticles (Fig. 2, Table S2†). Of all the
N : COOH ratios tested, only those between 1 : 0.8 and 1 : 0.3
formed stable PIC nanoparticles. This phenomenon could be
due to the lack of enough peptide below 1 : 0.3 to condense
B-PEI25 into particles, and the generation of neutral and
unstable coacervates at equimolar mixtures of positive and
negative charge, in agreement with the decrease in ζ-potential
observed with increasing peptide content (Fig. 2b). Interest-
ingly, we were not able to form PIC nanoparticles in the pres-
ence of an excess of COOH groups (i.e. peptide). We believe the
nucleation of these PIC nanoparticles is driven by complexation
of the anionic peptides onto the B-PEI25 backbone. Once the
positive charges on the surface of the growing nanoparticles are
Fig. 1 Relative amine content in samples of LasB responsive anionic
peptides evaluated in this work. Relative amine content was calculated
from fluorescamine conjugates formed following incubation with
enzymes for 4 hours and normalised to the fluorescence observed with
a model degradation peptide (P3, H2N-LA-E-OH) (Fig. S7†). Peptide
blanks (i.e. without enzyme) in black. n = 3.
Fig. 2 (a) Hydrodynamic diameter (DH) and (b) ζ-potential of P1SH PIC
nanoparticles prepared at different N : COOH ratios. (c) AFM characteri-
sation of PIC nanoparticles prepared at a 1 : 0.3 N : COOH ratio. D =
127 ± 42 nm, n = 48.
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neutralised, complexation of further peptide is hindered and
thus prevents the formation of negatively charged particles.
A clear trend was found in particle size, with smaller
particles being formed with decreasing amounts of peptide
(Fig. 2a). AFM measurements were carried out to confirm the
size and shape of these nanomaterials. PIC nanoparticles
prepared at a 1 : 0.3 N : COOH ratio were selected for AFM analy-
sis due to their narrow size distribution in DLS characterisation.
AFM images showed the presence of spherical nanoparticles of
127 ± 42 nm in diameter (Fig. 2c), in agreement with the 111 ±
35 nm hydrodynamic diameter measured by DLS.
Physiological stability of PIC nanoparticles
PIC aggregates are disrupted in the presence of other electro-
lytes, which can shield and weaken the electrostatic forces
holding the aggregates together, and potentially lead to the
rupture of the particles.25 In this regard, the high contents of
salts in the body could compromise the efficacy of PIC nano-
particles in biological settings. With this in mind, the stability
of PIC nanoparticles under physiological conditions was
assessed by diluting them into a final concentration of
154 mM NaCl and incubating them at 37 °C.39 The size of PIC
nanoparticles incubated under these conditions was moni-
tored by DLS over four hours (Fig. 3). All PIC nanoparticles
tested swelled under experimental conditions, as expected
from the addition of small Na+ and Cl− ions that can permeate
these soft nanoparticles and shield the interactions between
the polyions. A trend in the extent of this swelling was
observed and, in general, decreasing the amount of P1SH (i.e.
COOH component) resulted in nanoparticles with increasing
swelling. Interestingly, only the nanoparticles prepared at a
1 : 0.3 N : COOH ratio remained stable in size after the initial
swelling for the whole duration of the experiment, with all of
the other nanoparticles eventually reducing their size after two
hours of incubation. PIC nanoparticles prepared at high
N : COOH ratios were the most unstable and no aggregates
could be detected for most of these systems following incu-
bation for at least two hours (Fig. 3, hollow symbols).
DLS autocorrelation function curves (Fig. S10†), size distri-
butions (Fig. S11†) and count plots (Fig. S12†) strongly support
these observations: while PIC nanoparticles prepared with
higher concentrations of peptide (N : COOH ratios
1 : 0.8–1 : 0.6) were unable to scatter light following incubation
with NaCl, in some cases for as little as two hours, those prepared
with a lower proportion of peptide (N : COOH ratios 1 : 0.5–1 : 0.3)
did produce autocorrelation curves that could be fitted by the DLS
software. However, only those prepared at a 1 : 0.3 N : COOH ratio
were stable enough to scatter light over a prolonged period of
time, as observed in the detection counts. Consequently, PIC
nanoparticles prepared at this N : COOH ratio of 1 : 0.3 were
selected for biological studies due to their higher stability.
A similar effect was observed when particles were incubated
with other biologically relevant cations, such as Ca2+
(Fig. S13†). Multivalent cations have a high affinity for
polyanionic peptides and thus our PIC particles swelled when
exposed to CaCl2, as evidenced by the shift in their DLS
autocorrelation curves towards longer relaxation times. This
swelling was bigger with bigger amounts of CaCl2 added and
resulted in uneven light scattering profiles and multimodal
size distributions at the highest concentrations tested.
Enzymatic degradation of PIC nanoparticles
The enzyme-triggered disassembly of these (1 : 0.3)-PIC nano-
particles was evaluated first by DLS, monitoring the amount of
light scattered by three different batches of these nanomaterials
when exposed to LasB at 37 °C (Fig. 4, hollow circles). Even after
only one hour of incubation, PIC nanoparticles treated with
LasB scattered 25% less light, and this scattering kept decreas-
ing for the duration of the experiment, reaching 40% of the
initial scattering intensity after four hours.
As a comparison, incubation with HLE caused nano-
particles to scatter 15% more light after one hour incubation
and remained close to 100% of the initial scattering for the
duration of the experiment (Fig. 4, hollow squares). This
initial increase in scattering intensity may be due to the swel-
ling of the PIC nanoparticles after addition of the enzyme
Fig. 3 Relative change in size for P1SH PIC nanoparticles prepared at
different N : COOH ratios and incubated under simulated physiological
conditions (154 mM NaCl, pH 7.4, 37 °C). Particle size was normalised to
that of a control in the absence of NaCl (1×). n = 3.
Fig. 4 Normalised detection counts (%) for P1SH PIC nanoparticles pre-
pared at a 1 : 0.3 N : COOH ratio in the absence (●) and presence of LasB
(○) and HLE (□). Data normalised to the initial counts for each of the
individual experiments. n = 3.
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buffer (2.5 mM Na2B4O7, pH 8.0), in a similar fashion to the
swelling observed under physiological conditions (Fig. 3). A
similar swelling was observed when PIC nanoparticles were
incubated with this buffer in the absence of any of the
enzymes (Fig. 4, dark circles). No significant difference was
observed when this scattering was compared to that of HLE,
proving that the human enzyme was not having an effect on
the stability of these PIC nanoparticles. A similar effect could
be observed in the DLS size distributions (Fig. S14†) with
broader distributions and smaller sizes being observed upon
treatment with LasB, as opposed to the almost invariable
profile for HLE and the buffer controls.
The ability of LasB to degrade these PIC nanoparticles was
also assessed, as before, monitoring the formation of amines
upon enzymatic treatment. When PIC nanoparticles were
reacted with fluorescamine after four hours of incubation with
LasB or HLE, no significant difference in amine content was
observed for those treated with HLE when compared to PIC
nanoparticles incubated in the absence of any enzyme
(Fig. S15†). However, an increase in fluorescence emission (up
to 30%) was observed for the samples incubated with LasB.
This increase in the amount of amines, together with the DLS
data, confirms the selective cleavage of P1SH within the nano-
particle and consequent disassembly of these PIC nano-
particles when exposed to the bacterial elastase.
Antimicrobial activity of PIC nanoparticles
Having established the selectivity of the degradation of these
PIC nanoparticles in the presence of P. aeruginosa LasB, the
antimicrobial activity of these enzyme-responsive nano-
particles was assessed. P. aeruginosa PAO1V, a pathogenic
strain that secretes LasB, was incubated with PIC nanoparticles
(1 : 0.3 N : COOH ratio) or B-PEI25, aliquots were taken every
hour for four hours, and stained using the LIVE/DEAD® viabi-
lity kit. As expected, the antimicrobial activity for the PIC
nanoparticles was significantly reduced when compared to
B-PEI25, with the nanoparticles exhibiting, after two hour incu-
bation, less than 10% of the activity of B-PEI25 (Fig. 5), thus
confirming the potential of these PIC nanoparticles to reduce
the toxicity of antimicrobial polymers. This antimicrobial
activity was slowly recovered upon incubation with the bac-
teria, and up to 25% of the antimicrobial activity of B-PEI25
could be observed for PIC nanoparticles after four hours of
incubation, before the assay conditions become too harsh to
have viable controls of P. aeruginosa. When the same experi-
ment was performed with a LasB-deletion strain (ΔlasAB),
which does not produce this elastase, a similar reduction in
toxicity could be observed with the PIC nanoparticles (Fig. 5,
white bars), despite the slightly higher susceptibility of this
strain towards the antimicrobial polymer (Fig. S16 and S17†).
More importantly, the antimicrobial activity for the PIC nano-
particles against this ΔlasAB mutant remained constantly low
over the duration of the experiment, demonstrating that this
strain was unable to degrade the nanoparticle and thus release
the antimicrobial polymer.
Conclusions
Here, we have developed an easy methodology for the prepa-
ration, under aqueous conditions, of PIC nanoparticles from
an enzyme-responsive anionic peptide and a cationic anti-
microbial polymer. The size of these nanoparticles could be
tuned between 100 and 600 nm by simply adjusting the
N : COOH ratio. We have demonstrated that disulfide mediated
cross-linking and N : COOH ratios were fundamental to impart
these PIC nanoparticles with stability under physiological con-
ditions. Furthermore, we have shown that both the starting
peptide and the formed PIC nanoparticles can be selectively
degraded in the presence of LasB elastase, a virulence factor
secreted by the opportunistic pathogen P. aeruginosa, while no
degradation was observed in the presence of HLE, an elastase
secreted by human leucocytes. Finally, we demonstrate that
the toxicity of B-PEI25 was significantly reduced within these
nanoparticles. Antimicrobial activity was slowly recovered
when these PIC nanoparticles were incubated with a patho-
genic P. aeruginosa strain, while remaining non-toxic in the
presence of a strain that cannot produce the elastase.
We believe these enzyme-responsive PIC nanoparticles have
a great versatility and potential in the current fight against
antimicrobial resistance, and our efforts to optimise antimicro-
bial activity, while maintaining the low toxicity against non-
targeted cells we observe here, will be reported in due course.
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Fmoc-protected-L-amino	 acids	were	 purchased	 from	Merck	Millipore.	 Dimethylformamide	 (DMF),	 piperidine	 20%	
v/v	 in	DMF,	 5,5'-dithiobis(2-nitrobenzoic	 acid)	 (DTNB)	 and	 linear	 poly(ethylene	 imine)	 2.5	 KDa	 average	molecular	
weight	 (L-PEI2.5)	 were	 purchased	 from	 Sigma-Aldrich®.	 H2N-L-Glu(O
t
Bu)-2-chlorotrityl	 resin	 (0.58	 mmol/g)	 was	
bought	 from	 AGTC	 Bio	 Products	 Ltd.	 2-chlorotrityl	 chloride	 resin	 (1.49	 mmol/g)	 was	 obtained	 from	 Iris	 Biotech	
Gmbh.	 Linear	poly(ethylene	 imine)	 25	KDa	average	molecular	weight	 (L-PEI25),	 branched	poly(ethylene	 imine)	 1.2	
KDa	 average	 molecular	 weight	 (B-PEI1.2),	 N,N-diisopropylethylamine	 (DIPEA),	 triisopropylsilane	 (TIPS),	 1,2-
ethanedithiol	 (EDT),	 trifluoroacetic	 acid	 (TFA),	 casein	 from	 bovine	 milk	 (technical	 grade)	 and	 succinic	 anhydride	
were	 bought	 from	 Alfa	 Aesar®.	 N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium	 hexafluorophosphate	
Electronic Supplementary Material (ESI) for Polymer Chemistry.












spectra	were	obtained	on	 a	 Xevo®	G2-XS	 ToF	 (Waters)	 from	electrospray	 ionisation	 (ESI)	 and	 time-of-flight	 (TOF)	
measurement	in	positive	ion	mode.	High-resolution	MS	data	was	calculated	by	comparison	with	leucine-enkephalin	
as	 internal	 standard.	 Reverse	 phase	 (RP)	 HPLC	 analysis	 was	 run	 through	 a	 Kinetex®	 C18-EVO	 column	 (Phenom-
enex®):	5	µm,	100	Å,	250	x	4.60	mm.	A	gradient	from	3	to	20%	of	(CH3CN	+	0.05%	TFA)	 in	(H2O	+	0.05%	TFA)	was	
used	 at	 1	mL/min.	 The	 column	was	maintained	 at	 35°C	 and	UV-VIS	 detection	was	 set	 at	 210	nm.	UV-VIS	 spectra	








































































27.1(Cβ-Glu);	 30.0(Cγ-Glu);	 30.2(Cγ-Glu);	 40.8(Cβ-Leu);	 42.0(Cα-Gly);	 48.0(Cα);	 50.8(Cα);	 51.1(Cα);	 52.3(Cα);	
168.6(NHCO);	 169.8(Ac);	 171.6(NHCO);	 171.8(NHCO);	 172.2(NHCO);	 173.1(C-term);	 173.8(Cδ-Glu);	 174.0(Cδ-Glu)	
ppm.	MS	(ESI-TOF,	+eV):	m/z	614.2	[M+Na+CH3OH]+;	604.2	[M-H+2Na]+;	582.2	[M+Na]+.	HR-MS	(ESI-TOF,	+eV):	m/z	
582.2387	(calculated	for	[M+Na]+)	582.2385	(found).	Purity	by	HPLC	=	88%.	
P1SH,	 Ac-C-E-GLA-E-C-OH	 (214.3	mg,	 64%	 yield).	 1H-NMR	 (400	MHz,	DMSO-d6):	 δ	 0.84(dd,	 J=14.8,	 6.5	Hz,	 6H,	Hδ-
Leu);	1.20(d,	J=7.1	Hz,	3H,	Hβ-Ala);	1.43(t,	J=7.0	Hz,	2H,	Hβ-Leu);	1.50-1.63(m,	1H,	Hγ-Leu);	1.67-1.83(m,	2H,	Hβ-Glu);	
1.84-1.98(m,	2H,	Hβ-Glu);	1.87(s,	3H,	Ac);	2.18-2.29(m,	4H,	HΥ-Glu);	2.34(t,	 J=8.5	Hz,	1H,	 SH);	2.44(t,	 J=8.5	Hz,	1H,	
SH);	2.62-2.90(m,	4H,	Hβ-Cys);	3.70(dd,	 J=11.2,	5.7	Hz,	2H,	Hα-Gly);	4.19-4.41(m,	6H,	Hα);	7.87-7.92(m,	2H,	NHCO);	



























































































δ	 17.9(Cβ-Ala);	 18.1(Cβ-Ala);	 18.1(Cβ-Ala);	 22.5(Ac);	 26.4(Cβ-Glu);	 27.4(Cβ-Glu);	 30.0(Cγ-Glu);	 30.2(Cγ-Glu);	 47.8(Cα);	
48.0(Cα);	48.1(Cα);	48.1(Cα);	51.1(Cα);	51.8(Cα);	169.4(Ac);	171.1(NHCO);	171.6(NHCO);	171.8(NHCO);	171.9(NHCO);	





































A	modified	 procedure	 from	 the	 literature	was	 used	 for	 the	 preparation	 of	 SC:3	 commercial	 casein	 (500	mg,	 0.02	
mmol)	was	heated	at	60°C	with	succinic	anhydride	(400	mg,	4.00	mmol)	in	100	mL	of	NaHCO3	buffer	at	pH	8.0.	The	


























































N:COOH	RATIO	 DH	±	SD	(nm)	 ζ	±	SD	(mV)	 Notes	
1:2.0	 -	 -	 No	PIC	particles	formed	
1:1.5	 -	 -	 No	PIC	particles	formed	
1:1.0	 -	 -	 No	PIC	particles	formed	
1:0.8	 582	±	79	 6.7	±	4.7	 -	
1:0.7	 487	±	67	 9.8	±	3.2	 -	
1:0.6	 431	±	59	 11.3	±	4.5	 -	
1:0.5	 379	±	68	 13.4	±	4.7	 -	
1:0.4	 230	±	56	 17.2	±	7.1	 -	
1:0.3	 111	±	35	 18.9	±	6.4	 -	


































1	mL	of	a	PIC	nanoparticles	 (Table	S2),	prepared	as	described	 in	 the	main	 text,	was	diluted	with	182	µL	of	a	1	M	
























































































































































































































































































































































PIC (1:0.3) + buffer (control)








PIC (1:0.3) + LasB





















PIC (1:0.3) + LasB
A B
C D
Figure S18 DLS correlograms for P1SH PIC nanoparticles prepared at a 1:0.3 
N:COOH ratio incubated with Na2B4O7 buffer (A), HLE (B) and LasB (C) over 
time. Graph D shows a closer look at the framed section of plot C, where the 
arrow indicates increasing incubation times. DLS Size-Intensity plots for this 
dataset can be found in Fig. S14. 
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CHAPTER 3 
Elastase-sensitive peptides with higher mul-
tivalency form more stable polyion complex 
(PIC) nanoparticles with compromised 
susceptibility to enzymatic degradation 
 
Format: Paper draft (unpublished). 
 
Authors: I. Insua, M. Petit, L. D. Blackman, R. Keogh, A. Pitto-Barry, R. K. 
O'Reilly, A. F. A. Peacock, A. M. Krachler and F. Fernandez-Trillo. 
 
Overview: In this Chapter, we attempt to optimise the saline stability and activity 
of the enzyme-responsive PIC particles described in Chapter 2. Our motivation 
was double: Firstly, the swelling and even breakdown experienced by these na-
noparticles in the presence of salt can compromise their targeted properties by 
triggering the release of antibiotic in virtually any biological (i.e. saline) fluid. 
Hence the specificity of their antimicrobial action could be improved by develop-
ing more salt-tolerant nanomaterials, which only release the loaded antibiotic in 
the presence of the target pathogen. Secondly, only the antimicrobial properties 
of one PIC particle formulation were evaluated in the Chapter 2, as the nanopar-
ticles prepared at other charge ratios were not stable enough to be tested. Im-
proving the stability of PIC particles could allow the exploration of other formula-
tions, or charge ratios, which may display higher and/or faster antimicrobial ac-
tivities due to the distinct exposure of the peptides in the nanoparticle: for exam-
ple, charge ratios with an excess of negative component, which could not be pre-
pared in Chapter 2, would lead to an accumulation of peptide on the surface of 
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the nanoparticle, thus increasing its exposure to LasB and potentially trigger the 
release the antibiotic more rapidly. 
Here, based on the direct relationship between the polyelectrolytes’ net charge 
(i.e. multivalency) and their binding affinity described in Chapter 1, we present a 
collection of new LasB-responsive peptides with increased multivalency and 
cross-linking units, aiming to strengthen the attraction between the polyelectro-
lytes and the mechanical resistance of the resulting nanoparticles, respectively. 
As such, these modifications contribute to form more tightly bound and stable PIC 
particles, and hence could allow the preparation of new charge ratios. 
The nanoparticles obtained from these new peptides were characterised by a 
range of light scattering techniques and ζ-potential, and their stability under sim-
ulated physiological conditions and antimicrobial properties were evaluated. We 
found that peptides with higher multivalencies and cross-linking degree allowed 
the formulation of new charge ratios, and improved the saline stability of PIC par-
ticles. However, none of the resulting PIC particles tested were hydrolysed by 
LasB, hence no antimicrobial activity was displayed by these new PIC particles 
in the presence of pathogenic Pseudomonas aeruginosa. It was therefore con-
cluded that the activity of the PIC particles introduced in Chapter 2 could not be 
optimised by increasing the peptides’ multivalency and cross-linking degree. 
The observations described in this Chapter contribute to gain further insight into 
developing new PIC particle formulations, and how the polyelectrolyte’s multiva-
lency and cross-linking degree can impact the stability and enzymatic suscepti-
bility of PIC particles. An important contribution to this thesis is the structural anal-
ysis of PIC particles by SLS and SAXS presented exclusively in this Chapter, 
which provides further insight into the characteristics of these nanomaterials.  
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tion; and II, FFT and AMK designed the microbiological assays. MP synthesised 
and characterised the peptides. LDB, RK and RKOR designed and performed 
the SLS experiments. APB interpreted the SAXS data. II carried out all other ex-























Polyion	 complex	 (PIC)	 nanoparticles	 are	 soft	 colloids	 made	
from	oppositely	charged	polyelectrolytes	that	self-assemble	in	
solution.1	These	nanomaterials	have	drawn	a	lot	of	attention	
for	 being	 remarkably	 versatile	 vehicles	 for	 drug	 delivery	
applications.2	Such	nanomaterials	can	be	easily	prepared	from	
charged	 therapeutics	 in	 combination	 with	 an	 oppositely	
charged	polymer.	As	such,	PIC	particles	are	modular	systems	
that	 allow	 the	 control	 of	 the	 therapeutic	 properties	 of	 pre-
loaded	 drugs	 by	 simple	 formulation	modifications.	 The	 size,	
charge,	colloidal	stability	and	biological	activity	of	PIC	particles	
can	 be	 tuned	 by	 simply	 adjusting	 the	 relative	 content	 of	
polyelectrolytes.	The	assembly	of	these	nanomaterials	occurs	
spontaneously	 in	 water,	 does	 not	 require	 the	 chemical	
modification	 of	 charged	 therapeutics,	 and	 the	 ‘excipient’	
polyelectrolyte	 (i.e.	 pharmacologically	 inactive)	 can	 be	
adjusted	 in	 size	 and	 structure	 to	 tune	 the	 properties	 of	 the	
resulting	nanoparticles.3,4	
PIC	 particles	 have	 reduced	 the	 toxicity	 and	 improved	 the	
performance	 of	 charged	 antineoplastics,5	 antimicrobials,6-8	
and	allowed	the	delivery	of	nucleic	acids	to	the	inside	of	cells.2	
The	 release	 of	 drugs	 from	 these	materials	 occurs	 when	 the	
attractive	 forces	 between	 polyelectrolytes	 are	 weakened,	
leading	to	the	dissolution	of	their	components	and	breakdown	
of	 the	 nanoparticles.	 As	 such,	 polyelectrolytes	 that	 can	
degrade	 in	 the	 presence	 of	 certain	 stimuli	 can	 allow	 the	
assembly	 of	 responsive	 PIC	 particles	 that	 dissociate	 when	
exposed	 to	 a	 particular	 degrading	 agent	 or	 trigger.	 Particle	
dissociation	occurs	because	a	longer	polyelectrolyte	is	broken	




remarkable	 specificity,	 PIC	 particles	 prepared	 from	
polyelectrolytes	 that	 degrade	 in	 the	 presence	 of	 certain	
enzymes	 are	 particularly	 interesting	 for	 biomedical	
applications.9	Enzyme-responsive	PIC	particles	can	establish	a	
communication	 between	 the	 host	 (or	 pathogen)	 and	 the	




PEI)	 in	 the	 presence	 of	 Pseudomonas	 aeruginosa’s	 elastase	




the	 colloid	 when	 exposed	 to	 a	 pathogenic	 strain	 of	 P.	
aeruginosa	 that	produces	LasB.	However,	 these	PIC	particles	
suffered	 from	 poor	 stability	 to	 physiological	 salt	
concentrations,	swelling	up	to	twenty	times	their	original	size	
or	 even	 breaking	 down	 under	 simulated	 physiological	
conditions.	In	order	to	fully	exploit	the	therapeutic	potential	of	
this	 system,	 the	 salt	 stability	of	 these	nanoparticles	must	be	
improved	 to	 ensure	 their	 integrity	 in	 biological	 settings	 and	
control	over	the	release	of	the	antimicrobial.	
Here	we	present	a	collection	of	new	LasB-responsive	peptides	
prepared	 across	 a	 range	 of	 multivalencies	 and	 cross-linking	
units,	which	were	used	in	combination	with	B-PEI	to	assemble	
PIC	 particles.	 The	 characterisation	 of	 the	 resulting	
nanoparticles	 and	 their	 salt	 tolerance	 was	 evaluated	 as	 a	
function	of	the	multivalency	and	cross-linking	units	present	in	
these	peptides.	PIC	particles	were	characterised	by	a	range	of	
light	 scattering	 techniques	 to	 identify	 any	 structural	
differences	 caused	 in	 these	 nanomaterials	 by	 particular	
peptides.	 Finally,	 the	 antimicrobial	 activity	 of	 these	 PIC	







Enzymes	 (Pseudomonas	 aeruginosa	 Elastase	 (LasB):	 EC	
3.4.24.26	and	Human	Leucocyte	Elastase	(HLE):	EC	3.4.21.37)	




medium	 (DMEM)	 were	 bought	 from	 Sigma-Aldrich®.	
Fluorescamine	 and	 dimethylsulphoxide	 (DMSO)	 were	
purchased	from	Acros	OrganicsTM.	Ethylenediaminetetraacetic	
acid	 (EDTA)	was	purchased	 from	Alfa	Aesar®.	Nylon	0.45	μm	
syringe	 filters	 were	 purchased	 from	 Camlab.	 P.	 aeruginosa	
strains	 were	 kindly	 donated	 by	 Suzanne	 M.	 J.	 Fleiszig.	 We	









times	 at	 140	 V.	 A	 FLUOstar	 Omega	 (BMGLabtech	 Gmbh)	
microplate	 reader	was	used	 to	measure	 fluorescamine	 reac-	
tions.	Static	Light	Scattering	(SLS)	and	simultaneous	DLS	data	
was	 collected	 using	 an	 ALV/CGS-3	 Compact	 Goniometer	
System	operating	at	a	wavelength	of	633	nm.	Small	Angle	X-
ray	 Scattering	 (SAXS)	 measurements	 were	 performed	 at	
Diamond	Light	Source	on	beamline	B21,	at	a	photon	energy	of	
12.4	 keV	 and	 1	 Å	 wavelength	 (monochromatic	 beam),	 from	
samples	prepared	in	5	mM	HEPES	buffer	pH	7.4,	stabilised	at	
15.0	 °C	 and	 analysed	 from	 quartz	 capillary	 tubes	 with	 a	
diameter	 of	 1.6	 mm.	 SAXS	 spectra	 were	 recorded	 using	 a	
Pilatus	 2M	 detector	 (DECTRIS®)	 situated	 at	 4.04	m	 from	 the	
sample,	 and	 the	 fitting	 of	 SAXS	 spectra	 to	 structural	models	
was	performed	using	IGOR	Pro	(version	6.37)	by	WaveMetrics.	
Fluorescence-Activated	Cell	Sorting	(FACS)	was	performed	on	
an	 Attune®	 Acoustic	 Focusing	 Cytometer	 (Applied	







peptides),	 stock	 solutions	 of	 B-PEI	 (2.5	 mM	 in	 amines)	 and	
peptide	 (P2-4SH)	 (0.75	mM	 in	 carboxylate	 groups)	 in	 5	 mM	
HEPES	buffer	at	pH	7.4	were	prepared.	Then,	both	 solutions	
were	 filtered	 and	 mixed	 in	 equal	 volumes	 drop-wise	 under	
stirring.	The	reaction	mixture	was	stirred	at	room	temperature	
for	 24	 hours	 open	 to	 air	 to	 allow	 thiol	 oxidation.	 PIC	
nanoparticles	 prepared	 at	 different	 [N:COOH]	 ratios	 were	
obtained	 by	 changing	 the	 concentration	 of	 peptide	 stock	
solution	and	mixing	with	the	2.5	mM	B-PEI	stock	following	the	
same	 protocol	 (Table	 S1).	 After	 24	 hours,	 samples	 were	












aqueous	 2-propanol.	 Samples	 were	 resuspended	 and	















mixed	 with	 125	 μL	 of	 the	 same	 buffer	 without	 DMSO,	
containing	 15	 μg	 of	 enzyme	 (LasB	 or	 HLE).	 Solutions	 of	
enzymes	and	substrates	alone	were	prepared	as	blanks.	Every	
















buffer	 at	 pH	 8.0.	 As	 control	 experiments,	 PIC	 nanoparticles	
were	incubated	under	the	same	conditions	with	enzyme	(LasB	
or	 HLE,	 5	 μg)	 or	 Na2B4O7	 buffer	 to	 assess	 the	 enzymatic	
specificity	and	effect	of	salts	 in	the	buffer,	respectively.	Each	
sample	was	prepared	in	triplicate	from	three	different	batches	











modifications	were	proposed	 to	enhance	 the	 salt	 stability	of	
the	 resulting	 PIC	 particles:	 i)	 Additional	 glutamic	 acids	 were	
included	to	 increase	the	multivalency	(i.e.	net	charge)	of	this	
anionic	 peptide,	 potentially	 leading	 to	 a	 stronger	 affinity	 for	
antimicrobial	 B-PEI.	 ii)	 The	 incorporation	 of	 a	 third	 cysteine	
would	 allow	 these	 peptides	 to	 oxidise	 forming	 branched	
chains,	 which	 is	 expected	 to	 provide	 a	 more	 densely	 cross-




Peptides	 P2SH,	 P3SH	 and	 P4SH	 were	 thus	 prepared	 by	
conventional	solid-phase	peptide	synthesis,	and	 included	the	
amino	 acid	 sequence	 –GLA–,	 which	 is	 degradable	 by	 the	
pathogenic	 enzyme	 LasB.	 These	 peptides	 included	 two	
additional	glutamic	acids	(P2SH),	four	additional	glutamic	acids	
(P3SH),	 and	 four	 extra	 glutamic	 acids	 and	 one	 additional	
cysteine	 (P4SH)	 compared	 to	 P1SH.	 Therefore,	 peptides	 P2SH	
and	P3SH	were	 designed	 to	 study	 the	 effect	 of	multivalency,	




PEI	 in	 aqueous	 medium	 at	 physiological	 pH	 as	 previously	
reported.
10









Based	on	 their	 ζ-potentials,	 three	 regions	were	 found	 for	 all	
LasB-responsive	 peptides:	 one	 towards	 higher	 peptide	
contents	that	gave	negatively	charged	complexes;	another	at	





	 which	 consist	 of	 a	 neutral	 core	 made	 of	 a	
stoichiometric	mixture	of	oppositely	charged	polyelectrolytes,	
surrounded	by	 a	 corona	of	 the	polyion	 in	 excess.	 Therefore,	
the	ζ-potential	of	PIC	particles	will	have	the	sign	of	the	polyion	
in	excess	(i.e.	in	the	corona),	whereas	neutral	complexes	form	
at	 1:1	 charge	 ratios	 leading	 to	 the	 aggregation	 and	
sedimentation	 of	 particles	 without	 a	 stabilising	 corona.	 This	
neutralisation	point	was	found	between	the	[N:COOH]	ratios	
of	 1:0.8	 and	 1:0.5	 for	P2SH,	whereas	 peptides	P3SH	 and	P4SH	










	 Similarly,	 since	 more	 multivalent	
peptides	 should	 have	 stronger	 affinities	 for	 B-PEI,	 the	
exchange	of	peptides	P3SH	and	P4SH	between	PIC	particles	and	
the	solution	should	be	slower	than	for	P2SH,	ultimately	leading	




that	governs	 the	 self-assembly	of	 this	 collection	of	peptides.	
Regardless	of	the	peptide	used,	the	[N:COOH]	ratio	1:0.2	did	
Figure	1	Structures	of	LasB-responsive	peptides	P2SH	(Ac-C-EE-GLA-EE-C-OH),	P3SH	(Ac-C-
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not	 form	 PIC	 particles,	 probably	 due	 to	 the	 lack	 of	 enough	
peptide	in	these	formulations	to	condense	B-PEI.	






strongly	 and	 tightly	 bound	 polyelectrolyte	 networks	 within	
these	nanoparticles.	For	all	peptides,	formulations	prepared	at	
a	[N:COOH]	ratio	of	1:0.3	gave	the	smallest	PIC	particles,	with	
an	average	DH	 of	ca.	 110	nm	and	 ζ-potential	of	+19	mV	–	 in	







integrity	 of	 PIC	 particles	 may	 be	 compromised	 by	 the	 high	
concentrations	of	salts	present	in	biological	fluids.	In	order	to	
assess	 their	 tolerance	 to	 physiological	 salinity,	 PIC	 particles	
were	incubated	in	the	presence	of	154	mM	NaCl	at	37	°C,	and	
their	 DH	 was	 monitored	 over	 four	 hours	 (Figure	 3).	 It	 was	
observed	that	all	PIC	particles	swelled	when	exposed	to	NaCl,	




hours	 at	 a	 [N:COOH]	 ratio	 of	 1:1	 (Figure	 3A).	 Nevertheless,	
P2SH	 complexes	 showed	 better	 physiological	 stabilities	 than	
those	made	 from	 the	 less	multivalent	P1SH,
10	 reinforcing	 the	
direct	 correlation	 between	 peptide	 multivalency	 and	 PIC	





ratio	were	 less	affected	by	 this	 saline	medium,	displaying	14	
times	their	original	size	after	4	hours	(Figure	3C).	These	results	





on	 the	 structure	 of	 PIC	 particles,	 these	 nanomaterials	 were	
characterised	by	Static	Light	Scattering	(SLS)	and	Small	Angle	
X-ray	 Scattering	 (SAXS).	 PIC	 particles	 prepared	 from	 all	 four	
peptides	 at	 a	 [N:COOH]	 ratio	 of	 1:0.3	were	 selected	 for	 the	




20	 to	 100°,	 and	 their	 DLS	 profiles	 were	 simultaneously	
recorded.	 Due	 to	 the	 intense	 scattering	 observed	 for	 these	
samples	at	low	angles	(below	40°),	all	PIC	particle	suspensions	
had	to	be	filtered	through	0.45	µm	nylon	filters	to	remove	any	
larger	 scatterers	 than	 the	 expected	 nanoparticles	 –	 which	
were	all	smaller	than	the	filter’s	cut-off	size	according	to	our	
previous	 DLS	 characterisation	 (Figure	 2).	 Thus,	 the	 angle	
dependency	observed	for	the	unfiltered	samples	in	their	Zimm	
plots	 could	 be	 corrected	 (Figure	 S13),	 allowing	 the	 linear	
regression	of	K·c/Rq	versus	q
2	for	filtered	PIC	particles;	where	
K	 is	 a	 constant	 containing	 the	 optical	 parameters,	 c	 is	 the	
concentration	of	the	sample	and	Rq	 the	Rayleigh	ratio	of	the	
particles	at	a	given	scattering	angle	(q),	and	q	is	the	scattering	
wave	 vector.8	 As	 such,	 linear	 Zimm	 plots	 allowed	 the	
calculation	of	the	radius	of	gyration	(Rg)	of	the	nanoparticles	




basis,	 PIC	 particles	 prepared	 from	 peptides	 P2-P4SH	 showed	
Rg/RH	 values	 of	 1.0,	 which	 are	 considerably	 higher	 than	 the	
theoretical	 maximum	 of	 0.775	 expected	 for	 the	 core-shell	




aggregate,	 as	 observed	 when	 their	 DH	 was	 monitored	 over	
time	under	shelf	storage	conditions	(Figure	S14):	Whereas	PIC	
particles	 prepared	 from	 peptides	P2-4SH	 displayed	 the	 same	
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The	 SLS	 characterisation	 of	 these	 nanoparticles	 was	 in	
agreement	with	the	Rg/RH	values	previously	reported	for	other	
PIC	 particle	 systems,	 ranging	 between	 1	 and	 2.13,14	 The	
deviation	above	the	theoretical	Rg/RH	value	for	a	solid	sphere	
(0.775)	 has	 been	 explained	 from	 the	 intrinsic	 high	
polydispersity	of	PIC	particles.13,15	
Additionally,	 the	 structural	 features	 of	 PIC	 particles	 were	
studied	 by	 SAXS	 at	 the	 Diamond	 Light	 Source	 synchrotron.	
Nanoparticle	samples	at	a	[N:COOH]	ratio	of	1:0.3	were	chosen	
for	the	analysis	to	be	compared	with	the	previous	SLS	results.	
All	 four	 samples	 showed	 almost	 identical	 SAXS	 profiles	
regardless	of	the	peptide	used	(Figure	5).	It	must	be	noted	that	
the	 interpretation	of	 these	SAXS	spectra	was	difficult	due	 to	
lack	of	a	Guinier	region	and	very	noisy	results	at	high	q	values.	
Firstly,	 the	data	was	 fitted	 to	a	Guinier-Porod	 (GP)	model	 to	








73.0	 and	 77.3	 nm.	 Although	 these	 Rg	 values	 should	 not	 be	
taken	 as	 accurate	 due	 to	 lack	 of	 experimental	 data	 in	 the	
Guinier	 region	 to	 validate	 the	GP	 fit,	 they	 are	 in	 agreement	
with	the	Rg	obtained	by	SLS	–	considering	that	SAXS	samples	
were	 not	 filtered,	 unlike	 for	 SLS	 analysis,	 and	 therefore	 a	
higher	Rg	is	expected	in	the	samples	analysed	by	SAXS	from	the	
contribution	 of	 additional	 large	 scatterers.	 Having	 thus	
accepted	 this	 GP	 fit	 based	 on	 the	 c2	 and	 Rg	 obtained,	 this	
model	 allowed	 the	 calculation	 of	 the	 shape	 parameter	 ‘S’,	
which	 displayed	 values	 between	 0.11	 and	 0.15	 for	 all	 PIC	
particles,	characteristic	of	spherical	materials.	




scores.	 ‘Not	 hard’	 spherical	 models	 were	 explored	 instead,	
taking	into	consideration	all	experimental	points	between	the	
q	values	of	0.004	and	0.3,	and	the	only	good	fit	identified	was	
that	 of	 fractal	 polydisperse	 spheres	 (FPS,	 Figure	 5).	 PIC	
particles	 of	 cationic	 hyperbranched	 polymers	 and	DNA	 have	
been	 reported	 to	 self-assemble	 into	 spherical	 sponges	 or	
fractals.17	 These	 electrostatic	 interactions	 do	 not	 allow	 the	
formation	 of	 hard	 sphere	 objects,	 but	 give	 porous	 particles	
with	some	short	repeat	units	that	can	be	associated	to	fractal	
dimensions.	 Hence,	 analysis	 of	 such	 objects	 by	 SAXS	 often	
involves	 the	 use	 of	 fractal	models.	 Also,	 the	weakening	 and	
eventually	disappearance	of	oscillations	in	the	Porod	region	is	
known	 to	 be	 directly	 proportional	 to	 the	 sample’s	
polydispersity,18	 which	 is	 consistent	 with	 the	 straight	 Porod	
region	 shown	by	 these	 samples	 (Figure	5),	 and	 confirms	 the	
high	 polydispersity	 of	 PIC	 nanoparticles	 observed	 by	 DLS	
(Table	S1),	also	inferred	from	the	high	Rg/RH	values	obtained	





values	determined	by	SLS	 (Figure	4)	and	 the	spherical	 shape	
previously	 observed	 for	 some	 of	 these	 PIC	 nanoparticles	 by	
imaging	 techniques.10	 However,	 in	 the	 absence	 of	
experimental	 data	 points	 in	 the	 Guinier	 region	 to	 verify	 the	
goodness	of	 the	GP	 fit,	 the	 size	 and	 shape	of	 these	 samples	
inferred	from	SAXS	are	merely	indicative.	
In	 summary,	both	SLS	and	SAXS	consistently	 indicate	 that	all	










and	 can	 hydrolyse	 this	 sequence	 between	 the	 Gly	 and	 Leu	
residues.20	Additionally,	in	order	to	assess	their	degradation	by	
host	 enzymes,	 the	 peptides	 were	 also	 evaluated	 against	
Human	Leukocyte	Elastase	(HLE),	an	elastase	released	by	white	























































































normalised	 to	 the	 fluorescence	 emission	 of	 the	 peptide	
fragment	that	would	form	upon	enzymatic	cleavage	(P5,	H2N-
LA-E-OH)	 at	 the	 same	 concentration,	 accounting	 for	 100%	
hydrolysis.		





simply	 an	 effect	 of	 their	 multivalency.	 However,	 circular	
dichroism	 analysis	 suggested	 all	 peptides	 had	 a	 random	
conformation	 (Figure	S16),	without	 any	 structural	 difference	
between	 them.	 Interestingly,	 while	 peptide	 P3SH	 showed	 a	
complete	 specificity	 as	 substrate	 for	 LasB	 over	 HLE,	 the	
addition	 of	 an	 extra	 Cys	 residue	 in	 peptide	 P4SH	 caused	 a	
severe	loss	in	selectivity,	which	was	degraded	ca.	50%	as	much	
by	HLE	as	by	LasB.	Hence,	peptide	P3SH	was	selected	 for	 the	






or	WT)	 that	 produces	 LasB	was	 incubated	with	 PIC	 particles	
prepared	 at	 [N:COOH]	 ratios	 of	 1:0.3	 and	 1:1.0.	 These	 two	
formulations	 were	 selected	 to	 test	 both	 positively	 and	
negatively	 charged	 nanoparticles,	 respectively	 (Figure	 2).	 In	
this	experiment,	the	antimicrobial	activity	of	PIC	particles	was	
correlated	to	the	number	of	cells	stained	in	red	with	propidium	
iodide,	 a	 fluorescent	 probe	 that	 only	 stains	 bacteria	 with	
damaged	 membranes.	 The	 antimicrobial	 activity	 of	 PIC	
particles	was	measured	every	hour	over	 four	hours,	 and	 the	
red	stained	(i.e.	dead)	population	of	bacteria	was	normalised	
to	 that	 found	 in	 a	 positive	 (100%	 alive)	 and	 negative	 (100%	
dead)	controls	(Figure	S17).	
PIC	 particles	 displayed	 very	 weak	 antimicrobial	 activities,	
below	 13%,	 regardless	 of	 the	 bacterial	 strain	 or	 incubation	
time	(Figure	7).	Unexpectedly,	no	distinct	activities	were	found	
for	any	of	the	PIC	particle	formulations	tested	between	strains.	






of	 B-PEI	 after	 3	 hours	 (Figure	 S18),	 PIC	 particles	 were	
dramatically	 less	 toxic	 than	 the	 uncomplexed	 antimicrobial	
polymer	 B-PEI.	 These	 results	 highlight	 the	 capacity	 of	 these	
nanomaterials	 to	 improve	 the	 therapeutic	 profile	 of	 certain	
drugs,	 allowing	 in	 this	 case	 an	 excellent	 reduction	 in	 the	
toxicity	of	the	antimicrobial	B-PEI.	
Enzymatic	degradation	of	PIC	particles	
To	 understand	 the	 lack	 of	 enzyme-specific	 antimicrobial	











these	 PIC	 particles	 remained	 unaffected	 by	 LasB	 was	
confirmed	by	 the	 fluorescence	quantification	of	amines	with	

































Figure	 6	 Normalised	 peptide	 hydrolysis	 quantified	 with	 fluorescamine	 after	 4	
hours	of	incubation	of	the	peptides	with	bacterial	(LasB)	or	human	(HLE)	elastase.	
n	=	3,	mean	values	±	SD.































active	 peptide	 P3SH	 were	 assessed.	 These	 nanoparticles,	 for	
having	 a	 negative	 ζ-potential	 (Figure	 2),	 should	 have	 their	
surface	 coated	 with	 anionic	 peptide,	 thus	 exposing	 the	
enzyme-responsive	component	more	than	positively	charged	






6),	 their	 complexation	with	 B-PEI	 inhibits	 the	 activity	 of	 this	




multivalent	peptides	 like	P2-P4SH	 for	B-PEI	than	P1SH,	 leading	
to	more	tightly	bound	and	less	accessible	peptide	chains	within	
PIC	 particles.	 The	 selective	 enzymatic	 degradation	 of	 PIC	
particles	based	on	the	multivalency	of	 their	components	has	
been	 previously	 observed	 in	 other	 polyelectrolyte	 systems.	
Leclercq	et	al.	reported	faster	degradation	rates	by	proteases	
when	 PIC	 particles	 were	 prepared	 from	 poly(L-lysine)	 with	
shorter	 poly(L-lysine	 citramide)	 chains.
22
	 Fischer	et	 al.	 found	
that	the	degradation	of	DNA	by	nucleases	was	prevented	when	





it	 has	 been	 proposed	 that	 polyelectrolytes	 with	 high	
multivalencies	 can	 inhibit	 the	 enzymatic	 degradation	 of	
oppositely	 charged	 materials	 by	 acting	 as	 a	 physical	 and	




(i.e.	 [N:COOH]	 =	 1:1),	 with	 loose	 peptide	 chains	 on	 their	
surface,	did	not	show	any	reactivity	towards	LasB.	We	think	the	















We	 have	 successfully	 synthesised	 and	 characterised	 a	
collection	 of	 three	 LasB-responsive	 peptides	 with	 increasing	
multivalencies	 and	 cross-linking	 units	 (P2-4SH).	 PIC	 particles	
were	assembled	 from	these	peptides	 in	combination	with	B-
PEI,	 and	 displayed	 tunable	 sizes	 and	 charges	 depending	 on	
their	[N:COOH]	ratio.	It	was	also	found	that	the	stability	under	
simulated	 physiological	 conditions	 of	 PIC	 particles	 improves	
with	the	multivalency	and	cross-linking	degree	of	the	peptides	
(P1SH<P2SH<P3SH<P4SH).	 The	 internal	 structure	 of	 these	
complexes	was	evaluated	by	SLS,	DLS	and	SAXS,	and	suggested	
that	 these	 samples	 are	 highly	 polydisperse	 spheres,	with	 no	
distinct	 structural	 features	 between	 them.	 The	 enzymatic	
degradation	of	these	peptides	was	assessed	against	bacterial	
(LasB)	 and	 human	 (HLE)	 elastase,	 and	 it	 was	 found	 that	
additional	 Cys	 and	 Glu	 residues	 have	 an	 effect	 on	 their	
enzymatic	susceptibility.	Finally,	it	was	observed	that	these	PIC	
particles	dramatically	 reduced	 the	 toxicity	of	B-PEI,	 however	
no	 LasB-specific	 antimicrobial	 activity	 was	 triggered	 in	 the	





This	 effect	 was	 not	 found	 previously	 for	 a	 less	 multivalent	
peptide	 (P1SH),	 and	 suggests	 that	more	multivalent	 peptides	
(P2-4SH)	lead	to	more	tightly	bound	polyelectrolytes	within	the	
PIC	 particles,	 thus	 compromising	 their	 enzymatic	
susceptibility.	 Alternatively,	 anionic	 PIC	 particles	may	 inhibit	
LasB’s	 activity	 by	 chelating	 and/or	 displacing	 its	 metal	
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N-Fmoc-protected	 L-amino	 acids	were	 purchased	 from	Merck	Millipore.	 Dimethylformamide	 (DMF),	 piperidine	
20%	v/v	in	DMF	and	acetic	anhydride	were	purchased	from	Sigma-Aldrich®.	H-L-Cys(Trt)-2-chlorotrityl	resin	(0.49	







MS	 spectra	were	obtained	on	a	Xevo®	G2-XS	ToF	 (Waters)	 from	electrospray	 ionisation	 (ESI)	 and	 time-of-flight	










minutes.	 Then,	 solutions	 of	 Fmoc-L-amino	 acid	 (3	 eq),	 N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium	
hexafluorophosphate	 (HBTU)	 (2.8	 eq)	 and	N,N-diisopropylethylamine	 (DIPEA)	 (2.8	 eq)	 in	DMF	were	 added	 to	 a	
final	 volume	 of	 5	 mL.	 The	 reaction	 mixture	 was	 rolled	 for	 1	 h	 at	 room	 temperature,	 after	 which	 a	 negative	




the	 peptide	 was	 capped	 by	 reacting	 with	 5	 mL	 of	 acetic	 anhydride:DIPEA:DMF	 (1:1:3)	 for	 1	 h	 at	 room	
temperature.	Then,	the	resin	was	thoroughly	washed	with	DMF	and	diethyl	ether,	and	the	peptide	was	cleaved	
from	the	resin	with	5	mL	of	a	mixture	containing	TFA	(80%),	TIPS	(8%)	and	EDT	(12%)	for	2	h.	After	this	time,	the	






















5H,	NHCO);	12.20(br.s,	 4H,	COOH)	ppm.	 13C-NMR	 (400	MHz,	DMSO-d6):	δ	17.4(Cβ-Ala);	21.4(Hδ-Leu	 );	 22.3(Ac);	
22.9(Hδ-Leu);	 23.9(Hγ-Leu);	 25.2(Cβ-Cys);	 25.9(Cβ-Cys);	 26.7(Cβ-Cys);	 27.2(Cβ-Glu);	 29.7(Cγ-Glu);	 29.8(Cγ-Glu);	
29.8(Cγ-Glu);	 29.9(Cγ-Glu);	 40.7(Cβ-Leu);	 41.6(Cα-Gly);	 48.0(Cα);	 50.6(Cα);	 51.4(Cα);	 51.5(Cα);	 51.8(Cα);	 52.0(Cα);	
54.2(Cα);	 55.0(Cα);	 168.5(NHCO);	 169.8(Ac);	 170.2(NHCO);	 170.9(NHCO);	 171.0(NHCO);	 171.1(NHCO);	


































































































































ppm.	 13C-NMR	 (400	MHz,	DMSO-d6):	 δ	17.4(Cβ-Ala);	 21.4(Hδ-Leu);	 22.3(Ac);	 22.8(Hδ-Leu);	 23.9(Hγ-Leu);	 25.2(Cβ-
Cys);	25.9(Cβ-Cys);	26.7(Cβ-Cys);	27.0(Cβ-Glu);	27.1(Cβ-Glu);	27.2(Cβ-Glu);	29.9	(Cγ-Glu);	40.8(Cβ-Leu);	41.6(Cα-Gly);	
48.0(Cα);	 50.6(Cα);	 51.5(Cα);	 51.6(Cα);	 51.7(Cα);	 51.8(Cα);	 51.9(Cα);	 54.2(Cα);	 54.9(Cα);	 168.5(NHCO);	 169.7(Ac);	
170.1(NHCO);	 171.0(NHCO);	 171.0(NHCO);	 171.2(NHCO);	 171.4(NHCO);	 171.4(NHCO);	 171.9(NHCO);	
172.3(NHCO);	 174.0(COOH)	 ppm.	 MS	 (ESI-TOF,	 +eV):	 m/z	 1282.4	 [M+H]+;	 668.7	 [M+H+Na+CH3OH]2+;	 660.7	









































































































































P4SH,	Ac-CEECEGLAEEEC-OH	 (208.0	mg,	98%	yield)	 1H-NMR	 (400	MHz,	DMSO-d6):	δ	0.84(dd,	 J=14.5,	6.6	Hz,	6H,	
Hδ-Leu);	 1.19(d,	 J=7.0	Hz,	 3H,	Hβ-Ala);	 1.36-1.46(m,	 2H,	Hβ-Leu);	 1.51-1.61(m,	 1H,	Hγ-Leu);	 1.67-1.81(m,	 6H,	Hβ-
Glu);	1.83-1.95(m,	6H,	Hβ-Glu);	1.87(s,	3H,	Ac);	2.17-2.31(m,	12H,	Hγ-Glu);	2.36(dt,	J=8.5,	2.8	Hz,	2H,	SH);	2.44(t,	
J=8.5	Hz,	 1H,	 SH);	 2.62-2.89(m,	 6H,	Hβ-Cys);	 3.70(ddd,	 J=54.5,	 16.7,	 5.8	Hz,	 2H,	Hα-Gly);	 4.19-4.42(m,	 11H,	Hα);	
7.90-8.20(m,	 12H,	NHCO);	 12.16(br.s,	 5H,	 COOH)	 ppm.	 13C-NMR	 (400	MHz,	 DMSO-d6):	 δ	 17.4(Cβ-Ala);	 21.4(Hδ-
Leu);	 22.3(Ac);	 22.9(Hδ-Leu);	 23.9(Hγ-Leu);	 25.2(Cβ-Cys);	 25.9(Cβ-Cys);	 26.8(Cβ-Cys);	 27.0(Cβ-Glu);	 27.1(Cβ-Glu);	
27.1(Cβ-Glu);	 27.2(Cβ-Glu);	 40.8(Cβ-Leu);	 41.6(Cα-Gly);	 48.0(Cα);	 50.5(Cα);	 51.5(Cα);	 51.6(Cα);	 51.7(Cα);	 51.9(Cα);	














































































































































































Peptide	 [N:COOH]	ratio	 DH	±	SD	(nm)	 ζ-potential	±	SD	(mV)	 Notes	
P2SH	
1	:	2.0	 371	±	51	 -9.6	±	3.9	 -	
1	:	1.5	 329	±	42	 -10.0	±	3.1	 -	
1	:	1.0	 293	±	30	 -9.1	±	3.5	 -	
1	:	0.8	 -	 -	 No	particles	found	
1	:	0.7	 -	 -	 No	particles	found	
1	:	0.6	 -	 -	 No	particles	found	
1	:	0.5	 -	 -	 No	particles	found	
1	:	0.4	 419	±	67	 +11.7	±	5.2	 -	
1	:	0.3	 91	±	32	 +19.1	±	6.2	 -	
1	:	0.2	 -	 -	 No	particles	found	
P3SH	
1	:	2.0	 227	±	50	 -21.3	±	6.3	 -	
1	:	1.5	 204	±	51	 -18.5	±	6.4	 -	
1	:	1.0	 198	±	47	 -18.3	±	6.7	 -	
1	:	0.8	 212	±	44	 -16.5	±	6.0	 -	
1	:	0.7	 224	±	45	 -16.0	±	6.8	 -	
1	:	0.6	 280	±	55	 -15.8	±	4.8	 -	
1	:	0.5	 -	 -	 No	particles	found	
1	:	0.4	 240	±	47	 +13.9	±	5.1	 -	
1	:	0.3	 103	±	42	 +21.3	±	7.9	 -	
1	:	0.2	 -	 -	 No	particles	found	
P4SH	
1	:	2.0	 198	±	45	 -20.6	±	6.1	 -	
1	:	1.5	 192	±	43	 -20.6	±	7.2	 -	
1	:	1.0	 191	±	41	 -20.2	±	5.8	 -	
1	:	0.8	 173	±	36	 -17.0	±	7.4	 -	
1	:	0.7	 176	±	39	 -17.7	±	7.2	 -	
1	:	0.6	 205	±	39	 -11.1	±	7.5	 -	
1	:	0.5	 -	 -	 No	particles	found	
1	:	0.4	 225	±	46	 +15.2	±	5.4	 -	
1	:	0.3	 143	±	40	 +17.7	±	7.7	 -	
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PIC particles from P3SH, [N:COOH] = 1:0.3






















































































































































































PIC + borate (control)




















PIC + borate (control)
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Overview: The enzyme-responsive nanoparticles described in Chapters 2 and 3 
did not have the desired antimicrobial properties they were designed for: most of 
these PIC particles did not display any antimicrobial effect in the presence of the 
targeted pathogen Pseudomonas aeruginosa, and even the ones that did show 
a pathogen-specific action, displayed very weak activities compared to that of the 
antimicrobial polymer loaded into them (i.e. PEI). At this stage, we argued that 
the poor antimicrobial activity of these PIC particles could due to the limited hy-
drolytic activity of the pathogenic enzyme LasB towards complexed peptides, 
which may be less accessible to LasB when aggregated into PIC particles. How-
ever, we also considered that the intrinsically weak antimicrobial activity of PEI 
could be limiting the results we were observing, and so it was proposed to eval-
uate the activity of PIC particles loaded with a stronger antibiotic. 
The FDA-approved antibiotic polymyxin B (Pol-B) was selected as an alternative 
to PEI for its important clinical application, currently used as last resort treatment 
against multidrug-resistant Gram-negative infections. As such, we explored the 
 97 
assembly of PIC particles from Pol-B and the anionic peptides presented in Chap-
ters 2 and 3. Unfortunately, none of the Pol-B/peptide mixtures tested formed PIC 
nanoparticles, probably due to the low multivalency of both polyelectrolytes, 
which makes the assembly of PIC particle more difficult – as explained in Chapter 
1. It must be noted that the studies to assemble Pol-B/peptide PIC particles are 
not described in this Chapter, written as a paper not linked to the previous work 
described in this thesis. 
Based on the stronger binding between more multivalent polyelectrolytes (Chap-
ter 1), we decided to approach the challenging assembly of PIC particles from 
small pentacationic Pol-B with an anionic polymer of very high multivalency. 
Thus, the low net charge of this antibiotic could be compensated with a macro-
molecular polyelectrolyte. We selected poly(styrene sulfonate) (PSS) to this end 
for being commercially available and FDA-approved, hence biocompatible. 
Pol-B was successfully complexed with PSS, and the resulting PIC particles dis-
played tuneable physiological stabilities and antimicrobial properties based on 
their charge ratios (i.e. Pol-B/PSS blends). 
Unlike the bacteria-targeted nanoparticles described in Chapters 2 and 3, these 
Pol-B/PSS PIC nanoparticles cannot sense bacterial enzymes, and the mecha-
nism they follow to release the antibiotic is their unspecific swelling in physiolog-
ical media and diffusion of the pre-loaded drug (i.e. passive release). However, 
although these nanoparticles cannot vectorise Pol-B to the pathogen, this system 
allows the preparation of PIC particles loaded with an approved antibiotic, and 
thus brings the development of the antimicrobial PIC particles investigated in this 
thesis closer to a potential clinical application. These nanoparticles can be useful 
tools to better control the dosing and minimise sub-inhibitory concentrations of 
antibiotics, which can prevent the development of new antimicrobial resistances. 
 
Contributions: All authors contributed to the experimental set-up and discussed 
the results. II and FFT designed the nanoparticle synthesis and characterisation, 
and II, FFT and AMK designed the microbiological assays. II and SM carried out 
the microbiological assays, and II carried out all other experiments. II and FFT 
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analysed the data and wrote the paper, with all other authors contributing to the 























Preparation and antimicrobial evaluation of polyion complex
(PIC) nanoparticles loaded with polymyxin B
Ignacio Insua a,c, Sieta Majok b,c, Anna F.A. Peacock a, Anne Marie Krachler b,c,
Francisco Fernandez-Trillo a,c,⇑
a School of Chemistry, University of Birmingham, B15 2TT Birmingham, UK
b School of Biosciences, University of Birmingham, B15 2TT Birmingham, UK
c Institute of Microbiology and Infection, University of Birmingham, B15 2TT Birmingham, UK
a r t i c l e i n f o
Article history:
Received 7 July 2016
Received in revised form 23 August 2016
Accepted 24 August 2016






a b s t r a c t
Here, we describe novel polyion complex (PIC) particles for the delivery of Polymyxin B
(Pol-B), an antimicrobial peptide currently used in the clinic as a last resort antibiotic
against multidrug-resistant gram-negative bacteria. A range of conditions for the con-
trolled assembly of Pol-B with poly(styrene sulphonate) (PSS) has been identified which
let us prepare stable colloidal PIC particles. This way, PIC particles containing different
Pol-B:PSS ratios have been prepared and their stability under simulated physiological
conditions (i.e. pH, osmotic pressure and temperature) characterised. Furthermore, prelim-
inary evaluation of the antimicrobial activity of these Pol-B containing PIC particles has
been performed, by monitoring their effect on the growth of Pseudomonas aeruginosa, an
opportunistic gram-negative bacterium.
! 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The increasing number of drug-resistant bacteria poses a serious risk to global health [1,2]. This increase in antimicrobial-
resistant strains and the lack of new drugs reaching the market is encouraging the use of alternative approaches for the treat-
ment of these infections [3,4]. One of these strategies is the resurgence of ‘‘old” antibiotics such as polymyxins, which are
now prescribed more often as last-resort antimicrobials against gram-negative multidrug-resistant strains [5–7]. However,
polymyxins are toxic, and therefore strategies are required to minimise this toxicity and ensure that effective dosing of the
antimicrobial is achieved [8]. Moreover, with the emergence of transmittable resistance to polymyxins [9,10], strategies that
can minimise systemic exposure to polymyxins are highly desirable.
Toxicity in polymyxins is associated with their amphiphilic and cationic nature. Therefore, the current strategy to
minimise their toxicity is either to reduce the number of cationic residues and amphiphilic character [11], or to synthesise
pro-drugs where cationic groups are masked to give a negatively-charged derivative [12,13]. However, both strategies often
result in a loss of antimicrobial activity, because this activity is directly linked to the presence of these cationic charges.
The synthesis of polymer-drug conjugates has been employed as an alternative [14,15], but this strategy still relies
on the covalent attachment of polymyxin (or derivatives) to the polymer backbone, with the resulting loss in activity [14,16].
http://dx.doi.org/10.1016/j.eurpolymj.2016.08.023
0014-3057/! 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: School of Chemistry, University of Birmingham, B15 2TT Birmingham, UK.
E-mail address: f.fernandez-trillo@bham.ac.uk (F. Fernandez-Trillo).
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There are several strategies for the delivery of antimicrobial peptides and derivatives [17,18]. We and others have been
exploring the use of polyion complex (PIC) nanoparticles as a platform for the delivery of this type of antimicrobials [19–24].
In this approach, the positive charge in cationic antimicrobial polymers and peptides is neutralised in the presence of a neg-
atively charged ‘‘polymer”. Under the right conditions, coacervate particles are formed upon neutralisation [25]. This way,
positive charges are shielded from solution, without having to modify the structure of the antimicrobial (Fig. 1). In this article
we describe the preparation of PIC nanoparticles as drug carriers for cationic polymyxin B sulphate (Pol-B), prepared by com-
plexation of this antimicrobial with anionic poly(styrene sulphonate) (PSS). Different formulations were obtained by adjust-
ing the Pol-B loading within these nanoparticles, and the formed PIC particles were characterised by Dynamic Light
Scattering (DLS), f-potential and Transmission Electron Microscopy (TEM). Then, the stability of these nanomaterials was
assessed under simulated physiological conditions. Finally, preliminary evaluation of the antimicrobial activity of these
Pol-B:PSS PIC particles was done against Pseudomonas aeruginosa, an opportunistic gram-negative bacterium, and compared
to that of free Pol-B to evaluate the differences in antibiotic activity of free and complexed drug.
2. Experimental
2.1. Materials
Polymyxin B sulphate (Pol-B) was purchased from Alfa Aesar!. Sodium poly(styrene sulphonate) 70 KDa average molec-
ular weight (PSS), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), phosphotungstic acid hydrate and Luria Ber-
tani (LB) broth (Miller) were bought from Sigma-Aldrich Co. Nylon 0.45 lm syringe filters were purchased from Camlab Ltd.
Carbon-coated copper TEM grids (200 mesh) were purchased from Agar Scientific Ltd. Float-a-Lyzer! G2 (20 KDa MWCO)
dialysis membranes were purchased from Spectrum Laboratories Inc. Dulbecco’s phosphate buffered saline (DPBS),
9.5 mM in phosphate and without Ca2+ and Mg2+, was bought from Lonza. Agar was purchased from Sigma-Aldrich Co.
2.2. Instrumentation
Dynamic light scattering (DLS) and f-potential measurements were carried out in a Zetasizer Nano ZS (Malvern Instru-
ments Ltd.) stabilised at 37 "C. DLS was read at 173" (backscattering) for 60 s in triplicate and f-potentials were recorded
30 times at 140 V. TEM images of PIC nanoparticles were acquired on a JEM-1200EX (JEOL USA Inc.). PIC particle size was
measured from TEM micrographs using ImageJ software (version 1.48v) and measuring each nanoparticle twice: both in
their longest and shortest diameters. Reverse phase HPLC analysis was run through a Kinetex! C18-EVO column (Phenom-
enex!): 5 lm, 100 Å, 250 ! 4.60 mm, stabilised at 35 "C and fitted to a SPD-M20A UV–vis detector (Shimadzu Co.) monitor-
ing absorbance at 210 nm. A Loctite! LED flood array (Henkel Ltd.) operating at 405 nm was used to sterilise the samples
studied in the bacterial growth experiment. A FLUOstar Omega (BMG Labtech GmbH.) microplate reader was used to incu-
bate and measure the optical density at 600 nm (OD600) in the bacterial growth experiments. Pictures of agar plates were
taken on a ChemiDocTM MP imaging system (Bio-Rad laboratories Inc.).
2.3. Preparation of PIC nanoparticles
PIC particles from Pol-B and PSS were prepared following the protocol previously described by our group [20]. The dif-
ferent formulations of PIC particles are defined by their [N:SO3Na] ratio, which represents the proportion of amines in
Pol-B over sulphonate groups in PSS. As an example, for the preparation of PIC particles at 0.5 [N:SO3Na] (i.e. half the amount
of amines compared to sulphonate groups), solutions of Pol-B (0.25 mM) and PSS (2.5 mM in monomer units) were prepared
separately in 5 mM HEPES buffer at pH 7.4. Then, both stock solutions were filtered through 0.45 lm nylon syringe filters
and mixed in equal amounts drop-wise under stirring. PIC nanoparticles at other [N:SO3Na] ratios were obtained by
Fig. 1. Assembly of PIC nanoparticles from cationic antimicrobial polymyxin B and anionic PSS.
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changing the concentration of the Pol-B stock solution and mixing with 2.5 mM PSS following the same protocol. After 24 h,
samples were characterised by DLS and f-potential without prior dilution nor filtration.
2.4. Stability of PIC nanoparticles in simulated physiological conditions
To a sample of PIC particles (1 mL), prepared as described above, 182 lL of a 1 M solution of NaCl in water was added and
the mixture was incubated at 37 !C to obtain physiological osmotic pressure and temperature. Every hour, the sample was
analysed by DLS as described above.
2.5. Pol-B release from PIC particles
2.5 mL of a PIC particle sample prepared at 0.7 [N:SO3Na] ratio were transferred into a pre-conditioned dialysis mem-
brane (Float-a-Lyzer" G2), which was dialysed against 15 mL of DPBS at 37 !C under stirring (300 rpm). 500 lL of dialysate
were taken at different time points and replaced with fresh DPBS. The dialysate samples were analysed by HPLC using an
adaptation of the method previously reported by Orwa et al. [26], using a 50:23:22:5 mixture of 50 mM Na2SO4 in H2O:
H2O: AcCN: 5% (v/v) dilution of 85% (m/m) H3PO4 in H2O running at 1 mL/min. 3 replicates were studied under the same
conditions. At every time point, the area under the peak of Pol-B (Rt = 2.7 min) found in each dialysate sample was nor-
malised to the area found in a 2.5 mL sample of Pol-B prepared at the same concentration as that contained in PIC particles
at 0.7 [N:SO3Na] ratio (175 lM) diluted with 15 mL of DPBS (100% release). The same protocol was followed using a 175 lM
Pol-B sample in 5 mM HEPES buffer pH 7.4 instead of PIC particles.
2.6. Growth curves of bacteria with PIC particles
50 lL aliquots of P. aeruginosa PAO1V cultures in LB broth (OD600 = 0.2) were loaded in the designated positions of a 96-
well microplate. These bacterial cultures were mixed with 50 lL of PIC particles or free Pol-B in 5 mM HEPES buffer pH 7.4 to
compare the antimicrobial activity of free and complexed (within PIC particles) Pol-B at the same concentration. In addition,
these bacterial cultures were mixed with 50 lL of 5 mM HEPES buffer pH 7.4 as positive growth control and 1.25 mM (in
monomer units) PSS in 5 mM HEPES buffer pH 7.4. Finally, 100 lL of a 1:1 mixture of the LB broth and 5 mM HEPES buffer
pH 7.4 was also spotted in the microplate to confirm the sterility of the media. All samples were prepared in triplicate, with
mean values and standard deviations reported. The microplate was incubated at 37 !C and orbital shaking, and the OD600 was
monitored every 30 min for at least 15 h. The samples of PIC particles, free Pol-B, PSS and 5 mM HEPES buffer 7.4 were ster-
ilised prior to this experiment by exposure to blue light (405 nm) for 2 h at a distance of 15 cm from the light source.
2.7. Antimicrobial assay of PIC particles: CFU counting
100 lL aliquots of a P. aeruginosa PAO1V culture in LB broth (OD600 = 0.2) were mixed with 100 lL of either PIC particles
prepared at different [N:SO3Na] ratios or Pol-B solutions at the same concentration found in the PIC particles. In addition, the
P. aeruginosa PAO1V culture was mixed likewise with 5 mM HEPES buffer pH 7.4 and a 1.25 mM PSS solution in this same
buffer as controls. All mixtures were incubated at 37 !C for 22 h. After this time, 10 lL of each sample were spotted in trip-
licate on an agar plates in serial dilution, from undiluted down to a 108-fold dilution in 102 increments. These agar plates
were then incubated at 37 !C. After 16 h of incubation, the agar plates were photographed and bacterial concentrations in
CFU/mL were calculated from the highest dilution that showed individual colonies. All samples were sterilised prior to this
experiment by exposure to blue light (405 nm) for 2 h at a distance of 15 cm from the light source.
3. Results and discussion
Our aim was to develop and evaluate a novel nanoparticle system for the delivery of Pol-B, easy to prepare, inexpensive
and with tuneable antimicrobial loading capacity. Based on the pentacationic structure of Pol-B, we postulated the prepara-
tion of polymeric nanoparticles by incubating this antibiotic under mild conditions with a negatively charged polyelec-
trolyte. We anticipated that a strong polyelectrolyte such as PSS would facilitate complexation of Pol-B, and compensate
for the relative low multivalency (i.e. number of cationic residues) of this antibiotic: Pol-B has five amine residues derived
from diaminobutanoic acid (Fig. 1). At physiological pHs, these amines should be ‘‘fully” cationic with at least 95% protona-
tion (pKaH 9–10) [27], giving Pol-B only five positive charges. Moreover, a considerably high molecular weight PSS (70 KDa)
was selected to maximise the entropic gain upon PSS:Pol-B complexation. Also, PSS presents a hydrophobic styrene back-
bone, which could facilitate interactions with the hydrophobic residues in Pol-B and its aliphatic chain, that gives Pol-B
an amphiphilic character (Fig. 1). Finally, it should be mentioned that PSS is an already approved pharmaceutical ingredient
[28] and thus constituted an ideal starting point to develop our Pol-B containing PIC particles.
The preparation of Pol-B containing PIC nanoparticles was optimised by mixing stock solutions of this antimicrobial (in
5 mM HEPES buffer) with a 2.5 mM (per monomer) stock solution of PSS in the same buffer, following a protocol recently
employed in our laboratories for the preparation of PIC particles containing short enzyme-responsive peptides [20]. At first,
480 I. Insua et al. / European Polymer Journal 87 (2017) 478–486
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a broad range of [N:SO3Na] ratios was explored going from a 5-fold excess of cationic residues to a 5-fold excess of anionic
groups (Fig. S1y). Not surprisingly, when equimolar amounts of ammonium and sulphonate groups were mixed, unstable
suspensions were obtained that flocculated. The presence of these macroscopic aggregates suggested that neutral coacer-
vates were being formed, which were not stable in suspension and eventually phase separated. The same result was obtained
for all the formulations prepared using an excess of positive charge ([N:SO3Na] > 1) (Fig. S1y), suggesting that the sequential
adsorption of Pol-B molecules on PSS neutralises the initial negative charge in the primary complexes formed [25]. Further
addition of Pol-B once these neutral flocculates are formed is redundant, as they cannot be recruited into the forming par-
ticles due to the lack of negative charge in these aggregates. This behaviour has been observed in the literature during the
formation of PIC particles from small oligomeric electrolytes [20,23,25]. Interestingly, flocculation was also observed in mix-
tures below but very close to equimolarity (0.8 [N:SO3Na] ratio) suggesting that not all styrene units had a sulphonate group.
A commercial source of PSS was used in this work and the observed deviation from equimolarity could be explained because
the industrial production of PSS from polystyrene results in different degrees of sulphonylation.
Having established that colloidal particles were only obtained at sub-stoichiometric ratios of Pol-B, this range was again
explored but 10 different formulations were investigated (Fig. 2A). Again, flocculation was observed for those formulations
prepared with ratios close to equimolarity (1, 0.9 and 0.8 [N:SO3Na] ratios). Yet, we were able to obtain colloidal PIC particles
from 0.7 to 0.1 [N:SO3Na] ratios, all of which showed very similar sizes, with mean hydrodynamic diameters between 166
and 186 nm (Fig. 2B and Table S1y). All PIC particles obtained were negatively charged (f-potential of ca. !40 mV), as
expected the excess of PSS present in these formulations. Particles prepared at a 0.7 [N:SO3Na] ratio displayed a slightly
smaller f-potential of !30 mV (Fig. 2B). While the difference in charge was small, this reduction in charge follows the
expected trend towards less negatively charged particles as the formulation approaches equimolarity. TEM was performed
on PIC particles prepared at a 0.4 [N:SO3Na] ratio, selected as a representative example of all seven formulations charac-
terised by DLS (Fig. 2C and Fig. S2y). These images confirmed the spherical shape of these nanomaterials and an average par-
ticle diameter of 140 ± 30 nm (n = 58), slightly smaller than the hydrodynamic diameter measured by DLS (174 ± 49 nm).
This apparent reduction in size found by TEM can be attributed to drying upon sample preparation, which could result in
these highly hydrated nanomaterials shrinking as the solvent evaporates [29].
Having identified a range of ratios from which Pol-B containing colloidal PIC particles could be prepared, the stability of
these particles under simulated physiological conditions was assessed. It is well established that the presence of small elec-
trolytes can shield the electrostatic attraction between the oppositely charged components of these nanomaterials. This
screening normally results in particle swelling and can eventually lead to the disassembly of the PIC particle [25]. Since
Pol-B loading dictated the number of electrostatic cross-links present in these colloids, it was anticipated that different
[N:SO3Na] ratios would behave differently in the presence of biologically relevant salt concentrations. Thus, the seven dif-
ferent formulations of PIC particles identified so far were incubated with 154 mM NaCl at 37 !C and analysed over time
by DLS, to assess their tolerance to physiological conditions (i.e. osmotic pressure and temperature) (Fig. 3). Broadly, particles
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Fig. 2. (A) Macroscopic appearance of particles prepared at different [N:SO3Na] ratios. (B) Hydrodynamic diameter (DH, d) and f-potential (s) of PIC
particles prepared at different [N:SO3Na] ratios. (C) Representative transmission electron micrograph of PIC particles prepared at a 0.4 [N:SO3Na] ratio;
Scale bar = 1 lm.
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(1) A remarkable increase in particle size was observed for those PIC particles prepared at 0.7 and 0.6 [N:SO3Na] ratios
(Fig. 3A and B). Micron-sized aggregates could be identified for these formulations, probably due to a combination
of swelling and inter-particle aggregation as observed for other PIC particle systems [30].
(2) A region of high particle stability was found for formulations prepared between 0.5 and 0.2 [N:SO3Na] ratios, for which
the mean size remained almost unchanged during this experiment. For this group, only particles prepared at a 0.5 [N:
SO3Na] ratio changed their size significantly upon exposure to higher osmotic pressure, doubling their size after two
hours. These particles then remained swollen and unchanged for the following hours (Fig. 3 and Fig. S4y).
(3) PIC particles prepared at a 0.1 [N:SO3Na] ratio displayed very poor stability under these conditions, breaking into
small-sized amorphous aggregates, as suggested by the loss of a sigmoidal profile in their DLS autocorrelation function
curves (Fig. S3y). Overall, PIC particles at 0.1 [N:SO3Na] exhibited the lowest tolerance to salt.
These stability experiments suggested that PIC particles could break apart in the presence of physiological conditions and
therefore release the encapsulated Pol-B. To further demonstrate this release, PIC particles prepared at a 0.7 [N:SO3Na] ratio
were immersed in a dialysis tubing and this dialysis tubing suspended in DPBS buffer under mild agitation. Aliquots of the
dialysate were taken at different time points and analysed by HPLC to monitor the release of Pol-B over time (Fig. S5y). Over-
all PIC particles were able to slow the release of Pol-B, with less than 10% of the antibiotic released after 4 h and 80% released
after 48 h. However, these experiments were complicated by two main issues:
(1) There were interactions between Pol-B and the membranes used, as demonstrated by the ‘‘slow release” of free Pol-B
from the dialysis tubing (Fig. S5y, black squares). Membranes of different molecular weight cut-off (MWCO) were
tested to address this limitation, until significant release was observed (over 40% after 8 h) for a 20 KDa MWCO mem-
brane. We believe this ‘‘slow release” was mainly the result of self-assembly of Pol-B, forming supramolecular aggre-
gates with bigger hydrodynamic radius than the membrane porosity. Also, some interaction of Pol-B with the
membrane was evident for the smaller MWCOs tested, with membranes turning opaque after the experiment.
(2) Under the experimental conditions used, Pol-B is a mixture of species (Fig. S6y), and only one of those (peak at 2.7 min)
can be clearly identified in the dialysate.
We then evaluated the effect of encapsulating Pol-B inside these PIC nanoparticles on the activity of this antimicrobial.
We anticipate that upon dilution in media, other electrolytes (e.g. NaCl) will screen the electrostatic interactions between
Pol-B and PSS, facilitating disruption of the particle and the release of Pol-B. Towards this end, changes in optical density
at 600 nm in P. aeruginosa cultures were monitored. This is a well-established indirect measurement of microbial growth
that correlates any increase in the optical density of the culture to an increase in bacteria numbers [31]. Therefore, the effect
PIC particles prepared between 0.7 and 0.1 [N:SO3Na] ratios had on the growth of this pathogen was evaluated this way, and
compared to the growth in the presence of free Pol-B and free PSS (Fig. 4). While PSS had no effect on the growth of this
opportunistic pathogen (Fig. 4A–H, ), with changes in optical density mirroring those for P. aeruginosa alone (Fig. 4A–H, ),
Fig. 3. Autocorrelation function (ACF) curves and representative size-intensity distributions (inset) for PIC particles prepared using six different [N:SO3Na]
ratios in the absence (control) and presence of 154 mM NaCl at 37 !C over time (1–4 h). 0.7 (A), 0.6 (B), 0.5 (C), 0.4 (D), 0.3 (E), 0.2 (F) [N:SO3Na] ratio.
Because of the dispersion in DLS measurements observed for unstable particles (i.e. 0.1:1 [N:SO3Na] ratio) only representative plots are shown. 3 technical
replicates were recorded for each sample.
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all of the concentrations of Pol-B tested (122.5–17.5 lg mL!1, Fig. 4A–G, ) inhibited P. aeruginosa’s growth for at least 16 h.
A similar effect on growth could be observed for most of the PIC particles evaluated, with P. aeruginosa’s growth inhibited for
at least 8 h. The antimicrobial effect of these PIC particles seemed to be formulation dependent, with those incorporating
more Pol-B inhibiting the pathogen’s growth for longer (e.g. up to 14.5 h for particles prepared at a 0.7 [N:SO3Na] ratio).
The lower activity of these PIC nanoparticles compared to free Pol-B was expected, since these nanomaterials should act
as reservoirs of Pol-B that is then slowly released from the nanoparticle. More surprising though was the fact that optical
density in the presence of the particles was often higher than that in the presence of the same amount of Pol-B ( vs
for each of the particles examined). This difference was more pronounced for those particles containing higher concentra-
tions of Pol-B, with those prepared at a 0.7 [N:SO3Na] ratio exhibiting an initial OD600 of 0.3, which was maintained through
the duration of the experiment. Since these particles were able to scatter light (Fig. 2), and the intensity of this scattering was
dependent on the formulation but also the conditions to which these particles were exposed (Fig. 3), we decided to evaluate
if these particles could affect the optical density of the media in the absence of any microorganism. Incubation of particles
with LB media in the absence of P. aeruginosa confirmed that this was the case, with particles increasing the optical density of
the media in a formulation dependent fashion (Fig. 5A). No increase in optical density was observed for any of the individual
components (Fig. S7Ay), suggesting that the observed increase in optical density was a result of the addition of PIC particles.
Particles containing more Pol-B led to higher optical densities at 600 nm, with those prepared at a 0.7 [N:SO3Na] ratio
exhibiting an initial OD600 of 0.28 ± 0.01, very similar to that observed in the presence of P. aeruginosa (Fig. 5B). Overall, this
initial optical density was maintained for the duration of the experiment for most of the PIC particles evaluated, with only
small changes in the optical density observed. Only particles prepared at a 0.7 and 0.6 [N:SO3Na] ratios exhibited significant
changes in OD600. Both formulations increased the optical density of the media initially, but particles prepared at 0.7 [N:SO3-
Na] ratio eventually resulted in an overall reduction in optical density, with an OD600 of 0.23 after 15 h of incubation
(Fig. 5A). This difference in behaviour may reflect the different stabilities of the PIC particles in this media (1:1 LB:HEPES),



























































































Fig. 4. Change in optical density at 600 nm (OD600) for P. aeruginosa cultures in the absence ( ) and presence of PSS ( ), Pol-B ( ) and PIC particles ( )
prepared at 0.7 (A), 0.6 (B), 0.5 (C), 0.4 (D), 0.3 (E), 0.2 (F) and 0.1 (G) [N:SO3Na] ratio. In each case, the concentration of Pol-B was adjusted to that in the PIC
particles employed. Optical density of each of the controls including the media employed (1:1 LB:HEPES, ) is shown for comparison (H). n = 3.
Fig. 5. Representative changes in optical density at 600 nm (OD600) with time ( 0 h, 2 h, 5 h, 10 h, 15 h) for PIC particles, prepared at different [N:
SO3Na] ratios, suspended in 1:1 LB:HEPES media in the absence (A) and presence of P. aeruginosa (B). Changes in OD600 represent the difference between the
initial OD600 (t = 0 h) and the OD600 at each time point. No increase in optical density was observed for any of the individual components in the absence of
P. aeruginosa (Fig. S7Ay). n = 3. Each colour represents a different particle formulation.
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To further investigate the behaviour of the particles in media, a new experiment was set-up in which particles were
diluted even more in growth media (1:0.4 LB:HEPES). A similar trend was observed, both in the absence and presence of
P. aeruginosa, although the higher content of LB media seemed to have a detrimental effect in some of the formulations
(Fig. 6A). This effect was more evident for those particles that had a higher effect on the optical density of the media (0.7
and 0.6 [N:SO3Na] ratios). As before, in the absence of bacteria, these two formulations increased the optical density of
the media, in this case to an OD600 of approximately 0.33. However, optical density for these two formulations was then
reduced, suggesting some degree of instability under these conditions. As before, inhibition of growth for P. aeruginosa in
the presence of the particles was formulation dependent, with particles prepared at a 0.7 [N:SO3Na] ratio sustaining the
longest antimicrobial effect (Fig. 6B and Fig. S8y).
Finally, we also investigated the antimicrobial activity of these Pol-B containing particles by incubating P. aeruginosawith
these particles and counting the resulting colony forming units (CFU). This assay correlates the amount of viable bacteria in a
culture to the number of colonies that are formed after spotting an aliquot of this culture on agar plates [31]. Several dilu-
tions were employed to spot the agar plates, to identify suitable conditions for colony counting (Fig. 7A). In agreement with
the observed antimicrobial activity during growth measurements using changes in OD600, all of the concentrations of free
Pol-B tested inhibited the growth of P. aeruginosa, and no colonies were observed. Also, the antimicrobial activity of the par-
ticles was smaller than that of the free Pol-B (Fig. 7). This effect was formulation dependent but did not correlate with the
amount of Pol-B incorporated in each nanoparticle. For instance, particles prepared at a 0.3 [N:SO3Na] ratio had a higher
activity than those prepared at a 0.4 [N:SO3Na] ratio, despite having almost 25% less amount of Pol-B (Table S1y). However,
particles prepared at 0.6 [N:SO3Na] ratio had a higher activity that those prepared at 0.5 and 0.4 [N:SO3Na] ratios, as
expected from the amount of Pol-B encapsulated and the stability of the particles formed (Table S1y and Fig. 3). We believe
there are several competing mechanisms affecting the observed antimicrobial activities. On the one hand, particle instability
will result in ‘‘easier” release of Pol-B from unstable particles such as those prepared at 0.7, 0.6 or 0.1 [N:SO3Na] ratios. On
the other hand, the amount of Pol-B available will then strongly depend on the amount of Pol-B included in the formulation,
with those prepared at a 0.1 [N:SO3Na] ratio expected to have the lower activity. Overall, all of the concentrations tested
Fig. 6. Representative changes in optical density at 600 nm (OD600) with time ( 0 h, 2 h, 5 h, 10 h, 15 h) for PIC particles, prepared at different [N:
SO3Na] ratios, suspended in 1:0.4 LB:HEPES media in the absence (A) and presence of P. aeruginosa (B). Changes in OD600 represent the difference between
the initial OD600 (t = 0 h) and the OD600 at each time point. No increase in optical density was observed for any of the individual components in the absence



























Fig. 7. (A) Representative agar plates used to evaluate antimicrobial activity of Pol-B containing PIC particles. Lane 1: No dilution, lane 2: 102-fold dilution,
lane 3: 104-fold dilution, lane 4: 106-fold dilution, and lane 5: 108-fold dilution. (B) CFU/mL of P. aeruginosa in the absence (media, ) and presence of PSS
( ) or PIC particles prepared at different [N:SO3Na] ratios (dots, each colour represents a different particle formulation). Experiments were done in
triplicate in 1:1 LB:HEPES media.
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(except those prepared at a 0.7 [N:SO3Na] ratio, which seems to be an outlier) were able to reduce the number of CFU/mL by
approximately 2 orders of magnitude, and a relative reduction of the initial CFUs of over 97%.
4. Conclusions
Here we have presented our efforts towards the development of PIC particles for the delivery of Pol-B, an antimicrobial
peptide of clinical relevance. Using 70 KDa PSS as the inert component of the formulation, we have identified a range of con-
ditions for which Pol-B containing PIC particles can be prepared. We have evaluated the stability of these particles under
simulated physiological conditions (i.e. pH, osmotic pressure and temperature). Preliminary evaluation of the antimicrobial
activity of these PIC particles has been performed by monitoring their impact on P. aeruginosa’s growth. Overall, particles
with a higher content of Pol-B can inhibit growth of this pathogen for longer, although this effect was formulation depen-
dent. Finally, we report that, in the absence of bacteria, Pol-B containing particles are able to increase the optical density
of the growth media in a particle-dependent fashion, an effect that can reflect the different stabilities of the PIC particles
in this medium. Our efforts to optimise antimicrobial activity, including the optimisation of the polymer carrier and the
development of degradable and targeted particles will be reported in due course.
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1. PIC particles preparation and characterisation 
 
Figure S1 Macroscopic appearance of particles prepared at different [N:SO3Na] ratios. 
Table S1 Hydrodynamic diameter (DH), -potential and concentration of Pol-B of PIC particles prepared at different [N:SO3Na] ratios. SD 
indicates the standard deviation found for the only size or charge population fitted by the software. 
[N:SO3Na] ratio DH ± SD (nm) PdI a -potential  SD 
(mV) 
[Pol-B] (µM) 
0.7 186 ± 50 0.07 -29.7 ± 10.2 175 
0.6 182 ± 43 0.06 -38.0 ± 9.2 150 
0.5 176 ± 41 0.05 -41.2 ± 9.6 125 
0.4 174 ± 49 0.08 -41.0 ± 8.2 100 
0.3 167 ± 37 0.05 -40.1 ± 10.0 75 
0.2 166 ± 38 0.05 -42.5 ± 7.3 50 
0.1 169 ± 47 0.08 -41.2 ± 9.2 25 
a Polydispersity Index (PdI) calculated using the formula: PdI = (SD/DH)2.[S1] 
1.1. TEM micrographs of PIC particles 
5 µL of a suspension of PIC particles were deposited on the surface of the TEM grid and it was left to dry at room temperature 
covered from dust. Once dried, 5 µL of a 1 mg/mL solution of phosphotungstic acid in water were deposited on the grid to stain 
the nanoparticles for a minute, after which the excess staining solution was removed. Finally, the grid was dried as before. 
For the measurement of the average PIC particle diameter, 58 nanoparticles were measured twice (in their longest and shortest 
diameters), giving an average of 140 nm with a standard deviation of 30 nm from a total of 116 measurements. 
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Figure S2 Representative TEM micrographs of PIC prepared at 0.4 [N:SO3Na] ratio with increasing magnification (left to right). 
1.2. Stability of PIC particles under simulated physiological conditions 
 
Figure S3 Autocorrelation function (ACF) curves (A) and representative size-intensity distributions (B) for PIC particles prepared at a 0.1 
[N:SO3Na] ratio in the absence (control) and presence of 154 mM NaCl at 37 °C over time (1-4 hours). 
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Figure S4 Evolution of PIC particle size (DH) as measured by DLS when incubated with 154 mM NaCl at 37 ºC over time. The size of the 
nanoparticles was normalised to that of a control in the absence of NaCl (time point 0 h), and was monitored over 4 hours after the addition 
of salt (time points 1-4 h). Each symbol represents a different [N:SO3Na] ratio.‡ n = 3. 
2. Pol-B release from PIC particles 
 
Figure S5: Pol-B content found in the dialysate of PIC particles prepared at 0.7 [N:SO3Na] ratio (red circles) over time. Content was 
normalised to that found in a 175 µM Pol-B sample (drug loading in these PIC particles) diluted down to the total dialysis volume (100%) 
and compared to the rate of release for a Pol-B solution at the same concentration (black squares). n = 3. 
                                                            
 
‡ PIC particles at 0.7 and 0.6 [N:SO3H] have not been included since when these formulations were exposed to NaCl, they swelled to give more 
than one size distributions as indicated in Figure 3. 
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Figure S6: Representative RP-HPLC chromatograms of 70 KDa PSS (top), Pol-B (middle) and PIC particles prepared at a 0.7 [N:SO3Na] 
ratio (bottom). Peak at Rt = 2.7 min was used to monitor the release of Pol-B. 
3. Antimicrobial activity of PIC particles 
 
Figure S7 Change in optical density at 600 nm (OD600) for media A) 1:1 LB:HEPES and B) 1:0.4 LB:HEPES; in the absence ( ) and presence 
of PSS ( ) and Pol-B ( ). 
 
Figure S8 Change in optical density at 600 nm (OD600) for P. aeruginosa cultures in the absence ( ) and presence of PSS ( ), Pol-B ( ) 
and PIC particles ( ) prepared at 0.7 (A), 0.6 (B), 0.5 (C), 0.4 (D), 0.3 (E), 0.2 (F) and 0.1 (G) [N:SO3Na] ratio. In each case, the 
concentration of Pol-B was adjusted to that in the PIC particles employed. Optical density of each of the controls including the media 
employed (1:0.4 LB:HEPES, ) is shown for comparison (H). n = 3. 
4. Additional references 
[S1]  Measuring the size of nanoparticles in aqueous media using batch-mode Dynamic Light Scattering, 1st ed., NIST, 
U.S. Department of Commerce, 2015. doi:10.6028/nist.sp.1200-6.





































































































4.3. Composition of commercial polymyxin B 
Given the multiple peaks detected in the HPLC analysis of commercial polymyxin 
B (Fig. S6, previous page), a discussion of the identity of each of these peaks 
and interpretability of these results is required. 
 
Polymyxin B is a mixture of lipopeptides naturally produced by the Gram-positive 
bacterium Bacillus polymyxa, which display antimicrobial activity towards Gram-
negative bacteria.1,2 It is commercialised as produced, containing seven main dif-
ferent subtypes based on a general structure with a cyclic cationic peptide and a 
pending aliphatic chain (Fig. S9).3,4 From these subtypes, polymyxins B1 and B2 
are the most abundant, accounting for ca. 50 and 24% of the total polymyxin B 
composition by HPLC, respectively. However, these seven subtypes only add up 
to 89% of the total composition of commercial polymyxin B by HPLC, and at least 
14 more subtypes have been detected in small amounts.4 
 
Having established that polymyxin B consists of a mixture of similar lipopeptides, 
we compared our chromatograms of polymyxin B with those reported by Orwa et 
al., who characterised the structure of the major HPLC peaks by NMR and MS.3 
Despite the slight differences between HPLC methods (Table S2), the traces of 
both chromatograms were very similar and allowed us to identify the major poly-
myxin B subtypes in our chromatograms with good confidence (Fig. S10). 
Figure S9 Main polymyxin B subtypes found in commercial samples of this 












































Same R/R’/R’’ as B1,




















Table S2 HPLC conditions used for the analysis of polymyxin B by Orwa et al.,3 
and those used in this thesis. Differences are highlighted in bold. 
 Orwa et al. (see Fig. S10A) This thesis (see Fig. S10B) 
Column C18, 5 µm, 250 x 4.6 mm, 120 Å 
C18, 5 µm, 250 x 4.6 mm, 
100 Å 
Mobile phase 
50 mM Na2SO4 : H2O : 
AcCN : 6.8% v/v H3PO4 
(50 : 22.75 : 22.25 : 5) 
50 mM Na2SO4 : H2O : 
AcCN : 5% v/v H3PO4 
(50 : 23 : 22 : 5) 
T (°C) 30 35 
Flow rate (mL/min) 0.5 1.0 
 
  
Figure S10 HPLC chromatograms of polymyxin B reported by Orwa et al. with 
the structure of each peak confirmed by MS and NMR (A),3,5 and that reported 
by us as a red trace (labelled as ‘Polymyxin B’) in Fig. S6 of this Chapter (B). 
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Based on the relative peak area and elution order, we can conclude that peak 
1b, which we monitored by HPLC in the dialysate of PIC nanoparticle samples to 
evaluate drug release (Fig. S5-6), does not correspond to any of the seven main 
polymyxin B subtypes by comparison to a reference chromatogram (Fig. S10). 
However, peak 1b in our sample could correspond to peak 1a in the chromato-
gram used as reference. Peak 1a has been characterised previously using MS, 
and corresponds to a polymyxin B derivative with the general cyclic peptide linked 
to a C8H15O2 tail, probably derived from a branched or linear hydroxylated oc-
tanoic acid, and accounts for less than 1% of the total sample by HPLC.4,6 
Whereas the relative composition of the main polymyxin B subtypes in our chro-
matogram (Fig. S10B) – 53.8 and 26.1% for polymyxin B1 and B2, respectively 
– is in good agreement with the values reported in the literature (Fig. S9),4 the 
relative composition of 1b (5.5%) is much higher than the 0.8% abundance pre-
viously reported for 1a.4 Therefore, although the elution order of 1a and 1b is 
similar, their very distinct relative abundance suggests they may not be the same 
compound. In addition, the fact that only compound 1b could be detected by 
HPLC in the dialysate of PIC nanoparticles (Fig. S6) suggests that the structure 
(i.e. polarity and Mw) of 1b is significantly different from the major polymyxin B 
subtypes, which could not diffuse through the dialysis membrane used. This ‘spe-
cific membrane permeability’ of 1b suggests that this is not a polymyxin B deriv-
ative, otherwise other polymyxin B subtypes of similar structure should have also 
appeared in the dialysate due to similar physico-chemical interaction with the di-
alysis membrane. As such, and considering that 1a has been characterised as a 
polymyxin B subtype,4 we can conclude with fair confidence that 1a and 1b are 
different compounds. 
 
The HPLC profile of a polymyxin B stock solution incubated under the same con-
ditions as PIC nanoparticles for drug release evaluation (37°C, PBS buffer, pH 
7.4) was also monitored over time. Whereas the area of the two most abundant 
polymyxin B subtypes (i.e. B1 and B2) decreased over time, the area of com-
pound 1b doubled from 1.7 to 3.5 a.u.·min after 20 hours of incubation (Figure 
S11). These results suggest that 1b could be a degradation product of polymyxin 
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B. It is known that polymyxin B has poor stability in phosphate buffer at pH 7.4, 
which causes rapid drug degradation, mostly by racemisation.7 Additionally, pol-
ymyxin B can also degrade in solution by reaction of amino acids within the pep-
tide fraction, which happens more rapidly at pH 7.4 than in more acidic media.8 
As such, it is plausible that compound 1b could be a degradation product of one 
or more of polymyxin B’s species. 
 
 
For all the above, we can conclude that the dialysis and HPLC experiments (Fig. 
S5-6) described in this Chapter to evaluate polymyxin B release from PIC nano-
particles are inconclusive. This is due to the monitoring of a peak of unknown 
identity by HPLC (Fig. S10-11; 1b), and the absence of HPLC peaks for the most 
Figure S11 HPLC chromatogram of a polymyxin B solution in PBS incubated 
at 37°C and pH 7.4 at different time points (0, 3, 20 h; arrows indicate time 
evolution) (A), and the area of the three labelled peaks over time (B). 
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abundant polymyxin B isoforms in the dialysate of PIC nanoparticles. Although 
these results may be also interpreted as if polymyxin B were not released from 
PIC nanoparticles, this would be in disagreement with the antimicrobial activity 
displayed by these nanoparticles (Fig. 4-7), which must stem from polymyxin B 
release given the lack of antimicrobial activity of the polymer PSS. Therefore, this 
section clarifies some of the experimental issues previously described in this 
Chapter regarding the drug release experiments, and supports the concerns 
stated before about the interpretability of this data (see page 103). 
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Effect of polyelectrolyte strength and degree 
of polymerisation on the formation, stability 
and activity of antimicrobial polyion com-
plex (PIC) particles carrying polymyxin B 
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Overview: In this Chapter, we continue the investigation of the nanoparticles for 
the passive release of polymyxin B (Pol-B) presented in Chapter 4. Here, we 
evaluate the impact of the nature and degree of polymerisation of the anionic 
polymer used to complex Pol-B on the properties of these PIC particles. 
Since the affinity between oppositely charged polyelectrolytes is directly propor-
tional to their multivalency, or net charge, we considered that shorter poly(styrene 
sulfonate) (PSS) chains than those previously explored in Chapter 4 (70 kDa in 
average) could lead to more weakly bound PIC particles with faster Pol-B release 
kinetics, and hence stronger antimicrobial activity. A collection of three PSS 
sources with molecular weights (i.e. degrees of polymerisation) below 70 kDa 
were explored, investigating the size, charge, saline stability and antimicrobial 
properties of their resulting PIC particles prepared in combination with Pol-B. 
Additionally, weaker polyacids (i.e. those with higher pKa values) can lead to 
weaker polyelectrolyte interactions when working at pH values close to their pKa, 
as a result of their partial deprotonation and hence loss of multivalency. As such, 
weaker polyacids than PSS could also lead to more loosely bound PIC particles 
with faster drug release profiles, similar to the effect of the polymer’s Mw de-
scribed above. For this reason, we also investigated a collection of poly(acrylic 
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acid) (PAA) sources, a weaker polyacid than PSS, with degrees of polymerisation 
matching those of the PSS here reported, to evaluate the effect of the polyacid’s 
strength on the properties of these PIC particles. 
In summary, we present a dual study in this Chapter: the effect of the degree of 
polymerisation and acidity of six polyanions, on the assembly, saline stability and 
antimicrobial properties of PIC particles loaded with Pol-B. 
It was found that, whereas all PSS and PAA sources allowed the assembly of 
PIC particles with overall very similar salt stabilities, there was a remarkable im-
pact on their antimicrobial properties: PSS displayed stronger activities with 
shorter polymers, and the weaker PAA showed very strong antimicrobial effects 
regardless of its degree of polymerisation. 
The results presented in this Chapter make a number of significant contributions 
to the understanding and development of PIC particles as new antimicrobial ther-
apies: 1) Demonstrate that Pol-B can be formulated into PIC particles using pol-
yanions of weaker affinity for Pol-B than the polymer previously explored in Chap-
ter 4, thus further challenging the minimum net charge necessary to assemble 
PIC particles from small polyelectrolytes. 2) Highlight how simply the antimicro-
bial activity of Pol-B can be tuned when formulated into PIC particles by two 
means: adjusting the charge ratio of the nanoparticles and/or selecting different 
polymer sources. 3) Illustrate the remarkable versatility of PIC particles as drug 
delivery vehicles, which can be prepared in a number of different formulations 
from inexpensive and readily available materials, allowing the rapid development 
of many nanoparticle systems with distinct antimicrobial activities. 
 
Contributions: All authors contributed to the experimental set-up and dis- 
cussed the results. II and FFT designed the nanoparticle synthesis and charac-
terisation, and II, FFT and AMK designed the microbiological assays. II carried 
out all experimental work. II and FFT analysed the data and wrote the paper, with 





























spontaneous	 aggregation	 of	 oppositely	 charged	
polyelectrolytes	 in	 aqueous	 media.1	 Due	 to	 their	
straightforward	 preparation	 and	 versatility,	 PIC	 particles	 are	
particularly	 suited	 for	 the	delivery	of	charged	 (bio)molecules	
(e.g.	nucleic	acids	and	proteins),	which	are	prevalent	in	nature.	
This	way,	delivery	vehicles	can	be	formulated	without	the	need	
to	 introduce	 chemical	modifications	 to	 these	 (bio)molecules	
and	 as	 a	 result,	 the	 biological	 activity	 of	 these	 therapeutics	
should	be	maintained	upon	release.	PIC	particle	formation	and	
stability	are	dominated	by	entropic	effects	making	them	ideal	
for	 the	 delivery	 of	 “large”	 and	 densely	 charged	
macromolecules	 such	as	nucleic	 acids.2,3	More	 challenging	 is	
the	use	of	PIC	particles	for	the	delivery	of	proteins,4	peptides5	
or	 small	 molecules,1	 which	 often	 lack	 the	 required	 charge	
density	 to	 form	 stable	 PIC	 particles.	 However,	 many	 of	 the	
characteristics	of	PIC	particles	makes	 them	 ideally	 suited	 for	
the	delivery	of	antimicrobial	peptides,	which	are	small	cationic	
peptides	 that	 have	 been	 harnessed	 as	 last-resort	
antimicrobials	 or	 as	 alternatives	 to	 current	 antibiotics:6-8	
Cationic	 residues	 in	 antimicrobial	 peptides	 can	 be	 shielded	





B)	 by	 complexation	 with	 poly(styrene	 sulphonate)	 (PSS).9	
These	 Pol-B	 containing	 particles	 displayed	 a	 tunable	
antimicrobial	 effect	 against	 Pseudomonas	 aeruginosa,	 an	
opportunistic	 gram-negative	 bacterium,	 for	 which	 Pol-B	 is	
currently	 used	 as	 a	 last	 resort	 antimicrobial.	 Based	 on	 the	
correlation	between	the	stability	of	PIC	particles	and	the	net	
charge	of	their	consisting	polyelectrolytes,	the	formulation	of	
Pol-B	 with	 shorter	 and/or	 weaker	 polyelectrolytes	 can	
potentially	 result	 in	 more	 permeable	 PIC	 particles	 with	
stronger	antimicrobial	properties.	 In	 this	communication,	we	
investigate	 the	 effect	 of	 the	 degree	 of	 polymerisation	 (i.e.	
molecular	weight)	 and	 polyelectrolyte	 strength	 (-SO3Na	 vs	 –
COONa)	on	the	stability	and	biological	activity	of	the	resulting	








of	 15	 (35%	wt.	 in	water),	 8	 (45%	wt.	 in	water)	 and	 1.8	 kDa	
average	 Mw,	 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic	
acid	 (HEPES),	 phosphotungstic	 acid	 hydrate,	 agar	 and	 Luria	
Bertani	 (LB)	 broth	 (Miller)	 were	 bought	 from	 Sigma-Aldrich	
Ltd.	Nylon	0.45	µm	syringe	filters	were	purchased	from	Camlab	
Ltd.	 Carbon-coated	 copper	 TEM	 grids	 (200	 mesh)	 were	








times	 at	 140	 V.	 Transmission	 Electron	 Microscopy	 (TEM)	
images	of	PIC	nanoparticles	were	acquired	on	a	 JEM-1200EX	
(JEOL	 USA	 Inc.).	 PIC	 particle	 size	 was	 measured	 from	 TEM	
micrographs	 using	 ImageJ	 software	 (1.48v)	 and	 measuring	
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each	 nanoparticle	 twice:	 both	 in	 their	 longest	 and	 shortest	
diameters.	A	Loctite®	LED	flood	array	(Henkel	Ltd.)	operating	
at	 405	 nm	 was	 used	 to	 sterilise	 the	 samples	 studied	 in	 the	












different	 formulations	 of	 PIC	 particles	 are	 defined	 by	 their	
[n+/n-]	ratio,	which	represents	the	proportion	of	ammonium	




HEPES	 buffer	 at	 pH	 7.4.	 Then,	 both	 stock	 solutions	 were	
filtered	 through	 0.45	 µm	 nylon	 syringe	 filters	 and	 mixed	 in	
equal	amounts	drop-wise	under	stirring.	PIC	nanoparticles	at	
other	 [n+/n-]	 ratios	 were	 obtained	 by	 changing	 the	
concentration	of	the	Pol-B	stock	solution	and	mixing	with	2.5	
mM	PSS	or	PAA	following	the	same	protocol.	After	24	h,	 the	















To	 a	 sample	 of	 PIC	 particles	 (1	 mL),	 prepared	 as	 described	
above,	182	μL	of	a	1	M	solution	of	NaCl	 in	water	was	added	
and	the	mixture	was	incubated	at	37	°C	to	obtain	physiological	








to	 compare	 the	antimicrobial	 activity	of	 free	and	complexed	































In	 recent	 work,	 our	 group	 reported	 the	 preparation	 of	 PIC	
particles	via	self-assembly	of	the	cationic	antibiotic	polymyxin	
B	 (Pol-B)	 and	 the	 polyanion	 poly(styrene	 sulphonate)	 (PSS).
9
	
These	 nanoparticles	 displayed	 a	 formulation-dependent	
antimicrobial	effect	against	P.	aeruginosa,	and	were	presented	
as	 an	 alternative	 delivery	 vehicle	 to	 the	 conventional	 use	 of	
antibiotics.	Although	the	complexation	of	Pol-B	is	challenging	
due	 to	 its	 low	net	 charge	or	multivalency	 (Figure	1),15,16	 this	
antibiotic	was	successfully	assembled	into	PIC	particles	using	a	
very	high	molecular	weight	PSS	(70	kDa).	The	low	multivalency	




















Since	 the	 stability	 of	 PIC	 particles	 strongly	 depends	 on	 the	
multivalency	 of	 their	 constituent	 polyelectrolytes,1	 we	
propose	here	that	the	complexation	of	Pol-B	with	lower	DP	PSS	
would	 lead	 to	 weaker	 polyelectrolyte	 complexes	 with	
potentially	 faster	 Pol-B	 release	 profiles	 and	 higher	
antimicrobial	 activities.	 To	 test	 this	 hypothesis,	 we	
investigated	the	assembly	of	PIC	particles	from	Pol-B	and	PSS	
with	 average	molecular	weights	 below	 70	 kDa.	We	 selected	
commercial	 PSS	 sources	of	 32	and	17	kDa	 to	 test	half	 and	a	
fourth	of	the	Mw	previously	reported.	Moreover,	the	shortest	
commercially	 available	 PSS	 found	 (10	 kDa)	 was	 also	 tested	
(Table	1).	
Pol-B	 was	 therefore	 mixed	 with	 each	 PSS	 in	 ten	 different	
proportions	(i.e.	charge	ratios),	denoted	as	[n+/n-],	indicating	
the	 number	 of	 ammonium	 groups	 in	 Pol-B	 divided	 by	 the	
number	 of	 sulphonates	 in	 PSS	 present	 in	 each	 nanoparticle	
formulation.	 The	 evaluation	 of	 a	 range	 of	 charge	 ratios	 is	
critical	because	 this	parameter	not	only	dictates	 the	dose	of	
antibiotic	 loaded	 inside	 these	 nanoparticles,	 but	 it	 can	 also	
affect	 their	 stability	 in	 solution.	 The	 range	 of	 [n+/n-]	 ratios	
explored	 here	 was	 selected	 from	 our	 previous	 observations	





and	 ζ-potential	 (Figure	 2,	 Table	 S1).	 Colloidal	 particles	were	
obtained	for	most	of	these	formulations	even	when	as	little	as	
0.1	equivalents	of	Pol-B	was	employed.	As	observed	for	other	
polyelectrolytes,17-19	 we	were	 not	 able	 to	 form	 PIC	 particles	
with	any	of	the	PSS	tested	at	[n+/n-]	ratios	around	equimolar	
range	 (i.e.	 1.0,	 0.9,	 and	 even	 0.8	 for	 PSSH),	 which	 led	 to	
unstable	 aggregates	 that	 flocculated	 due	 to	 charge	
neutralisation	(Figure	2).	
Having	 identified	 suitable	 conditions	 for	 the	 preparation	 of	
Pol-B	 containing	 particles	 with	 as	 little	 as	 ca.	 50	 styrene	
sulphonate	 units,	 we	 decided	 next	 to	 explore	 the	 effect	 of	
changing	 the	 nature	 of	 the	 electrolyte.	 Carboxylic	 acids	 are	
softer	 electrolytes,	 15,20	 which	 will	 be	 partially	 protonated	
under	physiological	conditions.	Softer	electrolytes	often	result	
in	 less	 stable	 PIC	 particles	 because	 of	 their	 partial	
(de)protonation	 with	 changes	 in	 pH,1	 and	 as	 mentioned	
before,	 this	 reduced	 stability	 can	 be	 beneficial	 for	 the	
antimicrobial	activity	of	the	particles.	To	this	end,	poly(acrylic	
acid),	 a	 common	 ingredient	 in	pharmaceutical,	 cosmetic	and	
food	formulations21	was	selected	as	a	representative	example.	




to	 evaluate	 the	 most	 unfavourable	 scenario	 for	 the	
preparation	of	PIC	particles.	
Like	in	the	case	of	PSS,	most	of	the	formulations	with	PAA	gave	
stable	 Pol-B	 containing	 particles	 (Figure	 3).	 In	 this	 case,	 all	
particles	prepared	at	equimolar	 [n+/n-]	ratios	flocculated.	As	









All	 particles	 prepared	 from	 PSS	 showed	 almost	 identical	
hydrodynamic	 diameters	 (DH)	 and	 ζ-potentials	 regardless	 of	
the	DP	of	the	polymer,	with	average	values	of	192	nm	(±	4%)23	
in	DH	and	-49.6	mV	(±	6%)	 in	charge	(Figure	2).	Similarly,	PIC	
particles	 prepared	 from	high	 and	medium	PAA	 showed	 very	
similar	size	and	charge,	with	mean	values	of	147	nm	(±	12%)	












Although	 overall	 differences	 were	 not	 significant,	 a	 trend	
towards	smaller	particles	could	be	identified	when	lower	ratios	
of	 Pol-B	 were	 used,	 a	 phenomenon	 also	 observed	 in	 the	
preparation	 of	 PIC	 particles	 from	 other	 small	 charged	
peptides.22,24	Similarly,	a	more	positive	average	ζ-potential	of	-
26.9	mV	(±	16%)	was	observed	for	PAAL	particles.	These	results	











particles	 prepared	 from	 PAAL	 were	 selected	 for	 TEM	
characterisation	 to	 assess	 whether	 such	 loose	 complexes	






nanoparticles	 will	 collapse	 upon	 drying	 during	 sample	
preparation	for	TEM	analysis.25	
Having	 identified	 and	 characterised	 the	 [n+/n-]	 ratios	 that	
allowed	 the	 preparation	 of	 colloidal	 PIC	 particles,	 we	 then	
focused	on	assessing	their	stability	to	physiological	conditions.	
Since	 small	 electrolytes	 in	 solution	 can	 shield	 the	 ionic	
networks	 that	 cross-link	PIC	particles,	 it	 is	 expected	 that	 the	
salts	present	in	biological	fluids	can	compromise	the	integrity	





be	 discussed	 next,	 representing	 high	 and	 low	 Pol-B	 loading	
respectively.	 The	 DLS	 data	 for	 all	 the	 other	 nanoparticle	









the	 nature	 of	 the	 polymer	 and	 its	 DP.	 The	 stability	 of	 the	
nanoparticles	prepared	from	PSS	was	directly	proportional	to	
the	 DP	 of	 these	 polymers.	 Formulations	 containing	 PSSH	
showed	almost	no	changes	in	their	autocorrelation	functions	
(ACFs)	and	size	distributions	by	DLS,	with	only	a	2-fold	increase	
in	 size	 after	 4	 hours	 (Figure	 5).	 However,	 PSSM	 and	 PSSL	
experienced	more	pronounced	swellings,	increasing	7	and	20	
time,	respectively,	their	initial	hydrodynamic	diameters	after	4	
hours.	 Whereas	 PSSH	 did	 not	 show	 any	 difference	 between	
[n+/n-]	ratios,	probably	due	to	the	strong	complexation	of	Pol-
B	 by	 this	 polymer,	 PSSM	 and	 PSSL	 formed	 more	 stable	
complexes	at	a	[n+/n-]	ratio	of	0.4	than	0.7.	This	is	evidenced	
by	 the	 loss	 of	 the	 characteristic	 sigmoidal	 profile	 in	 the	ACF	
curves	of	these	nanoparticles	(e.g.	Figure	5B	vs	E),	which	can	
be	attributed	to	these	particles	breaking	down	into	amorphous	










PAAH	 formulations	 had	 almost	 identical	 DLS	 profiles	 to	 PAAL	
despite	this	polymer	being	8	times	smaller	(Figure	6).	The	PIC	
particles	prepared	 from	 these	 two	PAAs	 increased	up	 to	10-
fold	in	size	after	one	hour	of	incubation	in	154	mM	NaCl	and	
remained	 unchanged	 for	 the	 rest	 of	 the	 experiments.	
However,	PAAM	led	to	nanoparticles	with	less	tolerance	to	salt,	
as	evidenced	by	their	ACF	curves	with	intercepts	above	1	and	
inconsistent	 size-intensity	 fits	 (Figure	 6B,E).	 These	 results	




stability	 of	 the	 particles,	 particles	 prepared	 using	 polymers	
with	 matching	 DPs	 were	 compared.	 Overall,	 the	 data	
suggested	that	PSS	containing	particles	were	less	likely	to	swell	






be	 observed	 when	 comparing	 the	 formulations	 made	 from	
polymers	 with	 the	 medium	 DP	 (Figure	 S2	 and	 Figure	 S5),	
although	 in	 this	 case	more	 formulations	were	unstable	after	
incubation	under	these	simulated	physiological	conditions.			
Interestingly,	 PIC	 particles	 prepared	 from	 PAAL,	 despite	
forming	 particles	 over	 a	 smaller	 range	 of	 formulations,	
resulted	 in	 quite	 stable	 particles	 under	 physiological	
conditions,	with	4	out	of	5	formulations	giving	ACFs	curves	that	
could	be	fitted	even	after	4	hours	of	incubation.	This	was	not	













conditions	 of	 the	 different	 formulations	 prepared,	 we	 then	
evaluated	 the	 antimicrobial	 activity	 of	 these	 nanoparticles	
against	P.	aeruginosa.9	Experiments	were	focused	on	particles	
prepared	 at	 0.7	 and	 0.4	 [n+/n-]	 ratios,	 because	 the	 stability	
under	 physiological	 conditions	 demonstrated	 that	 these	
formulations	 were	 representative	 examples	 of	 the	 whole	
series.	 First,	 we	 monitored	 the	 optical	 density	 at	 600	 nm	
(OD600)	of	P.	aeruginosa	cultures	in	the	absence	and	presence	
of	 different	 PIC	 particle	 formulations,	 and	 their	 different	
components.	This	is	a	routine	technique	used	in	microbiology	











with	 this	 weaker	 polyelectrolyte	 in	 biological	 media,	 as	
suggested	 by	 the	 experiments	 performed	 under	 simulated	
physiological	 conditions	 (Figure	 6).	We	 think	 PAA	 containing	
particles	 will	 also	 swell	 more	 in	 the	 growth	media	 used	 for	
these	experiments,	 leading	 to	particles	breaking	apart	 and	a	
potential	 rapid	 release	 of	 the	 antimicrobial.	 This	 way,	 all	





initial	 increase	 in	 the	OD600	of	 the	culture	 in	 the	presence	of	
these	particles,	an	increase	that	was	mainly	dependent	on	the	
Pol-B	content	(Figure	8A	vs	Figure	8B).	This	increase	in	OD600	is	
attributed	 to	 swelling	when	 the	particles	are	exposed	 to	 the	
biological	 medium	 used	 in	 this	 assay,	 as	 observed	 with	
experiments	performed	in	the	absence	of	bacteria	(Figure	8C).	
Formulations	at	a	0.7	 [n+/n-]	 ratio	 increased	 the	 turbidity	of	
the	media	much	more	dramatically	than	their	analogues	at	0.4.	
Moreover,	 particles	 prepared	 with	 PSSH	 showed	 a	 steady	
increase	in	OD600,	suggesting	that	these	particles	were	swelling	
but	 remained	 stable	 under	 assay	 conditions.	 Particles	
prepared	 with	 PSSM	 and	 PSSL	 however	 showed	 a	 bigger	
increase	 in	 OD600,	 but	 both	 suspensions	 quickly	 lost	 their	
turbidity,	 suggesting	 that	 particles	 were	 eventually	 breaking	
apart	 and	 releasing	 the	 antimicrobial.	 This	 data	 was	 in	
agreement	 with	 the	 stability	 observed	 under	 simulated	
physiological	conditions	(Figure	5),	with	formulations	prepared	
with	 PSSH	 giving	 more	 stable	 particles	 that	 swelled	 less.	 A	













with	 particles	 prepared	 with	 PSSL	 showing	 the	 longest	
inhibition	effect	(Figure	8B).	
To	 facilitate	 the	 visual	 comparison	 of	 these	 antimicrobial	
results,	representative	data	from	PSS	containing	particles	were	






of	 the	 experiment.	 We	 could	 also	 see	 that	 reducing	 the	
amount	of	antimicrobial	 in	this	case	had	a	detrimental	effect	
in	the	antimicrobial	activity	of	the	particles,	with	formulations	
prepared	 with	 PSSL	 at	 a	 0.4	 [n+/n-]	 ratio	 having	 already	
recovered	the	baseline	turbidity	after	20	hours	of	incubation.	
This	was	 the	 case	 for	 the	other	 PSS	 used,	with	 formulations	
prepared	at	 a	 0.7	 [n+/n-]	 ratio	having	 a	higher	 antimicrobial	
effect	than	those	prepared	at	a	0.4	[n+/n-]	ratio.	However,	no	
significant	 differences	 were	 observed	 in	 the	 growth	 when	






Samples	 from	 these	 growth	 assays	 were	 collected	 after	 24	
hours	of	incubation	and	spotted	on	agar	plates	to	quantify	the	




effect	 on	 this	 growth	 (Figure	 9	 and	 Figure	 S8).	 Both	
concentrations	 of	 Pol-B	 used	 to	 prepare	 the	 nanoparticles	
completely	inhibited	the	growth	of	P.	aeruginosa	(control),	as	
expected.	 Interestingly,	 all	 formulations	 displayed	 some	
degree	of	antimicrobial	effect	as	evidenced	by	the	decrease	in	
at	 least	 to	 two	orders	of	magnitude	 in	 the	number	of	 viable	
bacterial	 colonies	 found	 in	 these	 samples.	 Nanoparticles	
prepared	with	PSSL	at	a	0.7	[n+/n-]	ratio	showed	a	remarkable	
change	 in	 the	 number	 of	 CFU/mL	 of	 over	 6	 orders	 of	
magnitude	(Figure	9B),	in	agreement	with	the	turbidity	assays	
that	 suggested	 that	 this	 was	 the	 most	 active	 formulation	
(Figure	8D).	In	addition,	no	viable	colonies	were	observed	for	
any	 of	 the	 formulations	 prepared	 for	 PAA	 (Figure	 S8),	
supporting	 the	 results	 obtained	 using	 turbidimetry	 assays	
(Figure	7B).		
CONCLUSIONS	
We	 have	 successfully	 prepared	 and	 characterised	 Pol-B	
containing	 PIC	 particles	 using	 six	 different	 PAA	 and	 PSS	
selected	across	a	wide	range	of	degrees	of	polymerisation.	We	
have	assessed	the	physiological	stability	of	these	nanoparticles	
and	 their	 antimicrobial	 activity	 against	 P.	 aeruginosa,	 an	
opportunistic	 pathogen	 currently	 treated	 with	 Pol-B.	 Our	
results	indicate	that	nanoparticles	prepared	with	the	stronger	
polyelectrolyte	 PSS	 have	 a	 higher	 tolerance	 to	 salt	 than	




nature	 of	 the	 polyanion	 and	 the	 [n+/n-]	 ratio	 used.	 In	 this	
regard,	 all	 nanoparticles	 prepared	 from	 PAA	 inhibited	 P.	
aeruginosa’s	 growth	 and	 lead	 to	 non-viable	 cultures	 of	 this	
pathogen.	However,	when	particles	were	prepared	with	PSS,	
those	 with	 the	 shortest	 polyelectrolyte	 showed	 the	 highest	
antimicrobial	 activity.	 Also,	 the	 antimicrobial	 activity	 of	 the	
particles	prepared	with	PSS	of	 low	degree	of	 polymerisation	
was	 dependent	 of	 the	 [n+/n-]	 ratio,	 an	 effect	 not	 found	 in	
formulations	prepared	from	longer	polymers.	We	believe	our	
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Polymer	 [n+/n-]	ratio	 DH	±	SD	(nm)	a	 PdI	b	 ζ-potential	±	SD	(mV)	a	 Notes	
PSSH	
1.0	 -	 -	 -	 Flocculation	
0.9	 -	 -	 -	 Flocculation	
0.8	 -	 -	 -	 Flocculation	
0.7	 199	±	58	 0.08	 -55.1	±	10.7	 -	
0.6	 194	±	58	 0.09	 -54.7	±	9.9	 -	
0.5	 196	±	61	 0.10	 -56.8	±	10.4	 -	
0.4	 193	±	67	 0.12	 -51.4	±	12.4	 -	
0.3	 190	±	60	 0.10	 -52.7	±	9.2	 -	
0.2	 193	±	71	 0.14	 -50.3	±	11.0	 -	
0.1	 182	±	58	 0.10	 -46.6	±	14.2	 -	
PSSM	
1.0	 -	 -	 -	 Flocculation	
0.9	 -	 -	 -	 Flocculation	
0.8	 201	±	57	 0.08	 -49.5	±	7.3	 -	
0.7	 202	±	61	 0.09	 -48.5	±	8.5	 -	
0.6	 197	±	59	 0.09	 -50.0	±	8.8	 -	
0.5	 202	±	73	 0.13	 -49.8	±	7.9	 -	
0.4	 197	±	62	 0.10	 -49.5	±	9.1	 -	
0.3	 192	±	55	 0.08	 -49.6	±	9.3	 -	
0.2	 179	±	62	 0.12	 -48.1	±	9.7	 -	
0.1	 180	±	65	 0.13	 -49.2	±	9.6	 -	
PSSL	
	
1.0	 -	 -	 -	 Flocculation	
0.9	 -	 -	 -	 Flocculation	
0.8	 196	±	60	 0.09	 -45.7	±	9.3	 -	
0.7	 201	±	72	 0.13	 -46.5	±	8.1	 -	
0.6	 189	±	49	 0.07	 -46.7	±	7.1	 -	
0.5	 194	±	68	 0.12	 -48.9	±	8.9	 -	
0.4	 193	±	60	 0.10	 -49.5	±	9.2	 -	
0.3	 186	±	56	 0.09	 -46.8	±	8.0	 -	
0.2	 185	±	56	 0.09	 -48.0	±	9.2	 -	
0.1	 182	±	53	 0.08	 -47.9	±	9.4	 -	
PAAH	
1.0	 -	 -	 -	 Flocculation	
0.9	 174	±	58	 0.11	 -28.3	±	8.9	 -	
0.8	 160	±	56	 0.12	 -31.6	±	8.4	 -	
0.7	 153	±	47	 0.09	 -33.2	±	9.1	 -	
0.6	 146	±	48	 0.11	 -36.5	±	9.4	 -	
0.5	 142	±	46	 0.10	 -37.5	±	10.5	 -	
0.4	 142	±	44	 0.10	 -41.0	±	9.7	 -	
0.3	 119	±	28	 0.06	 -35.5	±	10.8	 -	
0.2	 147	±	43	 0.09	 -34.6	±	9.0	 -	
0.1	 101	±	13	 0.02	 -36.3	±	4.9	 -	
PAAM	
1.0	 -	 -	 -	 Flocculation	
0.9	 173	±	50	 0.08	 -28.8	±	8.2	 -	
0.8	 170	±	58	 0.11	 -33.1	±	6.8	 -	
0.7	 157	±	52	 0.11	 -32.6	±	8.0	 -	
0.6	 153	±	50	 0.11	 -34.1	±	9.5	 -	
0.5	 140	±	47	 0.11	 -37.1	±	10.7	 -	
0.4	 151	±	49	 0.10	 -35.4	±	7.2	 -	
0.3	 142	±	49	 0.12	 -36.5	±	7.6	 -	
0.2	 146	±	46	 0.10	 -33.5	±	12.0	 -	
0.1	 136	±	40	 0.09	 Not	characterised	 Poor	signal	
PAAL	
1.0	 -	 -	 -	 Flocculation	
0.9	 -	 -	 -	 Flocculation	
0.8	 -	 -	 -	 Flocculation	
0.7	 175	±	39	 0.05	 -22.0	±	5.9	 -	
0.6	 193	±	42	 0.05	 -25.4	±	5.9	 -	
0.5	 164	±	44	 0.07	 -28.2	±	8.1	 -	
0.4	 119	±	33	 0.08	 -30.9	±	11.3	 -	
0.3	 92	±	25	 0.08	 -28.2	±	8.3	 -	
0.2	 -	 -	 -	 Poor	signal	
0.1	 -	 -	 -	 Poor	signal	









































PSSH [n+/n-] = 0.3








PSSH [n+/n-] = 0.1








PSSH [n+/n-] = 0.5






















Figure	 S2.	DLS	 autocorrelation	 function	 (ACF)	 curves	of	 PIC	particles	prepared	 from	PSSM	at	different	 [n+/n-]	 ratios	 in	 the	
absence	(control)	and	presence	of	154	mM	NaCl	over	time	(1-4	hours).	
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Figure	S4.	DLS	autocorrelation	 function	 (ACF)	 curves	of	PIC	particles	prepared	 from	PAAH	at	different	 [n+/n-]	 ratios	 in	 the	
absence	(control)	and	presence	of	154	mM	NaCl	over	time	(1-4	hours).	
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Figure	S5.	DLS	autocorrelation	 function	 (ACF)	 curves	of	PIC	particles	prepared	 from	PAAM	at	different	 [n+/n-]	 ratios	 in	 the	
absence	(control)	and	presence	of	154	mM	NaCl	over	time	(1-4	hours).	
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The overall goal of this Thesis was the study of PIC nanoparticles as targeted 
and passive drug delivery vehicles for antimicrobial agents. Enzyme-responsive 
PIC nanoparticles were developed from the antimicrobial polymer poly(ethylene 
imine) (PEI) in combination with peptides degradable by a bacterial protease 
(LasB), thus aiming to direct the degradation of these nanoparticles, and hence 
drug release, to bacterial niches (Chapter 2). These nanoparticles specifically 
degraded in the presence of LasB and not a human protease, also displaying 
specific antimicrobial effects towards virulent bacterial strains that produced 
LasB. These enzyme-responsive PIC nanoparticles showed promising properties 
as targeted antimicrobial agents, but their poor stability in saline media compro-
mised their biological application. Attempts to improve the stability of these PIC 
nanoparticles involved the modification of the LasB-responsive peptides (i.e. an-
ionic component of the nanoparticles) to include more charged and cross-linking 
residues (Chapter 3). These modifications allowed to access new PIC nanoparti-
cle formulations with excellent salt compatibility, but these highly-stable com-
plexes lost their susceptibility to LasB degradation and the resulting bacteria-tar-
geted properties. At this point, and to improve the antimicrobial activity of the 
materials under development, the weak antimicrobial PEI was replaced for the 
more potent and FDA-approved antimicrobial peptide Polymyxin B (Pol-B). Un-
fortunately, the low multivalency of both Pol-B and the LasB-responsive peptides 
was unable to drive the assembly of these polyelectrolytes into PIC nanoparticles. 
Alternatively, we studied the formulation of Pol-B with the highly multivalent poly-
electrolyte poly(styrene sulphonate) (PSS), which allowed the preparation of non-
targeted PIC nanoparticles for passive drug release with tunable antimicrobial 
activities as a function of their charge ratio (Chapter 4). Finally, we evaluated the 
impact of the polyelectrolyte assembled with Pol-B on the stability and antimicro-
bial properties of the resulting PIC nanoparticles (Chapter 5). It was found that 
the strength (i.e. pKa) and multivalency (i.e. degree of polymerisation) of the com-
plexing polyelectrolyte is critical to control the antimicrobial activity of Pol-B when 
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formulated into PIC nanoparticles, leading to stronger antimicrobial effects when 
using weaker and less multivalent polyelectrolytes. 
 
The work presented in this Thesis has expanded the previous knowledge about 
PIC nanoparticles with regards to their design, assembly, characterisation, sta-
bility and application in antimicrobial therapy. New polyelectrolytes, analysis tech-
niques, experimental setups and stimuli-responsive properties have been applied 
here for the first time to PIC nanoparticles. The key learnings derived from this 
Thesis are summarised below: 
1) PIC nanoparticles can be engineered to degrade in the presence of tar-
get enzymes. The enzyme-responsive design of PIC nanoparticles has been 
demonstrated here for the first time. Our results cannot only guide the devel-
opment of new bacteria-targeted antimicrobial agents, but also other biomed-
ical tools for virtually any pathology mediated by enzymes.  
2) Multivalency is the most important factor that regulates the formation, 
stability and activity of PIC nanoparticles. This conclusion is supported 
by: A) The inability of short LasB-responsive peptides and Pol-B to form PIC 
nanoparticles, even in the presence of cross-linking groups in the peptides. 
B) The requirement of a macromolecular and highly multivalent polyelectro-
lyte in all PIC nanoparticles presented in this Thesis to drive their assembly. 
C) Consistent trends in the saline stability of PIC nanoparticles with polyelec-
trolytes of very different nature – less multivalent polyelectrolytes leading to 
poorer stability –, as evidenced in Chapters 3 and 5 (see point 4 below). 
3) Cross-linking PIC nanoparticles can compensate weak multivalencies. 
This was exemplified in Chapter 2, where the low multivalent peptide P1 was 
unable to assemble PIC nanoparticles with poly(ethylene imine), whereas its 
derivative with cysteine residues P1SH, capable of cross-linking via disulphide 
bridging, led to well defined PIC nanoparticles under the same conditions. 
Nevertheless, P1SH was unable to assemble PIC particles with Pol-B despite 
the presence of cross-linkers in this system, which reinforces the foremost 
importance of multivalency over other structural parameters of polyelectro-
lytes for PIC nanoparticle formulation. 
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4) Intermediate stability is necessary in PIC nanoparticles for biological 
application. Whereas poor stability in solution leads to premature and indis-
criminate release of drug from PIC nanoparticles, very stable complexes 
have been shown in this Thesis to either lose their susceptibility to enzymes 
for targeted delivery (Chapter 3), or to trigger rather weak antimicrobial ef-
fects, probably due to very limited drug release (Chapter 4). As such, maxi-
mum particle stability should not be a fundamental goal when designing PIC 
particles for drug delivery, and a compromise between particle integrity and 
susceptibility should be established instead. 
 
This Thesis has expanded the knowledge and applications of PIC nanoparticles 
in the biomedical field, and opens new avenues for the design of nanomaterials 
for the targeted and passive delivery of charged therapeutics. The optimisation 
of the enzyme-targeted system presented in Chapters 2 and 3 has great potential 
to allow localised drug delivery, and tune the therapeutic effect in response to the 
pathology by exploiting enzymes (i.e. disease markers) to adjust the release of 
drug. As such, future efforts should focus on the optimisation of the enzyme-re-
sponsive design of PIC nanoparticles presented here, and its application to the 
formulation of small charged therapeutics (e.g. antibiotics and anticancer drugs). 
To this end, the oligomerisation of the enzyme-responsive peptides introduced in 
Chapters 2 and 3 seems the most feasible approach to increase their multiva-
lency, and thus aid the assembly of these responsive polypeptides with small 
charged drugs. 
 
 
 
 
 
 
 
